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Abstract 
 
Tauopathies are a group of neurodegenerative diseases associated with the build-up 
of intracellular aggregates of the microtubule-associated protein (MAP) tau, called 
neurofibrillary tangles (NFT). The tau found in NFTs is known to be highly 
phosphorylated, and as such a number of tau kinases have been examined for their 
ability to affect tau toxicity in animal models, including members of the AMPK-
related kinase family. Two members of this family, the brain-selective kinases 
(BRSKs), have been shown to phosphorylate tau in vitro and in vivo in an LKB1 and 
CaMKKα-dependent manner. BRSKs are prevalent in the central nervous system, in 
which they modulate neuronal polarisation via tau. They have also been shown to 
dramatically increase 0N4R tau toxicity in a Drosophila model. 
 
In order to determine the importance of phosphorylation to tau toxicity in this model, 
I have generated a group of 2N4R tau phosphorylation mutants. Based upon in vitro 
data linking phosphorylation at T212 to tau aggregation, and S262 to microtubule 
dissociation, these two residues underwent both non-phosphorylatable and phospho-
mimetic mutation and were inserted into Drosophila. Each of these mutations was 
found to alter tau toxicity upon expression in the fly eye, as measured by disruption 
of ommatidia, with the T212D and S262A mutations producing a milder phenotype. 
  
Each of these sites on tau has previously been shown to be a target of 
phosphorylation by BRSK2 in vitro. Through generation of a T212D S262D double 
mutant, I was able to investigate whether phenotypic changes caused by BRSK2 
were due to phosphorylation. BRSK2 was found to have a different effect on toxicity 
caused by 2N4R tau, causing a reduction in toxicity. This was found to be 
comparable to the phenotype of the double mutant. However, examination of the 
ability of BRSK2 to modulate the toxicity of the single tau mutants demonstrated a 
more complex phosphorylation profile, also dependent on other residues. 
 
Further experiments examined the consequences of tau and BRSK2 expression in the 
CNS. This demonstrated the toxicity of BRSK2 overexpression, in the absence of 
tau, in these tissues. Given that BRSK2 overexpression alone in the eye led to no 
observable phenotype, this tissue-dependent toxicity of the kinase demonstrates the 
importance of the choice of model in such studies. In addition, a deficiency screen 
for modulators of 0N4R tau/BRSK2 toxicity in the eye has generated multiple leads, 
including the fly homologue of the actin-binding protein profilin.  
 
This project has demonstrated the inequivalence of several phosphorylation sites in 
vivo, as well as an isoform-dependent aspect of tau toxicity. These data suggest that 
the influence of tau phosphorylation on toxicity is complex; expansion of the work 
presented here could help decipher the code of tau phosphorylation.  
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1| Introduction
2 
 
The microtubule-associated protein tau is both a key part of the neuronal 
cytoskeleton, and its dysregulation a common pathological signature of a number of 
neurodegenerative diseases, the tauopathies. Tauopathies are classified as any disease 
associated with a build-up of intracellular tau aggregates, known as neurofibrillary 
tangles (NFT). Most of these conditions present with dementia; indeed tauopathies 
together account for the majority of dementia cases globally. The most well-known 
and also most prevalent of these diseases is Alzheimer’s disease (AD), although 
more and more patients are being diagnosed with mixed dementia, with multiple 
brain pathologies (Schneider et al., 2007). According to the World Alzheimer Report 
2010, there were 35.6 million people suffering from dementia globally (Wortmann, 
2012), with this number expected to nearly double every 20 years as life expectancy 
increases. The same report also estimated the economic cost of dementia at US$604 
billion, or equivalent to 1% of global gross domestic product. With tau pathology 
associated with the vast majority of actual cases of dementia, a great deal of research 
has focused on determining the mechanisms responsible for the apparently 
pathogenic changes occurring in this cytoskeletal protein, ultimately leading to 
aggregation and neurodegeneration. This literature review covers the history of 
research into tau, its normal physiological function and the diseases with which it is 
associated. It also examines some of the theories attempting to explain tau pathology, 
with particular attention paid to the history of research into tau phosphorylation and 
tau kinases, the investigation of which was the primary goal of this work.  
 
1.1 Tau protein 
Human tau protein is transcribed from the gene MAPT (microtubule-associated 
protein tau). The gene encodes all six isoforms of tau found in the brain, through 
alternate splicing of three introns (Goedert et al., 1989a), which vary in length from 
352 to 441 amino acids (AA), as shown in Fig 1.1. It functions as a microtubule-
stabilising agent (Weingarten et al., 1975), a process which is very strongly regulated 
by phosphorylation (Lindwall and Cole, 1984). This ability of tau function to be 
rapidly modulated is likely reflected in the localisation and role of the protein, which 
is primarily axonal (Binder et al., 1985), where it is involved in the regulation of  
3 
 
 
Figure 1.1 The six isoforms of human tau found in the brain 
Alternate splicing of the MAPT gene can generate six isoforms of tau of different 
lengths. Exons 2 and 3 (29AA each) encode the N-terminal inserts labelled here 
respectively as N1 and N2. Exon 10 (31AA) encodes the second microtubule-binding 
domain, R2. The proline-rich region is contained within exon 7 and part of exon 9 
(Martin et al., 2011), and contains a large number of phosphorylation sites known to 
influence microtubule-binding and tau aggregation in vitro.  
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growth cone dynamics (Liu et al., 1999). In mammalian cells and in the fly, the 
function of tau is thought to be redundant, with no major phenotype recorded in tau 
null mutants (DiTella et al., 1996; Doerflinger et al., 2003). 
 
1.1.1 The discovery of tau  
Tau protein was first isolated in porcine brain in 1975, during relatively early 
experiments exploiting the then-novel ability to polymerise tubulin in vitro 
(Weingarten et al., 1975). Removal of tau during phosphocellulose chromatography 
from relatively pure microtubule samples was found to completely remove the 
ability of tubulin to polymerise in vitro. Tau was shown to increase the tendency of 
tubulin to polymerise stoichiometrically, with greater concentration of tau leading to 
increased formation of 36S oligomers, the subunits of microtubules composed of αβ-
tubulin dimers (Melki et al., 1989). The identification of the MAPT gene was 
completed shortly after the definitive association of tau with the NFT of Alzheimer’s 
disease by a trio of papers appearing in PNAS in 1988. Together, two groups form 
Cambridge managed to overcome the principle impediment to identification of the 
components of the paired helical filaments (PHF) of NFT, which was their 
insolubility. This was performed by screening of a cDNA library from the post 
mortem brain tissue of an Alzheimer’s patient using an oligonucleotide probe 
(Goedert et al., 1988); the probe was generated based on knowledge of a PHF-
derived six amino acid fragment(Wischik et al., 1988a; Wischik et al., 1988b). The 
screen identified the shortest 352AA tau isoform, which was shown to be found 
within the insoluble PHF core using a monoclonal antibody also generated by these 
groups. This was the first successful probe of the PHF core, and led to a dramatic 
increase in interest surrounding tau. Soon after, the number of sequenced mammalian 
tau proteins dramatically increased (Goedert et al., 1989a). 
 
1.1.2 The multiple isoforms of tau  
Prior to the first sequencing of the human tau AA sequence, it was already known 
that multiple tau isoforms existed (Cleveland et al., 1977a, b). Evidence had been 
found for only a single human tau gene, located within chromosome 17 (Neve et al., 
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1986), indicating the likelihood of alternative splicing leading to multiple tau 
isoforms. Further tau isoform cDNAs were subsequently isolated by probing with a 
17mer oligonucleotide complementary to the tau repeat region, first the 383AA, four 
microtubule-binding repeat isoform (Goedert et al., 1989b), and finally a 
comprehensive cDNA library screen revealed there to be six human brain tau 
isoforms in total (Goedert et al., 1989a). This revealed the presence of two additional 
N-terminal inserts, of 29AA each, of which the second was never present without the 
first. Upon complete sequencing of the tau gene, these inserts were shown to be 
contained within exons 2 and 3, with the additional microtubule-binding repeat in 
exon 10, placing it second among the four repeats of the longer isoform. Figure 1.2 
is a MAPT splicing diagram, indicating the multiple splicing variants of tau found in 
the brain and peripheral nervous system (PNS). The six brain tau isoforms range in 
molecular weight from 37 to 46kD. The established nomenclature for the different 
isoforms is based on the number of N (N-terminal) and R (microtubule-binding 
repeat) domains, ranging from 0N3R (352 AA) to 2N4R (441 AA). All of the 
isoforms have been found to migrate abnormally through SDS-PAGE gels, with 
apparent molecular weights of between 48 and 67kD, even after treatment with 
alkaline phosphatase to remove phosphate groups (Goedert and Jakes, 1990). In 
particular, the N-terminal inserts were found to affect migration disproportionately. 
Four-repeat tau isoforms were found to better stabilise microtubules by a factor of up 
to 3-fold compared with three-repeat isoforms; the N-terminal inserts were not found 
to affect microtubule stabilisation  (Goedert and Jakes, 1990). In adult brain samples, 
four major tau bands were found – the number and intensity of these bands did not 
differ between control and Alzheimer’s patients. These bands corresponded in size to 
the four smallest recombinant tau isoforms, indicating the lack of twin N-terminal 
repeat isoforms. The mRNA of the largest tau isoform had previously been detected, 
but in much lower concentrations than these four (Goedert et al., 1989a).  In foetal 
samples, the smallest three-repeat isoform was isolated, along with a second, slightly 
larger band which was smaller than any other recombinant isoform, indicating the 
primacy of three-repeat tau in the developing brain. In addition, foetal tau was found 
to be particularly highly phosphorylated; foetal tau is thus generally less capable of 
stabilising microtubules.  
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Figure 1.2 Splicing diagram of the MAPT gene 
Alternative splicing affects exons 2, 3, 4A, 6, 8, 10, 13 and 14 of MAPT. The N-
terminal inserts in exons 2 and 3, and the additional microtubule-binding domain in 
exon 10, are described above. In addition, three other alternatively spliced exons are 
more rare or never found in human brain (Liu and Gong, 2008). Inclusion of exon 
4A generates an 110kDa tau isoform found only in the peripheral nervous system 
(PNS). Exon 6 is found only in a minority of axonal tau in the CNS (A), and its 
inclusion can lead to C-truncated tau molecules with no microtubule-binding 
domains due to reading frame changes caused by use of two alternative splice sites 
(Luo et al., 2004). Exon 8 (?) has only been found in bovine tau mRNA (Andreadis, 
2005). Murine tau mRNAs have been found which vary in C-terminus length due to 
excision of the intron between exons 13 and 14. 
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The majority of research into tau isoform-specific differences has focused on 3R and 
4R tau. These two groups are both roughly equally expressed in the adult brain and 
cortical neurons specifically, whereas 0N, 1N and 2N isoforms are expressed at a 
ratio of roughly 37:54:9 (Deshpande et al., 2008). These isoforms are thought to 
adopt different secondary structures, with each isoform possessing distinct regions of 
influence over microtubule binding – the 3R isoforms depend on a C-terminal 
sequence to complement its binding, whereas the 4R isoforms depend solely on the 
repeat domains (Goode et al., 2000). Recorded differences between 3R and 4R 
isoforms, as well as altering microtubule stability, include 3R species decreasing 
taxol affinity for microtubules, either by competition or alteration of microtubule 
structure (Park et al., 2008); the ability of 3R tau to reduce heparin-induced 4R tau 
polymerisation, potentially signifying a role for 3R tau in the prevention of 
aggregation (Adams et al., 2010); and differences in the shapes of fibrils of these 
isoforms, with 4R tau forming longer, less twisted fibrils, potentially more apt for 
tangle formation (Furukawa et al., 2011). Each of these differences was found to be 
independent of the presence or absence of N-terminal inserts.  
More recently, some functional differences have been found between isoforms with 
different numbers of N-terminal inserts. For example, all six isoforms have been 
shown to possess differing arachidonic acid-induced aggregation kinetics in the 
presence of heat shock protein 70 (Hsp70), with aggregation of 3R isoforms 
inhibited at lower Hsp70 concentrations. N-terminal repeats were only consistently 
found to have an effect when assayed by laser light scattering, indicating reduced 
sensitivity to the aggregation inhibitor in 4R species containing N-terminal inserts, 
and the opposite effect in 3R species (Voss et al., 2012). This effect due to the N 
terminal inserts was less significant than differences between 3R and 4R isoforms, 
which increased Hsp70 resistance in all cases. The longer N-terminus has an 
increased negative charge compared to 0N tau isoforms, which has been posited to 
aid in the correct localisation of tau to the axon (Ittner et al., 2010). In addition, the 
N-terminal domains lead to an increased negative charge and size of the projection 
domain of microtubule-bound tau, created by repulsion of the N-terminus of tau by 
similarly-charged tubulin. This more negative charge has been used to explain the 
increased kinesin transport speed of microtubules primarily stabilised by 1N or 2N 
tau – bound tau can act as a “roadblock” for microtubule-based transport, preventing 
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kinesin from attaching. The negative charge of the projection domain could help 
redirect the positively-charged kinesin molecules around the intervening MAP, via 
sidestepping onto neighbouring tubulin (Tarhan et al., 2013). This is perhaps a more 
likely role for the N-terminal inserts, given that they have a much greater influence 
on transport dynamics than the extra R domain. The N-terminal inserts could also be 
of pathogenic interest. The projection domain has been shown to exist along tau 
fibrils, giving aggregated tau a “coat” of projection domains with a charge dependant 
on cellular pH and electrolyte concentration (Wegmann et al., 2013). Aggregates 
could thus be sensitive to cellular conditions (e.g. ionic concentrations), affecting 
their localisation and growth. 
 
1.1.3 Tau function 
Microtubules are composed of 8nm heterodimers of α and β tubulin, assembled into 
protofilaments, of which 13 can associate to form the cylindrical shape of 
microtubules (Desai and Mitchison, 1997). They form around microtubule 
organising centres (MTOCs), and conduct cell division, kinesin-driven transport and 
cell structure and growth. Tubulin has long been known to rely on guanine 
nucleotides for its polymerisation (Weisenberg et al., 1968), and the turnover of GTP 
on polymerised tubulin is at the heart of what is known as the dynamic instability of 
microtubules (Mitchison and Kirschner, 1984). Microtubules alternate between 
phases of gradual tubulin addition and rapid dissociation; the transition from 
microtubule elongation to reduction is termed catastrophe. The collapse of a 
microtubule is thought to occur once the rate of GTP hydrolysis outpaces that of 
GTP-tubulin addition; microtubule stability is thus dependent upon the presence of a 
cap of GTP-tubulin at the plus end, which will be lost without sustained 
polymerisation (Kirschner and Mitchison, 1986). One complication of this model is 
that although the growth rate is dependent on tubulin concentration, the frequency of 
catastrophe is less so, depending primarily on the rate of GTP hydrolysis, as shown 
by the use of a slow-hydrolysing GTP analogue (Janson et al., 2003). Several models 
have attempted to account for this, leading to the conclusion that catastrophic events 
involve multiple steps, likely dependent on binding of MAPs (Holmfeldt et al., 2002) 
as well as GTP hydrolysis and growth rate (Bowne-Anderson et al., 2013). 
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Relatively little is known about the precise role or mechanism of action of tau. Its 
localisation implies a role in axonal growth, steering and transport (Liu et al., 1999), 
and it has also been shown to play a role in neuronal polarisation (Caceres and 
Kosik, 1990). The ability of tau to stabilise microtubules is highly modulatable by 
phosphorylation, a characteristic which would make it more apt for localisation to 
the distal end of the axon, where greater cytoskeletal flexibility is required (Black et 
al., 1996). This is perhaps another reason why foetal tau is present in only the 3R 
isoforms, and in a highly phosphorylated state. This could also explain the existence 
of multiple isoforms of human tau, as a further method of flexibility. As for the 
variety of N-terminal projection domains, it is possible that they exist to regulate 
microtubule spacing, which is smaller in the axon than in dendrites, creating a closer 
network (Chen et al., 1992). This N-terminal domain also defines the various MAPs, 
with a far greater degree of variation in the projection domain than in the 
microtubule-binding region, with tau being particularly small. The spacing of tau on 
microtubules has been shown to be unusually distant, with one every 60 tubulin 
dimers, giving the protein a very high efficiency of action and increasing its 
sensitivity to modulation (Breuzard et al., 2013). Tau was shown to increase 
microtubule stability through conformational changes in microtubules, causing an 
increase in the rescue of assembly following microtubule shrinkage. 
Normal tau function is associated with correct neuronal polarisation, and the growth 
and orientation of, and transport along, axons. Tau dysfunction has been linked with 
a number of neurodegenerative diseases, which together constitute the majority of 
cases of dementia worldwide. The presence of NFTs in Alzheimer’s disease has 
arguably been the primary motivation behind the majority of research conducted into 
tau since the late 1980s.   
 
1.2 Alzheimer’s disease 
The recorded history of senile dementia extends as far back as the classical era. In 
the 7th century B.C. the ancient Greek physician Pythagoras said of old age, that “the 
system returns to the imbecility of the first epoch of the infancy” – a mental decline 
during old age was seen as unremarkable enough to be accounted for in Ancient 
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Greek law (Berchtold and Cotman, 1998). Much of the early contemplation of 
dementia centred around the view that it was an inevitable part of the aging process, 
even if not universal – according to the Roman philosopher Cicero of the 2nd century 
B.C., “madness or delirium is a characteristic, not of all old men, but only those who 
are weak in will”. The modern medical view of aging-related disease is of course far 
less fatalistic, and owes much to the onset of study of mental disorders more 
generally during the 16th century, culminating in the first acceptance of mental 
disorders as diseases in the early 19th century. It was during the 1800s that post-
mortem study of the brains of dementia patients began, revealing the physical 
changes underlying the loss of mental faculties. It was through such post-mortem 
examination, using novel histochemical techniques, that Alois Alzheimer first 
observed the joint characteristic pathologies of the disease which would come to bear 
his name. In a 1907 paper, Alzheimer described the case of a 51-year-old sufferer of 
early-onset senile dementia (Auguste Deter), in whose brain he had located two 
forms of neuropathological lesion (Alzheimer, 1907; Alzheimer et al., 1995). Of 
these, one was the “miliary focus” which was linked specifically to senile dementia 
by a competitor of Alzheimer, Oskar Fischer in a separate paper that same year 
(Fischer, 1907). These were also described as plaques, which are now known to be 
composed of β-amyloid, or Aβ (Masters et al., 1985). Alzheimer also described a 
novel characteristic of his case, using the Bielschowsky silver stain: intracellular 
tangles of neurofibrils, which were capable of surviving the death of the cell in 
which they had formed. The extent of these lesions, affecting 25% of ganglion cells 
in this patient “particularly in the upper cell layers” (Alzheimer et al., 1995), and the 
young age of disease onset were considered distinctive enough to constitute a novel 
disease, separate from the standard definition of senile dementia. It was described as 
“Alzheimer’s disease” by the revered psychiatrist Emil Kraepelin in 1910, and 
qualified as a form of pre-senile dementia only, despite the presence of each type of 
lesion having already been recorded in cases of senile dementia (Berchtold and 
Cotman, 1998). This distinction came to be widely believed to be an artificial one 
(Katzman, 1976), with AD and senile dementia eventually being classified together 
as “senile dementia of the Alzheimer’s type” (SDAT), or more commonly simply as 
Alzheimer’s disease. 
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1.2.1 Symptoms and progression of the disease 
Alzheimer’s disease is a progressive neurodegenerative condition, characterised by 
multiple cognitive deficits, initially of memory but in advanced cases of language, 
reasoning, attention and problem solving skills (Thies and Bleiler, 2011). Memory 
deficits are the best early indicator of AD, with individuals experiencing difficulties 
in performing well-known tasks, speaking, writing or orientation. That AD sufferers 
exhibit reduced levels of acetylcholine (ACh) has long been known, associated with 
a loss of cholinergic neurons (Davies and Maloney, 1976) and nicotinic receptors, as 
well as of the neurotransmitter itself, in the cerebral cortex (Quirion et al., 1986; 
Whitehouse et al., 1986). This preferential loss of cholinergic neurons implies a role 
for nicotinic ACh receptors (nAChR) in AD pathology. It has been suggested that Aβ 
functions via direct interaction with α7 nAChRs, leading to activation of the MAPK 
(microtubule-associated protein kinase) signalling pathway and leading to cell death, 
possibly involving tau hyperphosphorylation (Buckingham et al., 2009). This process 
helps to explain the early symptoms of the disease, with primarily hippocampal or 
para-hippocampal localisation of NFTs, but late-stage AD brains exhibit far wider 
neurotoxicity, with diffuse cerebral atrophy; the acceleration in brain atrophy in AD 
sufferers has been shown to be as high as 40 fold greater than control subjects (Fox 
et al., 1996). 
The relentless spread of NFTs over the course of the disease adds a great deal of 
weight to the idea that tau dysfunction is central to AD. At the same time, it has also 
been the source of some uncertainty regarding the mechanism by which these 
intracellular aggregates are spread throughout the cortex in a predictable fashion, 
apparently radiating from the locus coeruleus and trans-entorhinal region. Evidence 
has accumulated suggesting “prion-like” propagation of misfolded proteins in AD 
(Clavaguera et al., 2013b; Frost and Diamond, 2010; Nussbaum et al., 2012), by 
which pathogenic conformations of both tau and Aβ are capable of acting as 
templates, initiating toxic transformations of native, healthy proteins. In the case of 
tau, brain lysates from established mouse models of tauopathy (containing mutated, 
tangle-forming tau) were found to induce NFT formation in healthy mice following 
injection (Clavaguera et al., 2009). This catalysis of aggregate formation spread from 
the site of injection to other brain regions. A similar ability to induce native protein 
misfolding in mice has also been found in brain homogenates from a variety of 
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tauopathies (Clavaguera et al., 2013a). As for Aβ, small oligomers of truncated, 
polyglutamylated Aβ were found to be able to seed oligomerisation in Aβ oligomers 
through multiple serial dilutions (Nussbaum et al., 2012). An extracellular step in tau 
transmission, by which toxic tau oligomers are released from affected neurons to be 
absorbed by neighbouring healthy cells, has also been identified in cultured cells 
(Frost et al., 2009). Specifically, low molecular weight oligomers, a transitional step 
as monomers form fibrillar aggregates, were found to be internalised quite avidly by 
cultured neurons, both axonally and at the soma, via bulk endocytosis (Wu et al., 
2013a). The propagation of tau throughout the brain appears thus to have been 
explained as a system of template misfolding highly comparable to prionopathies. 
This progression of the disease, from the hippocampus and trans-entorhinal region 
into the wider cortical areas, also explains the breadth of psychiatric and behavioural 
symptoms of late-stage AD. These include depression, aggression, confusion and 
paranoia, as well as aimless movement, wandering and disruption of diurnal rhythms 
(Hope et al., 1999). Loss of awareness and confusion combine with deficiencies in 
communication and normal eating patterns (hypophagia) to increase susceptibility to 
many secondary conditions, particularly aspiration pneumonia (Kalia, 2003). The 
exceptional social cost of dementia is also directly attributable to this loss of 
autonomy and protracted disease course (Thies and Bleiler, 2011). 
Effective treatment for AD is not yet available, despite a number of promising 
breakthroughs and trials. Symptomatic treatments include acetylcholinesterase 
inhibitors to delay memory loss, particularly Donepezil (Birks and Harvey, 2006), 
and Memantine, the NMDA receptor antagonist, potentially through reduction of 
excitotoxic cell death (Areosa Sastre et al., 2004). Given this lack of a cure, much 
attention has been paid to the risk factors associated with AD.  
 
1.2.2 Alzheimer’s disease aetiology 
The prevalence of AD in the modern aging population has provided ample 
motivation for the epidemiological study of the disease. Whereas inroads have been 
made into mitigating the burden of many other aging-related diseases including 
many forms of cancer (Jemal et al., 2008), dementia is still considered a public 
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health “time bomb” (de la Torre, 2013). Although dementia is clearly primarily 
associated with aging, there are an ever-growing number of additional AD-associated 
risk factors. Familial Alzheimer’s disease (FAD) describes early-onset AD associated 
with mutations to the genes for amyloid precursor protein (APP) or the presenilins 
(Bertram and Tanzi, 2008), but which accounts for less than 4% of cases (Harvey et 
al., 2003). Late-onset AD has an ever-growing number of associated genetic risk 
factors, most importantly mutations to apolipoprotein E (ApoE), and twin studies 
suggest around 60% heritability, making genetics the single most important risk 
factor for the condition (Bergem et al., 1997). However, that does still leave many 
cases unaccounted for. 
Vascular complications are the principle emerging risk factor of AD, particularly 
among carriers of the ApoE ε4 allele (Bangen et al., 2013). Midlife exposure to a 
wide variety of vascular issues, up to and including infarction, increases the 
probability of cognitive decline and dementia in later life (Kivipelto et al., 2006). 
That diabetic drugs are also considered a vascular risk factor, and that both diabetes 
and most circulatory disorders are strongly associated with obesity also raises the 
likelihood of metabolic stress being relevant to AD, which has even been described 
by some as “Type 3 diabetes” – a brain-specific form of the metabolic disease (de la 
Monte and Wands, 2008). 
The majority of AD sufferers are female, in some part due to the longer life 
expectancy of women in the developed world. This is likely not the only cause 
however – like osteoporosis, it would seem that AD is also associated with 
decreasing oestrogen levels during menopause, with some protection provided by 
hormone supplementation (Janicki and Schupf, 2010; Paganini-Hill and Henderson, 
1994).  
As an aging-associated disease, eliminating many of the risk factors of AD depends 
on the maintenance of a healthy, moderately active lifestyle (Eggermont et al., 2006); 
aging well is likely the best protection against environmental factors, but is by no 
means capable of eliminating the risk completely (Pope et al., 2003). Any chance of 
curing or preventing AD will likely depend on a superior understanding of the 
underlying biology of the disease. The brain pathology of sufferers of AD has given 
research a good place to start. 
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1.2.3 The protein aggregates of AD 
The Alzheimer’s brain displays physical characteristics of both cerebral amyloidosis 
and tauopathy. The presence of two protein aggregates in the disease begs the 
question of which protein, if either, is primarily responsible for the condition. 
Increasingly, however, research suggests that it is an interaction between the two 
which is necessary for the disease, and which defines the condition as separate from 
the normal aging process.  
Amyloid plaques are composed of Aβ, fragments of the highly-conserved APP 
produced following cleavage by γ-secretase in the amyloidogenic pathway, as 
detailed in Figure 1.3 (Tharp and Sarkar, 2013). Cleavage of APP can occur at 
several locations, with the most disease-relevant being at residue 40 (Aβ40) or 
residue 42 (Aβ42). The longer form of Aβ is more associated with aggregation; the 
additional C-terminal peptides have been shown to be critical for nucleation of 
amyloid peptides, with Aβ42 capable of seeding the otherwise soluble Aβ40 and 
leading to aggregation (Jarrett et al., 1993). Formation of the rarer Aβ42 has been 
shown to occur at a distinct intracellular location in neurons, within the endoplasmic 
reticulum (ER), as opposed to Aβ40, generated within the trans-Golgi network 
(Hartmann et al., 1997). This is consistent with the association of the ER-located 
presenilins with Aβ42 production and familial AD; indeed all well-characterised 
mutations associated with familial AD occur within genes implicated in Aβ 
processing. The exact role of Aβ is still unclear, although it appears to be multi-
functional, including neuro-protective and cell signalling roles (Lahiri and Maloney, 
2010). It has also been implicated in the activation of the tyrosine kinase TrkA 
pathway, potentially inducing tau phosphorylation (Bulbarelli et al., 2009). The 
genetic links between APP and familial AD formed the basis of the amyloid cascade 
hypothesis, which theorised that all AD was dependent on Aβ aggregation, induced 
by an increase in the Aβ42: Aβ40 ratio, and which subsequently led to the 
development of other AD features, i.e. tau pathology. The principle argument in 
opposition to this hypothesis was based on the much closer association between NFT 
load and disease progression, compared with the less predictable deposition of 
plaques. 
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Figure 1.3 Processing the amyloid precursor protein (APP) 
Full length APP (APPFL) exists as a trans-membrane protein with an extended 
ectodomain. In the majority of cell types APP processing follows the non-
amyloidogenic pathway in which cleavage by α-secretase generates soluble 
extracellular APP (sAPPα) and the intracellular, 83AA C-terminal fragment (αCTF 
or C-83). Further cleavage by γ-secretase releases the C-terminal fragment of Aβ, 
p3. In neuronal cells, APP more commonly undergoes amyloidogenic cleavage via 
β-secretase, releasing the smaller soluble APP fragment sAPPβ. This leaves Aβ 
intact as part of the 99AA βCTF, which can be released via cleavage by γ-secretase 
at a number of sites; particularly disease relevant is at A42 to release Aβ1-42, the 
normally rare, more aggregation-prone species (Evin et al., 2003; O'Brien and 
Wong, 2011). In both cases, the APP intracellular domain (AICD) is left membrane-
bound. 
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The progression of hyperphosphorylated tau aggregates from the trans-entorhinal 
layer, through the hippocampus and into the limbic system and cortex correlates 
strongly with cognitive symptoms, and only poorly with amyloid deposition (Braak 
and Braak, 1991), which led to the Braak scale of classification of the disease based 
on tangle deposition. The ability of amyloid mutation to cause the disease, compared 
with the apparent necessity of tau pathology for disease progress caused a division of 
research interest into two camps, dubbed “BAPtist” (for β-amyloid protein) and 
“Tauist” (Mudher and Lovestone, 2002). Perhaps inevitably, the two ideas have 
found increasing reasons for a rapprochement as more links between their disease 
processes have been identified. 
Double-transgenic mouse models have shown a relationship between tau and 
amyloid. By crossing mice overexpressing mutant APP with a separate line 
overexpressing mutant P301L tau, the presence of mutant APP was shown to 
enhance both NFT load and distribution, leading to increased toxicity (Lewis et al., 
2001). Amyloid deposition has also been shown to be enhanced in similar 
experiments (Ribé et al., 2005). In the absence of mutant tau overexpression, the 
spread of NFTs in APP mutant mice is greatly delayed, by around 2.5 months 
compared with deposition of plaques (Samura et al., 2006), suggesting a compound 
effect of these two disease processes. That Aβ-induced toxicity is mediated by tau 
phosphorylation was shown more recently, when tau knockout mice were found to 
be resistant to memory impairment caused by exposure to Aβ42 (Shipton et al., 2011). 
Inhibition of the tau kinase glycogen synthase kinase 3 (GSK-3) was also found to 
block the amyloid-induced impairment, reinforcing the idea that the TrkA pathway 
could be an essential aspect of Aβ-induced toxicity – TrkA is thought to be capable 
of activating the Akt pathway, of which GSK-3 is a downstream target (Bulbarelli et 
al., 2009). There is additional evidence that tau dysfunction exacerbates Aβ-induced 
toxicity. A dendritic function for tau has been established, in the targeting of the Src 
kinase Fyn to the postsynapse (Ittner et al., 2010). Truncated tau, consisting of only 
the projection domain of tau, could still interact with Fyn but remained in the soma, 
reducing Fyn levels in dendrites and phosphorylation and stabilisation of NMDA 
receptors. It has been hypothesised that tau relocation to dendrites is caused by 
hyperphosphorylation, leads to higher Fyn levels and more active NMDA receptors, 
and induces excitotoxicity – tau knockout mice were protected against excitotoxic 
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seizures. Aβ toxicity is believed to be mediated by interaction with and 
overstimulation of NMDA receptors on dendritic spines; tau hyperphosphorylation 
could therefore sensitise neurons to Aβ toxicity (Haass and Mandelkow, 2010). 
Finally, interactions between tau and Aβ also help to explain the nature of cell death 
in AD. Aberrant cell cycle re-entry by post-mitotic neurons is the cause of much AD-
related cell death (Lee et al., 2009). This process was shown to be induced by 
exposure of cultured neurons to Aβ, but was prevented by loss of tau or blocking tau 
phosphorylation at Y18, S409 or S416 (Seward et al., 2013). 
That both amyloid plaques and NFTs are associated with neurodegenerative disease 
separately, but are concomitant in the most common neurodegenerative disorder is an 
intriguing aspect of this disease. The association of tau phosphorylation with Aβ-
induced toxicity further underlines the need to better understand tau phosphorylation 
in AD, as well as the other tauopathies. 
 
1.3 Tau is implicated in a variety of other diseases 
If tau is likely a co-conspirator in the most prevalent form of dementia, there are a 
number of other tauopathies in which the MAP appears as prime instigator. For as 
long as none of the genetic evidence for AD implicated MAPT as a cause of the 
disease, and more mutations in elements of the amyloid processing pathway were 
being found, many believed tau dysfunction to be purely a by-product of other 
amyloid-dependent disease processes. The isolation of MAPT mutation as the cause 
of the autosomal dominant condition FTDP-17 (frontotemporal dementia and 
Parkinsonism linked to chromosome 17) provided clear evidence of the ability of 
mutant tau protein to cause neurodegenerative disease (Hutton et al., 1998). This also 
had profound implications for the wide range of other tauopathies, such as Pick’s 
disease, progressive supranuclear palsy (PSP), senile dementia of the NFT type (SD-
NFT), corticobasal degeneration (CBD) and chronic traumatic encephalopathy 
(CTE). That these NFT-presenting diseases can be associated with genetics, aging or 
trauma implies multiple possible pathways leading to tauopathy. 
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1.3.1 Hereditary tauopathy 
The hereditary tauopathy FTDP-17 is a neurodegenerative disease of relatively early 
onset, with carriers often affected during their 40s or 50s (Wszolek et al., 2006a). It 
is an extremely rare condition, and relatively polymorphic, with the 100 affected 
family groups presenting over 35 different tau mutations. Some other 
symptomatically identical cases present with no tau mutation or NFT build up at all. 
The tau mutations can be divided into two groups, coding mutants and splicing 
mutants, with about equal numbers of each group identified. Among the coding 
mutations, none affect serine, threonine or tyrosine phosphorylation sites and all are 
located within exons 1, 9, 10, 11, 12 and 13 (see Table 1.1). Those mutations studied 
have been shown to reduce the microtubule-binding affinity of tau and in many cases 
to increase the propensity of tau for aggregation – both increasing the pool of 
unbound tau, and the number of filamentous tau aggregates. The splicing mutations 
are all within exon 10, or intronic and close to the 5’ splicing site of exon 10. These 
mutations have all been shown to alter the usual 1:1 ratio of 3R and 4R tau isoforms, 
in most cases increasing the amount of 4R tau (Rodriguez-Martin et al., 2009), 
although three mutants have been shown to favour 3R tau splicing, one of which has 
been found in both FTDP-17 sufferers and unaffected individuals (Wszolek et al., 
2006a). For an extended summary of these mutations, see Wszolek et al. (2005). 
Clinical diagnosis of FTDP-17 is based upon patients presenting with at least two of 
three characteristic signs, namely behavioural changes (including aggression and loss 
of inhibition), cognitive deficits (dementia, with later memory loss) and motor 
disturbance (Parkinsonism). As with the classification of FTDP-17 mutations, there 
are two broad symptomatic groups, depending on whether the patient presents with 
more severe dementia or parkinsonism; parkinsonism is potentially associated with 
relative increases in 4R tau levels (Reed et al., 2001). The discovery of several 
disease-causing tau mutations has provided research insights into the mechanisms of 
tau dysfunction, and also one of the most predominant animal models for tauopathy. 
The P301L tau mutation, common in Western FTDP-17 sufferers (Dumanchin et al., 
1998), is contained within the second R domain specific to 4R isoforms, and has 
been shown to cause tauopathy in a murine model (Lewis et al., 2000). This model 
was found to develop NFTs of hyperphosphorylated tau and motor impairment; it 
was this model which was shown to interact with mutant APP (Lewis et al., 2001). 
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Mutation Localisation Type 
3R:4R 
ratio 
R5H E1 Missense = 
R5L E1 Missense = 
K257T E9 Missense = 
I260V E9 Missense = 
L266V E9 Missense = 
G272V E9 Missense = 
E9+33 I9 Splicing N/A 
N279K E10 Missense > 
ΔK280 E10 Deletion < 
L284L E10 Silent > 
N296H E10 Missense > 
N296N E10 Silent > 
ΔN296 E10 Deletion = 
P301L E10 Missense = 
P301P E10 Silent = 
P301S E10 Missense = 
G303V E10 Missense > 
S305N E10 Missense > 
S305S E10 Silent > 
E10+3 I10 Splicing > 
E10+11 I10 Splicing > 
E10+12 I10 Splicing > 
E10+13 I10 Splicing > 
E10+14 I10 Splicing > 
E10+16 I10 Splicing > 
E10+19 I10 Splicing < 
E10+29 I10 Splicing < 
L315R E11 Missense = 
K317M E11 Missense = 
S320F E11 Missense = 
G335V E12 Missense N/A 
Q336R E12 Missense = 
V337M E12 Missense = 
E342V E12 Missense = 
S352L E12 Missense = 
K369I E12 Missense = 
G389R E13 Missense = 
R406W E13 Missense = 
T427M E13 Missense = 
Table 1.1 Tau mutations associated with FTDP-17 
FTDP-17-associated tau mutations are listed, alongside location, type and effect on 
3R:4R ratio, adapted from Wszolek et al. (2005). There are two broad types of 
FTDP-17 mutations: those which do not alter the 3R:4R tau balance reduce the 
ability of tau to bind microtubules (Wszolek et al., 2006b). Mutations with no 
published data regarding effects on isoform ratios are listed as N/A. 
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 The doxycycline-repressible rTg4510 line is now widely used in research (Ramsden 
et al., 2005). Interestingly, the P301L mutation has arisen in multiple, unrelated 
groups of FTDP-17 sufferers with apparently distinct origins and major symptoms 
(Kobayashi et al., 2002), perhaps indicating a polygenic influence on the disease. 
The discovery and study of FTDP-17 in many ways rejuvenated interest in tau in the 
context of neurodegeneration, though it is a very rare condition which, like all forms 
of dementia, is often symptomatically indistinct from a number of other diseases. 
The two groups of FTDP-17 mutation provide evidence for numerous theories of tau 
toxicity, based around microtubule dissociation, hyperphosphorylation and 
aggregation, without clearly privileging any individual process. That change in tau 
isoform ratios can lead to toxicity, and potentially Parkinsonism more specifically, 
should be of interest to all researchers using animal models for tau which often 
express single isoforms of tau. 
 
1.3.2 Aging-related tauopathy 
Though AD is characterised by the presence of two types of insoluble protein 
aggregates, variant forms of senile dementia have been identified which privilege 
one or other lesion in particular. So-called plaque-only Alzheimer’s disease was 
found in a significant minority of sufferers of senile dementia aged over 74 (Terry et 
al., 1987), and is classified by the total or near-total lack of tangles, though often 
these are replaced by Lewy bodies, Parkinson’s disease-associated aggregates of α-
synuclein (Hansen et al., 1993).Similarly, a subset of very elderly senile dementia 
patients have been found to lack amyloid plaques. Tangle-predominant dementia, or 
SD-NFT is an extremely rare subtype of senile dementia with an average age of 
onset of around 80 years, 6 years older than that of AD (Jellinger and Attems, 2007). 
Compared with plaque-only AD, SD-NFT (senile dementia of the NFT type) or 
tangle-only dementia (Yamada, 2003) is much less common, with early reports on 
incidence finding it to account for fewer than 2% of dementia cases (Bancher and 
Jellinger, 1994). Memory impairment is the predominant symptom of the disease, 
correlating with high levels of NFT in the hippocampus; other cognitive deficits are 
much less common (Yamada, 2003). 
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 The genetics of SD-NFT, such as have been determined, further distinguish it from 
AD – there is no association of the condition with ApoE ε4, very prevalent in cases 
of sporadic AD. SD-NFT may also provide some insight into the genetics of tau 
dysfunction. MAPT is contained within an inversion polymorphism on chromosome 
17 with two haplotypes, H1 and H2. The predominant H1 haplotype has been 
associated with increased α-synuclein levels in dementia with Lewy bodies (Colom-
Cadena et al., 2013), multiple other tauopathies (Pittman et al., 2006) and 
Parkinson’s disease (Skipper et al., 2004). SD-NFT has also been shown to be 
associated with H1 MAPT, as well as polymorphism in the 3’ untranslated region 
(Santa-Maria et al., 2012). That tau protein accumulation can be responsible for 
dementia in an amyloid-independent, aging-associated manner is significant for the 
study of tau toxicity. Given that tau accumulation in certain areas of the brain, in 
particular the locus coeruleus and hippocampus, has been shown to be a normal part 
of aging even in relatively young persons (Shin et al., 1991), it is possible that some 
unknown genetic or environmental factors may contribute to a pathological 
marshalling of the large pool of tau already present in elderly neurons, a process 
which could be hastened by amyloidosis, pre-existing mutation or trauma. 
 
1.3.3 Physical trauma and tauopathy  
In addition to genetics and aging, evidence has accumulated for the potential of 
physical trauma and inflammation to lead to tauopathy and dementia. Formerly 
known as dementia pugilistica or punch-drunk syndrome, chronic traumatic 
encephalopathy (CTE) is an early-onset form of dementia most often occurring in 
full-contact sportspeople. Originally identified in former boxers (Corsellis et al., 
1973), the at-risk group has since been expanded to any individuals experiencing 
repeated head injury, due to sport, profession, seizures or physical abuse (Gavett et 
al., 2011). This condition has received a recent increase in attention following its 
association with a number of high-profile suicides involving American sportsmen 
(Omalu et al., 2010). CTE is associated initially with increased aggression, followed 
by a wide range of cognitive deficits. Brains of CTE sufferers exhibit extensive 
atrophy, NFT deposition and (in some cases) amyloid plaques (McKee et al., 2009). 
That tau should accumulate in response to brain damage, leading to widespread 
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cortical atrophy, raises some questions. It has been posited that physical trauma leads 
to a dissociation of tau from microtubules, possibly due to increased kinase activity 
associated with calcium influx and excitotoxicity (McKee et al., 2013). One 
hypothesis which has arisen in an attempt to explain the spread of tau pathology 
throughout the brain in all tauopathies, and which seems especially relevant here 
(given the presumably localised nature of head trauma), is that tau is capable of 
spreading between neurons, potentially in a prion-like, misfolded state (Hall and 
Patuto, 2012). This idea has been bolstered by the discovery of the ability of 
cytokine release to increase tau phosphorylation and misfolding (Zilka et al., 2012). 
The diversity in cause of tauopathies speaks to multiple disease processes being 
involved in the development of tau pathology. As a consequence, there are a number 
of theories surrounding the nature of tauopathy which attempt to unite tau 
dysfunction with neurodegenerative processes. 
 
1.4 Theories of tau pathology 
The suggestion that tau dysfunction can be the cause of neurodegenerative disease is 
now widely accepted. Nonetheless, the processes underlying tau-induced toxicity 
remain unclear. Debate has surrounded the importance of tau phosphorylation, the 
toxicity of soluble versus insoluble tau oligomers and the predominant mechanism of 
cell death in tauopathy. This section explores some of the most widely-held ideas 
behind tau toxicity. 
 
1.4.1 Tau hyperphosphorylation 
Tau phosphorylation has been implicated in tau toxicity for as long as the 
predominance of tau in NFT has been known. Concurrently with the identification of 
the MAPT gene (Neve et al., 1986), a novel epitope for an apparently unknown 
protein enriched in Alzheimer’s brains was discovered (Wolozin et al., 1986). The 
antigen was named Alz-50, and the protein, which ran at 68kDa, A68. A68 was 
originally considered a potentially useful candidate biomarker for AD (Wolozin and 
Davies, 1987) but in the end was found to be much more significant. Originally 
23 
 
thought to be an additional component of NFTs alongside tau, A68 was eventually 
revealed as a highly phosphorylated form of tau, with a novel secondary structure but 
otherwise being identical (Brion et al., 1991; Carmel et al., 1996). This alternative, 
fixed secondary structure has been described as the “Alz-50 conformation”, differing 
from the transitory “paperclip conformation” that healthy tau is expected to form in 
that the N-terminus interacts with the microtubule-binding region instead of the C-
terminus. This is hypothesised to facilitate tau aggregation (Himmelstein et al., 
2012). The association of tau phosphorylation and PHF formation is now integral, 
with multiple PHF-labelling phospho antibodies in common use, most notably AT8 
which recognizes tau phosphorylated at both serine 202 and threonine 205 (Goedert 
et al., 1995). Tau hyperphosphorylation is now associated with a loss of microtubule 
affinity and an increase in aggregation, two processes believed to be fundamental in 
the development of tauopathy.  
The extent of potential tau phosphorylation is huge, with 85 candidate 
phosphorylation sites (see Table 1.2), of which more than half have been found to be 
phosphorylated in AD (Martin et al., 2011). The majority of these AD-associated 
sites are located within the P-rich region or at the C-terminus; however, one of the 
apparently most significant sites is S262, contained within the KXGS motif of the 
first microtubule-binding domain. Unsurprisingly, this site has been found to alter 
microtubule binding mechanics (Biernat et al., 1993). It has also been shown to 
reduce aggregation (Schneider et al., 1999), and yet phosphorylation at this site has 
been shown to be fundamental for tau toxicity in an animal model (Iijima et al., 
2010). The theory of tau hyperphosphorylation has been called into question by 
experiments attempting to simulate hyper- or hypophosphorylated tau by 
introduction of multiple phospho-mimetic or non-phosphorylatable tau mutations, 
creating E14 (containing 14 glutamate mutations) and S11A (containing 11 serine to 
alanine mutations) mutants, respectively. In separate experiments, S11A tau was 
found to increase tau toxicity, and E14 tau to alleviate it, leading some to wonder 
whether the hyperphosphorylated nature of tau in NFTs was merely a byproduct of 
the disease process (Chatterjee et al., 2009; Wu et al., 2013b). Either the idea that tau 
hyperphosphorylation leads to toxicity is wrong, or it is incomplete. It is possible 
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Sites only 
phosphorylated 
in AD brain  
Sites 
phosphorylated in 
AD and control 
brains 
Sites only 
phosphorylated 
in non-AD 
brain  
Putative sites 
without evidence 
for 
phosphorylation 
Y18 S46 T17 T30 
S68 T181 Y29 S61 
T69 S198 T39 T63 
T71 S199 T50 S64 
S113 S202 T52 T76 
T123 T205 S56 S129 
T153 T212 T95 S137 
T175 T217 T101 Y310 
T184 T231 T102 T319 
S185 S235 T111 T377 
S191 S396 S131   
Y197 S400 T135   
S208 S404 T149   
S210 S412 T169   
S214 S413 S195   
S237 S416 T220   
S238   S241   
S258   T245   
S262   T263   
S289   S285   
S356   S293   
Y394   S305   
T403   S316   
S409   S320   
S422   S324   
T427   S341   
S433   S352   
S435   T361   
    T373   
    T386   
    T414   
Table 1.2 A summary of the phosphorylation sites on human 2N4R tau 
Of the 85 known or putative sites of phosphorylation on the largest human brain tau 
isoform, 44 have been found to be phosphorylated in AD brains; 16 of these are also 
known to undergo phosphorylation in the healthy brain. 31 sites are known to be 
phosphorylated only in healthy brain. Evidence of phosphorylation at the final 10 
sites has not been found (Martin et al., 2013). Yellow: sites contained within the N-
terminal inserts of exons 2 and 3. Blue: sites contained within the P-rich region of 
exons 7 and 9. Red: sites contained within the microtubule-binding region (exons 9, 
10, 11 and 12). The majority of additional phosphorylation in disease occurs within 
the P-rich region; it would appear that there is a reduction in phosphorylation at 
many of the sites of the microtubule-binding domain in AD brain. 
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that the creation of such extensively mutated tau was jumping the gun to an extent, 
based on insufficient knowledge of tau phosphorylation dynamics. Smaller-scale 
phospho-mutation experiments point to greater complexity, and a possible link 
between phospho-residue location and role. In vitro experiments investigating the 
microtubule-binding dynamics of tau identify different key residues compared with 
experiments into tau aggregation dynamics (Chang et al., 2011; Kiris et al., 2011; 
Necula and Kuret, 2004); in each case however, changes in the phosphorylation state 
of tau are highly relevant. The cumulative effects of such mutations also appear to be 
unpredictable, both on microtubule dynamics and toxicity (Alonso et al., 2010; Kiris 
et al., 2011), perhaps explaining the surprising results of the highly-mutated forms of 
tau. This particular theory clearly requires further investigation. 
 
1.4.2 Cytoskeletal disruption in tauopathy 
A great deal of research into tau neglects to consider the normal, healthy 
physiological role of tau as a modulator of the microtubule cytoskeleton. In the case 
of animal models making use of human tau overexpression, this is justifiable, 
especially given the apparent at least partial dispensability of the protein in mice and 
the fly (Dawson et al., 2001; Doerflinger et al., 2003). However, the fact remains that 
cytoskeletal disruption is a feature of AD-affected neurons (Cash et al., 2003). That 
hyperphosphorylated tau should lose its ability to bind microtubules has long been 
established in vitro (Grundke-Iqbal et al., 1986); this has also been demonstrated in 
cells (Lovestone et al., 1996). More recently, Drosophila melanogaster has been 
used to effectively demonstrate cytoskeletal disruption in vivo. Overexpression of 
human 0N3R tau in Drosophila was shown to lead to a phosphorylation-dependent 
loss of microtubule stability, with a decidedly sparse microtubule cytoskeleton in 
transverse sections of larval neurons (Cowan et al., 2010). That this should be caused 
by overexpression of transgenic tau was explained by the demonstration of resultant 
impaired microtubule binding by native Drosophila tau. Conflicting evidence, 
indicating a complete lack of effect of human tau on native tau binding in the fly, and 
zero affinity of human tau for Drosophila microtubules, does exist (Feuillette et al., 
2010). However, a subsequent demonstration of the link between microtubule 
disruption and neuronal toxicity as measured by locomotor disruption by Quraishe 
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and colleagues (2013) is very compelling evidence for the importance of axonal 
transport in this model. The microtubule-stabilising agent davunetide was shown to 
rescue the locomotor phenotype caused by expression of human 0N3R tau in fly 
larvae, without any effect on tau phosphorylation or the sequestration of native tau 
by the transgenic. The drug was shown to stabilise microtubules in presence of both 
0N3R and 0N4R tau. 
It would appear that in transgenic animal models hyperphosphorylated human tau 
exhibits a gain of toxic function, by which it sequesters native tau and disrupts the 
microtubule cytoskeleton. The hurdle for this hypothesis as it has been established in 
the fly is the apparent irrelevance of Drosophila tau to human tau toxicity in the fly 
eye – removal of native tau has no effect on the phenotype created by overexpression 
of human tau (Feuillette et al., 2010). It is still possible that hyperphosphorylated tau 
is affecting axonal transport in this model, by binding other MAPs or perhaps some 
entirely separate mechanism of microtubule destabilisation. Alternatively, tissue-
specific differences in the nature of tau toxicity are possible. Regardless, such a gain 
of function has important implications for the role of tau aggregates in the toxic 
process. 
 
1.4.3 The role of aggregation in tau toxicity 
For most of the history of research into AD, the neurotoxic agents of the disease 
were assumed to be the accumulated, aggregated amyloid plaques and/or NFTs. In 
the case of NFTs in particular, their presence correlates well with disease 
progression, as does the total plaque burden. More recently however, this assumption 
has been challenged from multiple sides, with arguments that toxicity due to 
insoluble, large aggregates is less likely than from soluble rogue protein. In the case 
of Aβ, an early plaque-directed vaccine, abandoned due to excessive inflammation  
(Birmingham and Frantz, 2002), was later shown to have caused an increase in 
soluble Aβ. This was likely from disrupted plaques and potentially a cause of the 
encountered toxic side-effects (Lee et al., 2006; Patton et al., 2006). Neuronal 
impairment in animal models has been found to pre-date the appearance of plaques 
(Lesne et al., 2006), and to be entirely independent of tangle formation (Wittmann et 
al., 2001). The idea that insoluble aggregates may be less relevant to 
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neurodegenerative disease, or even potentially have a protective function, has thus 
gained traction (Cowan and Mudher, 2013; Spires-Jones et al., 2011). This does of 
course have profound implications for any putative amyloid or tau-focused treatment 
strategies, emphasising all the more the importance of early diagnosis and 
intervention. In the case of tau specifically, the conventional wisdom regarding the 
toxicity of NFTs has come under growing scrutiny. A large body of evidence now 
exists to support the idea that NFTs are evidence of a pathological process, rather 
than the cause of one. 
The rationale which places NFTs at the centre of tauopathy is easily understood: 
NFTs are present at the scene of the crime, and their distribution correlates strongly 
with disease progression. In the murine P301L tau model, regarded as the animal 
model which most closely mimics human disease, NFTs form alongside the onset of 
cell death and motor dysfunction (Gotz et al., 2001). The difficulty here though is 
that, in all cases in which fibrillar tau aggregates are measured, smaller intermediate 
tau oligomers will always be present and therefore cannot be ruled out as the source 
of toxicity; it is therefore likely too simplistic to discuss tau aggregation only in 
terms of monomeric tau and NFTs. Tau aggregation has been shown to lead to a large 
number of species of tau, of varying sizes, some of which may be intermediate forms 
of larger aggregates. As well as the dimers and PHFs mentioned earlier, a variety of 
small or large, soluble or insoluble, granular or filamentous oligomers have been 
discovered. Some of these are specific to certain tauopathies; others have been 
identified in animal models. For a more in-depth discussion of the variety of tau 
oligomers, see Cowan and Mudher (2013). In general, soluble tau oligomers are 
more often associated with toxicity than any insoluble oligomers in animal models in 
which they are sought, and in all cases smaller oligomers are more capable of 
leading to toxicity, or indeed cell-to-cell transmission of tau pathology as described 
earlier (Wu et al., 2013a). As an example of the way in which these ideas have 
changed, expression of the tau repeat domain (TauRD) with a pro-aggregant FTDP-17 
tau mutation (ΔK280) was found to be rendered less toxic by the addition of anti-
aggregant proline mutations, which also prevented the rapid tangle formation 
witnessed in the pro-aggregant construct (Mocanu et al., 2008). Subsequently, this 
model was found to recover cognitive deficits once TauRD expression had been 
turned off, despite persistence of pre-formed aggregates (Sydow et al., 2011): 
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expression of pro-aggregant tau was the determining factor of toxicity, rather than 
the presence of large fibrillar aggregates themselves. It is likely that some smaller 
intermediate tau oligomer was the source of neurodegeneration. This is also not the 
only example of tau toxicity being rescued without removal of tangles (Santacruz et 
al., 2005), and in the fly aggregation can be promoted by suppression of tau toxicity 
(Cowan and Mudher, 2013). These data speak to the gain-of-function hypothesis 
discussed in the previous section, as smaller or more soluble species are more likely 
to interact with and disrupt other cellular processes, potentially by sequestering 
functional tau species. They have also led to a controversial hypothesis regarding the 
role of NFTs, that they may in fact form as part of a protective response which 
attempts to reduce soluble protein levels following tau dysfunction, one which is 
doomed to fail as tau accumulation eventually causes a breakdown in transport and 
protein degradation (Spires-Jones et al., 2011). Given the apparent increased toxicity 
of certain tau oligomers, the alternative answer is that NFTs and insoluble aggregates 
are effectively toxicity neutral, and form as a by-product of toxic aggregation 
processes. 
One factor that unites most theories on the process by which tau leads to toxicity is 
phosphorylation. This is true when studying the biochemical mechanics of tau 
aggregation (Iqbal et al., 2013) or microtubule binding (Fischer et al., 2009), just as 
it is in post-mortem examination of brains of tauopathy sufferers. This has led to 
multiple attempts to characterise the causes of changes to the phosphorylation 
balance of tau, the majority of which have focused on tau kinases. In the next 
section, the importance of tau kinases in toxicity is considered, with particular 
attention paid to GSK-3β and the AMPK-related kinases. 
 
1.5 Tau kinases and disease 
Developmental studies in rats have demonstrated the normal progression of tau 
phosphorylation levels, which is much higher in developing brain in these animals 
and coincident with increases in activity in a large number of tau kinases (Yu et al., 
2009). This recalls the early demonstration of the hyperphosphorylated status of 
human foetal tau (Goedert et al., 1993). Is it possible that the increase in tau 
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phosphorylation in the brains of sufferers of tauopathy is due to similar regulation of 
kinase activity? No genetic evidence has been found as yet, but a number of tau 
kinases are known to be enriched or over-activated in the AD brain, and to co-
localise with tangles (Jin and Saitoh, 1995; Martin et al., 2013). Given the emerging 
likelihood of site-specific differences between phospho-residues, the target sites of 
some of these kinases have been examined, though usually in vitro (Liu et al., 2007; 
Yoshida and Goedert, 2011). In this section some of the major tau kinases are 
discussed in more detail. 
 
1.5.1 GSK-3β 
GSK-3β is perhaps the most widely-studied of the tau kinases. Originally isolated in 
rabbit skeletal muscle as a Ca2+-independent, highly specific kinase of glycogen 
synthase (Embi et al., 1980), GSK-3 was first associated with tau phosphorylation in 
1992 as part of a search for possible proline-directed kinases of tau (Mandelkow et 
al., 1992). There are two GSK-3 genes in humans, encoding two isoforms, α and β 
(Woodgett, 1990). Both were thought to have similar target sites on tau (Mandelkow 
et al., 1992), but research began to privilege GSK-3β following the demonstration of 
its enrichment in the AD brain and co-localisation with NFTs (Leroy et al., 2002; Pei 
et al., 1999). Some differences in substrate preference between the two isoforms 
have also been recorded (Soutar et al., 2010). The ability of GSK-3β to cause 
functional changes in tau was demonstrated in cells, in which tau phosphorylated by 
GSK-3β was shown to lose its ability to bind and stabilise microtubules (Lovestone 
et al., 1996). Today, GSK-3β is widely held to be a key player in tau-induced 
toxicity, particularly in AD where it is a prime candidate for the link between 
amyloid and tau pathology (Hernández et al., 2010; Muyllaert et al., 2008); this has 
been proposed to occur via either insulin or wnt signalling, both pathways which 
regulate GSK-3β and with which Aβ is thought to interfere. 
One useful characteristic of GSK-3β is its inhibition by lithium ions(Davies et al., 
2000; Stambolic et al., 1996), known to function via activation of the GSK-3β-
regulating wnt pathway; this was very rapidly used to identify GSK-3-induced tau 
phosphorylation in cultured neurons (Hong et al., 1997). The pre-eminence of GSK-
3β as a controller of tau phosphorylation-induced toxicity has led to a good deal of 
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interest in the kinase as a therapeutic target (Noh et al., 2013), and is likely the most 
hopeful candidate for tau phosphorylation-focused AD treatment. 
 
1.5.2 AMPK-related kinases 
AMP-activated protein kinase (AMPK) is a key enzyme of energy homeostasis, 
originally identified as a regulator of lipid metabolism (Hardie et al., 1989). Named 
for its potent allosteric activation by adenosine monophosphate or AMP (Ferrer et 
al., 1985), it was later found to be a highly sensitive monitor of the cellular 
AMP:ATP (adenosine triphosphate) ratio. AMPK is a heterotrimer composed of a 
catalytic α subunit with kinase function, a regulatory γ subunit (sensitive to increases 
in the aforementioned AMP:ATP ratio) and a connective β subunit (Carling, 2004; 
Hardie et al., 2003). Two isoforms of the α activatory subunit have been identified, 
along with two β and three γ variants.  AMPK was found to belong to a subfamily 
containing 12 other kinases with closely related protein kinase domains (Manning et 
al., 2002), of which all bar one were found to be regulated by the tumour suppressor 
liver kinase B1, or LKB1 (Lizcano et al., 2004). Expansion of this family later added 
one other LKB1-activated kinase, bringing the total number to 14 including both 
AMPKα isoforms (Alessi et al., 2006), Along with eight LKB1-independent 
members. Figure 1.4 illustrates the protein taxonomy of the kinase domain of this 
subfamily. 
The first AMPK-related kinase to be identified as a tau kinase was the 
microtubule/MAP-affinity regulating kinase (MARK), which was shown to 
phosphorylate tau at S262 and S356 (Drewes et al., 1995; Jenkins and Johnson, 
2000). MARK exhibits high specificity for the KXGS motifs of the microtubule- 
binding domains rather than proline-directed sites, and MARK4 in particular is more 
prevalent in the brain, where it colocalises with microtubules, particularly in neurites 
where microtubule dynamics are the most fluid (Drewes, 2004). It is thus highly 
likely that all four MARKs play a significant role in the healthy regulation of 
tau/microtubule binding (Gu et al., 2013), and indeed MARK2 has been shown in an 
in vitro model to upregulate neurite outgrowth in a tau-dependent manner (Biernat et 
al., 2002). The Drosophila homologue, PAR-1 also regulates microtubule stability, 
with PAR-1 mutants exhibiting reduced microtubule stability and defects in follicle 
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cell polarity (Doerflinger et al., 2003). Unlike in mammalian cells, this influence on 
microtubule dynamics was shown to be independent of the presence of Drosophila 
tau (dtau); despite being a substrate for PAR-1, dtau was shown to not be 
phosphorylated at KXGS motifs by the endogenous kinase, and loss of dtau in no 
way recapitulated the phenotype of PAR-1 mutants.  
More recently, AMPK has itself been shown to phosphorylate tau. It was found to be 
another target of the kinase cascade elicited by Aβ exposure in cultured primary 
neurons, activated by Ca2+/calmodulin-dependent protein kinase kinase β (CaMKKβ) 
and phosphorylating tau at KXGS motifs (Thornton et al., 2011). That AMPK is also 
activated by antidiabetic drugs, including metformin (Zhou et al., 2001) provides a 
link between treatment for diabetes and tau phosphorylation. This closely-related 
kinase subfamily is thus of great interest to the study of tau phosphorylation in 
disease, with increasing effort being made to characterise these enzymes (Yoshida 
and Goedert, 2011). Other candidate kinases from this family include the BRSKs 
(brain-selective kinases). 
 
1.5.3 BRSK2 is a brain-specific tau kinase 
Originally identified as part of a screen for regulators of synaptic development in 
Caenorrhabditis elegans, sad-1 (synapses of the amphid defective-1) was implicated 
in the establishment of neuronal polarity by mislocation of synaptic vesicles in 
mutants and sequence homology with par-1 (Crump et al., 2001). SAD-1 was also 
shown to be primarily localised to synaptic regions of the axon. There are two 
mammalian homologs, SAD-A and SAD-B, also known respectively as BRSK2 and 
BRSK1 which is a nomenclature more in keeping with the AMPK-related subfamily. 
The two mammalian kinases were shown to be redundant, but essential – loss of 
either kinase individually had no effect, but loss of both was shown to be lethal 
(Kishi et al., 2005). BRSK double mutants died shortly after birth, and exhibited 
abnormal development of the central nervous system with a smaller forebrain and 
disruption of the organisation of cortical sublayers. Loss of neuronal polarity was 
also a hallmark – failure of axonal growth and targeting was widespread, dendrites 
were elongated and tau localisation to the axon had failed. BRSKs were shown to be 
tau kinases, likely controlling neuronal polarity via regulation of tau-microtubule 
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binding as S262 was shown to be a target site of BRSK2. Later investigation of 
BRSK activity showed BRSK2 to be more effective at regulating tau-microtubule 
binding than BRSK1, though still not as potently as MARK1 (Yoshida and Goedert, 
2011); this could indicate a separate role for the BRSKs beside regulation of the 
microtubule cytoskeleton. The proline-directed site T212 was also revealed as a 
target phosphorylation site for the BRSKs. In common with many of the AMPK-
related kinases, BRSK activation is known to require LKB1. Unlike AMPK, 
however, BRSKs are not phosphorylated by CaMKKβ (Bright et al., 2008); they are 
however targets for CaMKKα at T189, equivalent to the T172 activation site on 
AMPK (Fujimoto et al., 2008). Another upstream kinase of BRSK2 is the cyclic 
AMP-dependent protein kinase A (PKA), via an alternative target site on BRSK, 
T260 (Guo et al., 2006). The discrepancy between BRSK1 and BRSK2 in terms of 
tau phosphorylation potency found by Yoshida and Goedert (2011) could also 
potentially be explained by alternative methods of activation – for example, BRSK1 
activity is boosted by association with lipid rafts, unlike BRSK2 (Rodríguez-Asiain 
et al., 2011). A dependency on the lipid environment could indicate some association 
of BRSK activity with energy metabolism, potentially in a similar manner to AMPK: 
BRSK2 has been shown to suppress insulin secretion by pancreatic β cells via 
PCTAIRE1, related to cyclin-dependent kinase (Chen et al., 2012). Yet another 
potential function of human BRSK is as a checkpoint kinase – UV-induced DNA 
damage has been shown to increase BRSK activity, leading to cell cycle arrest (Lu et 
al., 2004). 
The importance of the BRSKs to correct tau-mediated neuronal polarisation, acting 
via tau phosphorylation as shown by Kishi et al. (2005), was the motivation behind 
the decision made by the Moffat and Frenguelli labs in 2008 to begin investigating 
the BRSKs as sources of pathogenic tau phosphorylation.  Subsequently, additional 
evidence accumulated, improving the BRSKs’ prospects as pathologically-relevant 
kinases. The identification of CaMKKα as an upstream kinase of the BRSKs 
provided a link to calcium metabolism. The BRSKs were even shown to be 
upregulated in cultured differentiated primary hippocampal neurons following 
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Figure 1.4 The AMPK-related protein kinase family 
The phylogeny of AMPK-related protein kinases. Shaded in blue are kinases not 
activated by LKB1. Known tau kinases are shaded in red. Adapted from Alessi et al. 
(2006) 
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exposure to Aβ oligomers, alongside an increase in tau phosphorylation, Ca2+ levels 
and microtubule disruption (Zempel et al., 2010). The association of BRSK2 in 
particular with tau phosphorylation at two important sites (T212 and S262) by 
Yoshida and Goedert (2011) raised interesting questions regarding the consequences 
of BRSK-induced phosphorylation of tau, affecting as it does a proline-directed, 
aggregation-inducing site in the P-rich region as well as a KXGS motif associated 
with microtubule dissociation. In sum,  BRSK2 is found in the right place to induce 
tau phosphorylation, its activity is induced by multiple processes associated with 
AD, and it targets sites on tau believed to be relevant to tau pathology, making it a 
promising candidate kinase as a cause of pathogenic tau phosphorylation. 
 
1.6 Tau-directed therapies for Alzheimer’s disease 
The search for disease-modifying treatments for AD has led to a number of 
promising drug targets. Attempts to develop tau-centric disease therapies have seen 
increasingly promising results over recent years, in part due to an increase in 
understanding of the mechanisms of tau dysfunction and renewed interest in tau in 
the context of disease. Avenues of investigation include immunotherapy-based 
approaches, as have previously been examined for removal of Aβ. In addition, 
multiple novel targets have been suggested due to this MAP’s supposed disease 
pathways. Microtubule stabilising agents to combat tau loss-of-function, tau 
aggregation inhibitors to prevent the assembly of toxic oligomers and modifiers of 
tau post-translational modification are all under investigation. 
 
1.6.1 Immunotherapy approaches 
Immunotherapy has long been considered as a means of Aβ clearance and potentially 
disease protection, owing to the extracellular localisation of amyloid plaques 
(Lemere and Masliah, 2010; Schenk et al., 1999). More recently, the emergence of 
the prion hypothesis of tau propagation has increased interest in anti-tau 
immunotherapies (Golde et al., 2013); the ability of tau to spread between cells 
strongly suggests an essential extracellular step in tauopathy progression (Frost et al., 
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2009). In addition, the potential for neuronal uptake of antibodies (Mohamed et al., 
2002) creates the possibility of some intracellular protection against tau toxicity. 
Given the ability of Aβ immunotherapy to reduce plaque burden whilst failing to 
reduce cognitive deficit, or NFT load (Holmes et al., 2008), perhaps tau-directed 
immunotherapy or even a dual Aβ/tau approach would better combat progression of 
AD.  
An early investigation into the consequences of anti-tau immunisation showed its 
potential for neurotoxicity: C57BL/6 mice immunised to whole tau protein 
developed Alzheimer-like histopathological features, axonal damage and behavioural 
deficits (Rosenmann et al., 2006). This parity between the effects of tau auto-
immunity and over-expression implied a role for an anti-tau inflammatory response 
in the progression of tauopathies, and did not augur well for anti-tau immunotherapy. 
It is however important to note that this experiment made use of whole recombinant 
human tau, and as a result did not exploit a major strength of antibody therapies for 
protein disorders: specificity for the toxic protein conformations (Boimel et al., 
2010). Immunisation of mice expressing recombinant mutant P301L/S tau (FTDP-17 
P301 mutations) with a number of phospho-tau peptides led to a reduction in tau 
aggregates with no negative consequences due to inflammation (Asuni et al., 2007; 
Boimel et al., 2010). The study reported by Asuni et al. (2007) also indicated some 
improvement in a number of behavioural tasks.  Evidence has accumulated over the 
past five years for the ability of anti-phospho-tau antibodies to mitigate tau toxicity 
in animal models, including removal of tau aggregates and reversal of behavioural 
and memory deficits; see Gu and Sigurdsson (2011) for a review of many of these. A 
recent study has found a correlation between the ability of anti-tau antibodies to 
prevent seeding in vitro and their ability to decrease pathology in vivo, again in the 
P301S tau mouse model (Yanamandra et al., 2013). Three monoclonal tau antibodies 
were tested, using a bespoke biosensor system, for their ability to prevent seeding of 
tau repeat domain aggregation in cells exposed to brain lysates from 12-month-old 
P301S tau mice. The antibody most effective at preventing this seeding was also 
found to most effectively reduce phospho-tau levels, the seeding abilities of brain 
lysates of treated animals and associative learning deficits in P301S tau mice. This 
suggests that anti-tau immunotherapy could be highly effective at preventing 
transmission of toxic tau between cells, as is hypothesised by the prion-like model of 
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AD (Clavaguera et al., 2013b). This is unsurprising, given the largely extracellular 
location of these antibodies following treatment.  
Unlike for Aβ, there have yet to be any human trials using anti-tau immunotherapies. 
Given the disappointing results of the amyloid-focused clinical trials, it is possible 
that similar tau-focused therapies may also encounter problems involving 
inflammation or a lack of symptomatic efficacy. It has been speculated that the 
nature of the trials themselves may have obscured the greatest potential use of AD 
immunotherapies: as preventative measures (Golde et al., 2011). Clinical trials are 
conducted using patients already presenting with the major symptoms of AD, at 
disease stages which may be too far progressed for immunotherapy to be of best use. 
This could also explain the apparent risk of meningoencephalitis in certain trials 
(Lemere and Masliah, 2010). 
 
1.6.2 Tau aggregation inhibitors 
The nature of tau dysfunction presents several other tau-specific therapeutic targets. 
Although there may be some dispute over exactly which form of tau aggregate is the 
most toxic, there is generally a degree of consensus regarding the potential of tau 
aggregation to be detrimental. Thus, various tau aggregation inhibitors (TAI) have 
been examined as potential therapeutic candidates. One very well characterised anti-
aggregant drug is the phenothiazine methylene blue (MB), an extremely well-
categorised drug originally identified as an anti-malarial medication (Wainwright and 
Amaral, 2005). The discovery that MB can also act as a potent TAI (Wischik et al., 
1996) has led to the development of a number of MB-based compounds, taking 
advantage of its already established safety (Bulic et al., 2013). One MB derivative in 
particular, Rember, has already passed phase 2 clinical trials. Developed by TauRx, a 
company established by members of the lab which first discovered MB’s TAI 
properties, Rember was found to significantly reduce the rate of cognitive decline in 
a trial of 321 patients with mild-to-moderate AD (Bulic et al., 2013).  
Aggregation inhibitors have more often been investigated in the context of Aβ and 
plaque prevention. One notable example is that of tramiprosate, a soluble amyloid-
binding glycosaminoglycan mimetic. This drug successfully cleared phase 2 clinical 
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trials before being cancelled following a lack of efficacy in phase 3. One hypothesis 
for this failure is particularly intriguing: it has been shown to increase the 
aggregation of tau (Santa-Maria et al., 2007). Perhaps here again, multidrug 
therapies could prove particularly effective. A great many Aβ-focused drugs are 
currently undergoing trials (Anand et al., 2014), aimed at a number of different 
targets. Aggregation inhibitors are something of a special case however:  given the 
mechanistic overlaps between protein aggregation disorders these trials could also 
give rise to novel TAIs (Bulic et al., 2013). Indeed, the case of tramiprosate suggests 
they could well be an essential part of any successful future treatment. 
 
1.6.3 Microtubule-stabilising agents 
One obvious avenue of research is to ensure the maintenance of correct tau function 
in the face of disease by stabilising microtubules. The microtubule-stabilising agent 
paclitaxel (sold as Taxol) has already been used as a standard cell cycle-blocking 
treatment for some cancers, particularly breast cancer, where it has also 
demonstrated the negative consequences of excessive microtubule stabilisation in the 
form of peripheral neuropathies (Mielke et al., 2006). This is thought to be due to the 
increased density of microtubules, as well as to a loss of normal MT polarity as MTs 
are stabilised across their entirety (Baas and Ahmad, 2013). An alternative and rather 
counter-intuitive option more suited to neurons could be the use of low levels of 
microtubule destabilising agents, such as nocodazole. At very low levels, these drugs 
effectively promote microtubule stability by preventing excessive growth and, 
consequently, catastrophe. In short, if dosed correctly nocodazole can be used to 
create an equilibrium between rates of tubulin dimer loss and addition, constituting a 
less-invasive method of MT “kinetic stabilisation” (Baas and Ahmad, 2013). 
A major issue with the use of paclitaxel is its low blood-brain barrier penetrance, 
hence the PNS side-effects. A related drug, epothilone D (EpoD) has been shown to 
cross the BBB effectively, and to accumulate in brain tissues (Andrieux et al., 2006; 
Brunden et al., 2010), potentially reducing the risk of PNS damage. EpoD has 
already been used to treat P301S tau mice, where it has been shown to rescue MT 
density (Brunden et al., 2010). EpoD was not found to be toxic at the very low 
concentrations (0.3 mg/kg) required for noticeable improvements to MT 
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stabilisation, axonal damage and cognitive function in aged mice (Zhang et al., 
2012). EpoD was also capable of reducing tau pathology, with a reduction in 
hyperphosphorylated tau and insoluble tau staining recorded. The exact mechanism 
responsible for this is unclear, though it has been speculated that fast axonal 
transport may be improved by the use of paclitaxel and related compounds, a process 
which has previously been shown to be linked to tau phosphorylation levels (Zhang 
et al., 2012).  
An alternative non-paclitaxel-related MT-stabilising agent, with high BBB 
permeability and low toxicity, is the octapeptide NAPVSIPQ (NAP), the smallest 
active element of activity-dependent neuroprotective protein (Gozes et al., 2004). Its 
mechanism of action was determined to be via interaction with the brain-specific βIII 
tubulin subunit; this was competitively inhibited by paclitaxel (Divinski et al., 2006). 
NAP has been shown to reduce tau and even amyloid pathology and to enhance 
cognitive function in rodent tauopathy models (Matsuoka et al., 2007; Shiryaev et 
al., 2009). A study in Drosophila demonstrated the ability of NAP to reduce the 
symptom of tauopathy via MT stabilising specifically, though found no reduction in 
levels of tau hyperphosphorylation (Quraishe et al., 2013). This arguably provides 
further evidence for the idea that alternative, slower-acting mechanisms were the 
cause of the reduction in tau pathology found in older mice when treated with EpoD, 
as detailed above. 
The search for brain-specific microtubule-stabilising treatments for tauopathy has yet 
to progress to clinical trials, but this laboratory evidence is compelling. However, 
given the comparable early pre-clinical success of TAIs, it will likely still be some 
time before we know whether MT-focused treatments could be of use in AD. 
 
1.6.4 Modifiers of tau phosphorylation 
In each of these successful attempts to reduce tau toxicity in the long term, a 
reduction in levels of hyperphosphrylated tau was also recorded. Attempts to reduce 
tau hyperphosphorylation directly via modulation of tau kinases and phosphatases 
constitute the other major group of tau-targeted drug hopefuls. 
As has previously been mentioned, GSK-3β is considered the tau kinase most likely 
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to play a role in pathogenic phosphorylation in AD, particularly due to its potential to 
link tau and Aβ dysfunction (Takashima et al., 1996). Thus far, the only tau kinase 
inhibitors to have been tested in clinical trials have all targeted this kinase, due to the 
relatively superior specificity of GSK-3β inhibitors compared with other putative 
target kinases such as CDK5 or MAPK (Yoshiyama et al., 2013). Lithium has been 
the subject of multiple trials; those conducted for AD failed to show any effect on 
GSK-3β activity or disease progression in the short term (Hampel et al., 2009).  
More positive results for the feasibility of lithium-based treatments came from a 
study focusing on at-risk individuals, specifically suffering from amnestic mild 
cognitive impairment, a condition believed “to represent the clinical transition 
between the cognitive changes found in normal aging and those of early Alzheimer 
disease” (Petersen et al., 2006). After a year’s treatment, a significant decrease in 
hyperphosphorylated CSF tau was witnessed, alongside improvements in 
performance at AD-classifying cognitive tasks (Forlenza et al., 2011). This suggests, 
once again, that the greatest likelihood of combating AD is via prevention. Another, 
more specific GSK-3β inhibitor is NP12, or tideglusib. Administered to a double-
transgenic APP/tau mouse, this compound was found to be capable of reducing 
phosphorylated tau levels, amyloid plaque deposition, cell death and cognitive 
decline (Serenó et al., 2009). Clinical trials investigating tideglusib have already 
begun (Yoshiyama et al., 2013). 
The alternative route to reduced tau phosphorylation is by upregulation of 
phosphatases, particularly PP2A, known to be compromised in AD. PP2A accounts 
for the majority of phosphatase activity in the human brain (Liu et al., 2005); as a 
result, PP2A over-activation is likely to induce severe side effects and should be 
focused more on compensating for AD-specific lacunae in PP2A regulation. The 
NMDA blocker memantine has also been shown to lead to improved PP2A activity 
(Chohan et al., 2006), for example, perhaps explaining the reduction in tau 
phosphorylation following a year’s treatment (Degerman Gunnarsson et al., 2007). 
 In sum, our current understanding of tau pathology has provided a number of 
promising targets for tau-focused therapies for AD and other tauopathies. A 
consistent theme of the pre-clinical data is the correlation between tau 
phosphorylation and pathology, reinforcing the need for better understanding of the 
means by which phosphorylation might determine toxicity. 
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1.7 Drosophila melanogaster and tau research 
A great deal of biochemical exploration of the regulation and function of tau has 
been performed in vitro, particularly examination of phospho-mutant tau species. In 
order to determine whether the recorded effects of tau phosphorylation sites, on 
microtubule binding or aggregation for example, are relevant to any disease process 
in vivo study in animal models is required. An ideal model for early in vivo 
experimentation is the fruit fly, Drosophila melanogaster. The use of Drosophila as a 
model for neuroscience has become more and more commonplace over the past 15 
years. There is a perhaps surprising level of homology between fly and mammalian 
neural development, learning and memory, perhaps best exemplified by the 
conservation of pathways associated with human learning defects (Guo et al., 2000; 
Schenck et al., 2003). Neurodegenerative conditions studied in the fly include 
Alzheimer’s disease, other tauopathies, and Huntington’s and Parkinson’s diseases 
(Lu and Vogel, 2009).  
 
1.7.1 Drosophila tau 
Research into tau-induced neurodegeneration in the fly began after the identification 
of a putative Drosophila tau homologue in 2001, also named tau and which will 
subsequently be referred to here as dtau (Heidary and Fortini, 2001). Initial cDNA 
prediction was for a 361AA protein, containing five microtubule-binding domain 
repeats. Subsequently a second, 375AA transcript was also predicted, differing only 
in its C-terminus (Doerflinger et al., 2003). The 361AA isoform exhibits 46% 
identity and 66% similarity with the human protein, importantly preserving the four 
KXGS motifs found in four-repeat isoforms of human tau. Two residues known to be 
key mutation sites in FTDP-17, V337 and R406, are missing however, along with the 
aggregation-associated BRSK target site T212 (Figure 1.5). Dtau was shown to bind 
microtubules by binding assay (dtau pellets almost entirely with microtubules), and 
GFP-tagging (Doerflinger et al., 2003). However, this same study also demonstrated 
the dispensability of dtau, both in development and in the adult: no loss in viability 
or change in behaviour was observed in three different mutants with no detectable 
tau expression. It is proposed that some other MAP may have redundancy with dtau. 
41 
 
1.7.2 The fruit fly and human neurodegenerative disease 
An important early paper in the field demonstrated that human tau (htau) 
overexpression in the Drosophila retina was toxic, leading to reduced adult eye size 
and a rough, irregular pattern of the compound eye subunits, or ommatidia (Jackson 
et al., 2002). It also demonstrated exacerbation of this phenotype by the fly 
homologue of GSK-3β, Shaggy (Sgg) – Sgg loss of function ameliorated the 
damage, over-expression worsened the phenotype. This paper also presented 
evidence of filamentous tau aggregates, which were detected with the AT100 
antibody for phosphorylation at residues T212 and S214. Neither of these residues is 
conserved in dtau. Re-confirmation of the ability of htau to form fibrillar aggregates 
in the fly had to wait until 2013 (Wu et al., 2013), although other forms of htau 
aggregates have recently been identified in this model (Ali et al., 2012; Cowan and 
Mudher, 2013). The fly eye has since been used in multiple studies of tau toxicity 
(Ambegaokar and Jackson, 2011; Shulman and Feany, 2003).  
Another Drosophila homologue of a human kinase thought to be associated with tau 
toxicity is PAR-1 (homologous to MARK), which has been shown to phosphorylate 
human tau in Drosophila, also under the control of LKB1 (Iijima-Ando et al., 2010; 
Nishimura et al., 2004; Wang et al., 2007). Both PAR-1 and Sgg have been shown to 
cause some neurodegeneration upon overexpression in wild type Drosophila, with no 
extra expression of tau (Chatterjee et al., 2009); this could be due to interaction with 
dtau. Tau phosphorylation has been shown to strongly influence toxicity in this 
model, via small and large-scale mutation of phosphorylated residues (Iijima-Ando 
et al., 2010; Steinhilb et al., 2007).  
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1.7.3 Drosophila and human BRSK 
The Moffat and Frenguelli laboratories have begun to study the effect of BRSK2 on 
human 0N4R tau in Drosophila, using the fly eye as a model in a similar fashion to 
Jackson et al. (2002). Unpublished data from these experiments by Dr Ceri Lyn-
Adams showed a strong increase in htau-induced neurodegeneration by BRSK2. 
Compared with Sgg or PAR-1 overexpression, there was no change in external eye 
phenotype when expressing BRSK2 alone, indicating a lack of interaction with dtau. 
Unlike other kinases used in Drosophila, the fly BRSK homologue sugar free 
frosting (sff), or CG6114 (Baas et al., 2011) has no effect when overexpressed with 
or without human tau despite retaining important residues, including T189 
(unpublished data). This suggests that there is a lack of downstream conservation of 
this pathway; this could be due to the non-conserved T212 residue in dtau. This 
phenotype has been partially rescued by RNA inhibition of native LKB1 and the 
CaMKKα homologue CG17698. Addition of human CaMKKα is also able to 
compensate for CG17698 suppression, restoring the more severe phenotype. The 
conservation of the regulatory pathway upstream of BRSK makes it a strong 
candidate for the examination of phosphorylation-induced toxicity in this model. 
As a model organism, the fruit fly presents a number of strengths, not limited to its 
cost effectiveness and ease of rearing relative to mammalian models or cell culture. 
The Drosophila genetic toolbox allows for in-depth control of transgene insertion 
and expression. The existence of both spatial and temporal methods of expression 
control, in the form of the GAL4-UAS system and modifications such as the 
TARGET temperature-sensitive repression system and drug-inducible promoters 
including GeneSwitch, enables single transgenes to be tested under a variety of 
conditions.  The rapid reproductive cycle of the fruit fly facilitates screening of large 
numbers of mutant phenotypes, which has been exploited in the creation of extensive 
libraries of deficiency mutants. The Moffat and Frenguelli laboratories have 
exploited the flexibility of this model for several years, examining human tau/BRSK 
interactions in the fly eye. This thesis describes attempts to improve on this work, 
testing these interactions in a post-developmental, CNS context, as well as a 
deficiency screen for other elements of the tau/BRSK pathway. The major part of 
this project has been exploiting Drosophila as a first step in translating in vitro work 
to an in vivo setting. Use of site-specific integration in the fly (Groth et al., 2004), as 
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well as the transgene injection services available to Drosophila biologists, enables 
efficient generation of novel mutant libraries of comparable expression levels. In this 
thesis, the establishment of such a mutant library is described for the investigation, 
via site-specific mutation, of phosphorylation sites on tau believed to be relevant to 
disease. A wide range of genetic tools are used to examine the toxicity of human tau 
and BRSK across multiple tissues, in both developing and adult flies.  
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Figure 1.5 Human and Drosophila tau 
Comparison of the longest human tau isoform (2N4R) with the larger of the two 
Drosophila tau isoforms. Conserved residues include T231 and the KXGS motifs. 
The BRSK2 target site T212 and multiple FTDP-17-related mutations sites are not 
conserved. 
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1.8 Aims of this thesis 
The relationship between tau toxicity and phosphorylation is the subject of some 
controversy, after attempts to create generic hyperphosphorylated or 
hypophosphorylated tau species by mutation brought the hypothesis into question 
(Chatterjee et al., 2009). The use of S11A tau, containing 11 serine to alanine 
mutations, suggested that excessive microtubule binding of hypophosphorylated tau 
was also a cause of tau toxicity. This has led to speculation that there could be a 
disconnect between tau phosphorylation and toxicity. In addition to this, in vitro 
studies of individual tau phospho-mutations suggest a more complicated 
phosphorylation code, with individual sites playing distinct roles (Alonso et al., 
2010; Chang et al., 2011; Kiris et al., 2011). This thesis aims to demonstrate the 
relative importance of these sites to toxicity, using Drosophila as a model, enabling 
the rapid generation and analysis of a library of tau phospho-mutants. In addition, 
this thesis seeks to expand on previous work examining the potential of human 
BRSK2 as a tau kinase, using multiple tau isoforms and a deficiency screen. 
1. To generate a library of human 2N4R tau phospho-mutants in order to 
determine the relative toxicity of residues associated with tau aggregation and 
microtubule binding 
2. To use such a library to dissect the importance of phosphorylation to BRSK2-
enhanced tau toxicity 
3. To develop novel, high-throughput models of tau toxicity in the Drosophila 
central nervous system 
4. To expand knowledge of the pathways regulating human BRSK2 in the fly, 
via a deficiency screen of the fruit fly genome 
 
 
  
46 
 
2| Materials and Methods 
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All chemicals and reagents were supplied by Sigma Aldrich, UK, unless otherwise 
stated. 
 
2.1 Drosophila husbandry 
2.1.1 Drosophila stock maintenance 
Drosophila stocks were held at 25ºC, 23ºC or 18ºC in bottles or vials containing 
Sussex fly food (518g corn meal, 471g sucrose, 93g yeast, 28g agar boiled in 5L 
water, 75ml 10% w/v Nipagen M antifungal added when cool, supplemented with 
live yeast). 
2.1.2 Drosophila stocks used 
Genotypes and strain labels of stocks used are presented in Appendix 1. Expression 
of transgenes used the GAL4-UAS expression system, with eye-specific, PDF 
neuron-specific or pan-neuronal drivers, respectively, GMR (glass multimer 
reporter), PDF (pigment dispersing factor) and ELAV (embryonic lethal, abnormal 
vision). 
 
2.2 Deficiency screen 
2.2.1 Deficiency kits used 
The Bloomington deficiency kits for chromosomes 2 and 3 were acquired from the 
Bloomington Drosophila stock centre (BDSC), consisting of 147 and 179 lines, 
respectively of Drosophila hemizygous for defined chromosomal deletions. 
Secondary screening used RNAi lines from the Vienna Drosophila RNAi Centre 
(VDRC). 
2.2.2 Deficiency crosses 
Deficiency lines were crossed at 23ºC with GMR; tau,B2WT5 (human BRSK2 wild 
type line 5) virgins and the phenotypes of the progeny compared under light 
microscope for initial screening.  
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2.3 High resolution imaging and analysis of eye phenotypes 
2.3.1 Paraformaldehyde fixation and dehydration 
Female flies were fixed in 4% w/v paraformaldehyde (PFA) in phosphate-buffered 
saline (PBS) at 4ºC overnight, before undergoing dehydration using a series of 
acetone washes in 30%, 50%, 70% and 90% at room temperature, 20 minutes per 
cycle. Flies were then kept in 100% acetone at 4ºC for at least 2 days.  
2.3.2 Scanning electron microscopy 
Eye phenotypes caused by GMR-driven expression of transgenes were imaged using 
scanning electron microscopy (SEM). Dehydrated flies were attached to metal stubs 
with double-sided tape and kept on silica gel until imaging. Prior to imaging, flies 
were coated in gold by a sputter coater, with two coats lasting 60 seconds at 1.5kV, 
20 mA. The microscope used was a Zeiss Supra55 VP SEM, magnified 150X. 
2.3.3 Analysis of eye phenotypes 
High resolution SEM images of fly eyes were analysed using the Quantitative Edge 
Detection (QED) software for MatLab developed in collaboration with Mr Quentin 
Caudron and Dr John Aston (Caudron et al., 2013). 
QED generates edge sets from greyscale .tif images based on differences in contrast 
around ommatidia. Manual input is required to optimise the edge set, by tracing the 
eye outline, and then defining the Gaussian kernel width (determines the expected 
size in pixels of any edges) and the Sobel threshold (determines the minimum 
contrast shift over any edges), to make it as accurate a representation as possible of 
the eye structure (Figure 2.1).  QED measures three different parameters for each 
image. These are ommatidial roundness (a measure of regularity of ommatidial 
shape), and inter-ommatidial distances and angles (based on the regular hexagonal 
packing of healthy eyes). Neurodegeneration leads to disruption of ommatidial 
structure and regularity, and QED measures the level of disruption by generating an 
“ommatidial distortion coefficient” (DC) for each image, reflecting the increase in 
variation in the chosen parameters. Roundness was used as the measure in each case 
as it tests the entire area of the image selected, rather than the centremost seven 
ommatidia alone. 
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Figure 2.1 QED performs multiple operations to generate ommatidial edge sets 
Examples of edge set generation by QED, in both a relatively normal GMR eye (a) 
and an eye disrupted by expression of 2N4R tau (f). QED initially defines edges by 
width and luminosity using Marr-Hildreth (b and g) and Sobel algorithms (c and h). 
The program then attempts to account for the curvature of the eye by perspective 
transformation, stretching out the edges of the eye (d and i). QED uses this to 
generate a final edgeset, within which it identifies all complete ommatidia and their 
centres (e and j). 
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Origin7 was used for cumulative plots of DCs. Comparisons between populations’ 
DCs were performed using the Mann-Whitney U test 
 
2.4 Analysis of Drosophila activity 
2.4.1 The Drosophila Activity Monitor 
The Trikinetics Inc. Drosophila Activity Monitoring (DAM) system, specifically the 
DAM2 hardware, was used according to manufacturer’s instructions. This tracked 
movement of individual flies, placed in 65mm long capillary tubes, by number of 
laser beam breaks. Tubes were prepared by filling to around 15mm with food 
(melted in a microwave and poured into a glass beaker with tubes standing upright) 
and stoppering below food with a plastic cap. Flies were anaesthetised and added to 
tubes, plugged with cotton wool. Activity data was recorded by the DAMSystem303 
software at pre-set intervals of either 1 or 3 minutes.  
2.4.2 Activity experiment crosses 
Two promoters were used: ELAV-GAL80TS (a pan-neuronal driver with temperature-
sensitive repressor) and PDF (a driver specific for the interneurons of the Drosophila 
circadian pacemaker). ELAV crosses were performed at 18ºC to prevent expression 
during development; adults were then placed in DAM vials and placed in DAM2 
monitors at 29ºC, the permissive temperature of the GAL80TS repressor. PDF crosses 
and experiments were performed at 25ºC. A regular light/dark cycle was used for 5 
days before switching to constant darkness for the remainder of the experiment, in 
total lasting at least three weeks.  
2.4.3 Activity data analysis 
Activity data was analysed in two ways – comparison of average daily activity and 
analysis of circadian rhythm by summing counts into 30 minute bins using the 
DAMFileScan107 software. Activity levels were then plotted using Origin7, and 
actograms made of circadian data using the ImageJ plugin ActogramJ.  
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2.5 Generation of a library of tau phosphorylation mutants  
2.5.1 Mutagenesis and mutagenic PCR 
Human 2N4R tau in a pCMV FLAG-1 plasmid underwent mutagenesis of the sites 
T212, T231 and S262, performed using the Stratagene® QuickChange® 
mutagenesis kit. Mutagenic primers were designed using the QuikChange primer 
design program on the Stratagene website. All primers used in this thesis are listed in 
Appendix 2. 
Mutant plasmids were generated from wild type human 2N4R tau inserted into a 
pCMV Tag3b vector, using mutagenic polymerase chain reaction (PCR). This form 
of PCR used very long elongation steps to ensure full duplication of the entire 
plasmid. 
50μl mutagenic PCR reaction mix: 
5μl 10X Pfx Amplification buffer (Invitrogen) 
10μl 10X Pfx Enhancer solution (Invitrogen) 
1μl 50mM MgSO4 (Invitrogen) 
1.5μl 10mM dNTPs (Invtrogen) 
12.5μl of each mutagenic primer (10μg/ml) 
1μl DNA template (5ng/μl) 
1μl Pfx polymerase (Invitrogen) 
10.5 μl H2O 
Reactions were performed in an Eppendorf Mastercycler Gradient thermocycler with 
the following program: 
1. Initial denaturation: 2 minutes, 94°C 
2. Denature: 30 seconds, 94°C 
3. Primer annealing: 1 minute, 55°C 
4. DNA elongation: 6 minutes, 68°C 
5. Repeat steps 2-4 for 18 cycles 
Pfx Enhancer solution at 2X concentration was found to improve the reaction success 
rate. Reaction mixes were then digested using Dpn1 restriction enzyme for 2 hours at 
37°C in a water bath to remove template DNA. 
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2.5.2 Transformation in XL-1 Blue cells 
Transformation in XL-1 Blue Escherichia coli was performed according to 
manufacturer’s instructions. Ampicillin selection plates were used to identify 
transformed cells. 
 2.5.3 DNA isolation 
Colonies were picked into 5ml of Luria-Bertani (LB ) broth and amplified overnight 
at 37°C in shaking incubator. DNA was isolated using the QIAprep Spin Miniprep 
Kit (Qiagen) according to manufacturer’s instructions. 
2.5.4 Agarose gel electrophoresis 
Plasmids were checked on a 0.8% agarose gel, using a method based on Maniatis et 
al. (1982) – book 5, chapter 1, pages 150-162. 
DNA solutions were mixed with 5X loading buffer (30% v/v glycerol, 0.1% w/v 
bromophenol blue, 0.1% w/v xylene cyanol) and loaded onto 0.8% agarose gels 
(0.4g agarose and 2.5μl RedSafe (iNtRON Biotechnology) in 50ml TBE). Gels were 
run at 100V until dye had run over halfway down the gel. Gel images were taken 
using a UV transilluminator. 
2.5.5 Determination of DNA concentration 
DNA concentration was measured using a NanoDrop ND-1000 spectrophotometer 
(Thermo Scientific) and Nanodrop 1000 3.6.0 software. 
2.5.6 DNA sequencing 
Sequencing reactions were in a total volume of 10μl, with 50-500ng of DNA and 
5.5pmol of tau sequencing primers. Sequencing was carried out in house by 
Molecular Biology Services, School of Life Sciences, Warwick University on an ABI 
Prism Genetic Analyser 3130xl. Sequences were compared and mutations located 
using the programs Chromas and Clustal X2. This process from 2.5.1 onward was 
repeated using T212D mutant plasmid and S262D mutagenic primers in order to 
generate a double mutant. 
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2.5.7 Subcloning PCR reactions 
In order to increase the amount of DNA available for digestion, subcloning PCRs 
were performed to amplify mutated inserts. Subcloning PCR reactions used primers 
complementary to regions either side of the insert in the pCMV FLAG-1 plasmid. 
Reactions used the following 50μl formula: 
5μl 10X Pfx Amplification buffer (Invitrogen) 
1μl 50mM MgCl2 (Invitrogen) 
1μl 10mM dNTPs (Invtrogen) 
1.5μl of each subcloning primer (100μM) 
1μl DNA template (100ng/μl) 
0.8μl Pfx polymerase (Invitrogen) 
38.2 μl H2O 
Reactions were performed in an Eppendorf Mastercycler Gradient thermocycler with 
the following program: 
1. Initial denaturation: 5 minutes, 94°C 
2. Denature: 1 minute, 94°C 
3. Primer annealing: 30 seconds, 55°C 
4. DNA elongation: 90 seconds, 68°C 
5. Repeat steps 2-4 for 10 cycles 
6. Dentaure: 1 minute, 94°C 
7. Primer annealing (selecting for higher complementarity): 30 seconds, 65°C 
8. DNA elongation: 90 seconds, 68°C 
9. Repeat steps 6-8 for 25 cycles 
2.5.8 Gel extraction of DNA 
PCR products were run on an agarose gel to purify. The QIAquick Gel Extraction kit 
(Qiagen) was used according to manufacturer’s instructions. 
2.5.9 Restriction digestion  
The restriction enzymes NotI and EcoRI (Invitrogen) were used to excise mutated 
2N4R tau-FLAG from the PCR product with appropriate overhangs. The initial 
reaction used NotI in a 10μl reaction in REact 3 buffer for 3hrs at 37°C before 
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addition of EcoRI and further incubation overnight. The same digestion was 
performed on pUASTattB. Digests underwent a further gel extraction to remove 
digested ends. 
2.5.10 Ligation into pUASTattP2 
Ligation reactions used at least 3:2 ratios by weight of insert to vector, depending on 
available concentration.T4 DNA ligase (Invitrogen) was used in 10μl reactions, kept 
at room temperature overnight. 
2.5.11 Transformation into Escherichia coli and colony selection 
Ligation mixture was transformed into NEB 5α High or Subcloning Efficiency 
competent E. coli according to manufacturer’s instructions. Ampicillin selection 
plates were used to identify transformed cells. 
2.5.12 DNA isolation and injection 
Colonies were again amplified in 5ml LB and the QIAprep Spin Miniprep kit used to 
isolate DNA. This was sequenced a final time to check for any unintended sequence 
changes, before sufficiently high concentration DNA was sent to the Genetivision 
Corporation for injection into Drosophila at the specific PhiC31 integrase-mediated 
site P2 on chromosome 3. 
2.5.13 Bacterial strains 
XL-1 Blue Supercompetent E. coli genotype (Agilent): recA1 endA1 gyrA96 thi-1 
hsdR17 supE44 relA1 lac [F´ proAB lacIqZΔM15 Tn10 (Tetr)]. 
NEB 5α High Efficiency competent E. coli genotype (New England Biolabs): 
fhuA2Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 
thi-1 hsdR17 
NEB 5α Subcloning Efficiency competent E. coli genotype (New England Biolabs): 
fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80Δ (lacZ)M15 gyrA96 recA1 relA1 endA1 
thi-1 hsdR17 
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2.5.14 Media preparation 
LB broth: 1% w/v NaCl, 1% w/v tryptone, 0.5% w/v yeast extract, autoclaved. 
Ampicillin added at 100μg/ml. 
LB agar plates: LB broth with 1.5% w/v agar was autoclaved and cooled before 
pouring into petri dishes to set. Ampicillin added at 100μg/ml. 
 
2.6 Protein manipulations 
2.6.1 Protein extraction from Drosophila melanogaster 
In order to measure transgenic tau levels in the tau phosphorylation mutant library, 
animals homozygous for wild type or mutant 2N4R tau and hemizygous for the 
GMR promoter were reared at 25°C until two days post eclosion. Eight females were 
placed into eppendorfs for each sample and flash frozen in liquid nitrogen. These 
eppendorfs were vortexed to decapitate the animals. Heads were collected on dry ice 
then homogenised in 50μl lysis buffer using a mechanical pestle. Samples were then 
centrifuged at 13,000RPM for 30 minutes at 4°C, supernatant removed and 10μl 
protein loading dye added before heating at 90°C for 10 minutes and freezing at        
-20°C until use. 
Lysis buffer contained 50mM tris(hydroxymethyl)aminomethane-hydrochloric acid 
(Tris-HCl pH 7.5), 0.1mM ethylene glycol tetra-acetic acid (EGTA), 1mM ethylene 
diamine tetra-acetic acid (EDTA), 1% v/v Triton X-100, 1mM sodium orthovanadate 
(Na3VO4), 50mM sodium fluoride (NaF), 5mM sodium pyrophosphate (Na4P2O7), 
0.27M sucrose, 0.1% v/v β-mercaptoethanol and “complete” protease inhibitor 
cocktail (Roche, three tablets per 50ml). NaF and Na4P2O7 inhibit serine/threonine 
protein phosphatase activity, Na3VO4 that of tyrosine protein phosphatases. EDTA 
inhibits protein kinase activity as a Mg2+ ion chelator. EGTA chelates Ca2+ ions. 
Protease inhibitor cocktail inhibits aspartyl, cysteine, metallo- and serine protease 
activity. This buffer effectively protected the lysates from the activity of proteases 
and protein kinases and phosphatases. 
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2.6.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed using the BioRad Mini system. Samples were thawed 
and heated at 90°C for ten minutes before loading 8μl per lane, alongside ColorPlus 
prestained protein ladder (New England Biolabs), onto SDS-PAGE gels – 5% 
stacking gel and 10% resolving gel. Electrophoresis was performed in running buffer 
(0.1% w/v SDS, 0.3% w/v Tris and 1.44% w/v glycine) at 115V for 1.5-2 hours. 
Transfer onto nitrocellulose (GE Healthcare) in transfer buffer (0.3% w/v Tris, 
1.44% w/v glycine and 20% v/v methanol) lasted 3 hours at a constant current of 200 
amps. 
2.6.3 Immunoblotting 
Membranes were blocked with 5% w/v bovine serum albumin (BSA) in TBS-Tween 
(0.1% v/v) for 15 minutes at room temperature with agitation. Primary antibodies 
(listed in Table 2.1) were used at 1:1000 dilutions in 5% w/v BSA in TBS-Tween – 
membranes were exposed to 3ml of primary solution overnight at 4°C with rotation. 
Three ten minute washes in PBS-Tween of ten 10 minutes each removed unbound 
primary before incubation with horseradish peroxidase (HRP)-conjugated secondary 
antibodies (Thermo Scientific, see Table 2.2), all used at a 1:1000 dilution in 5% w/v 
dried skimmed milk in PBS-Tween, for 1 hour at room temperature. Three more 
washes in PBS-Tween removed excess secondary before membranes were dried and 
incubated with enhanced chemoluminscence (ECL) reagent (GE Healthcare) for 
three minutes. X-ray film was exposed to the membranes and developed, before 
being scanned using a CanoScan LiDE 700F scanner (Canon). Band density was 
measured using ImageJ. 
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Primary 
Antibody 
Source Species Incubation time 
T46 tau Abcam Mouse Overnight, 4°C 
P262 tau Abcam Rabbit Overnight, 4°C 
JL20 actin Millipore Mouse 
2.5 hours, room 
temperature 
FLAG Sigma-Aldrich Mouse Overnight, 4°C 
 
Table 2.1 Primary antibodies used in this study 
Primary antibodies used, their source, species and incubation time and temperature 
 
Secondary 
Antibody 
Source Species Incubation time 
Anti-rabbit HRP 
Thermo 
Scientific 
  Goat 1 hour, room temperature 
Anti-mouse HRP 
Thermo 
Scientific 
Rabbit  1 hour, room temperature 
 
Table 2.2 Secondary antibodies used in this study 
Secondary antibodies used, their source, species and incubation time and 
temperature 
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3| Characterisation of a library of 
human tau mutants in the 
Drosophila melanogaster eye 
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3.1 Introduction 
Early attempts to examine neurofibrillary tangles by monoclonal antibody screens 
led to the discovery of the Alzheimer’s-associated protein A68, characterised by 
immunoreactivity with novel antibodies such as Alz50 (Hyman et al., 1988). Since 
this was later demonstrated to be a hyper-phosphorylated, tangle-specific form of tau 
protein (Brion et al., 1991), a significant amount of the research conducted on the 
nature of tau toxicity has focused on the effects of kinase dysfunction. Early screens 
for tau kinases associated with PHF formation revealed the proline-directed kinase 
GSK3 to play an important role (Ishiguro et al., 1993; Mandelkow et al., 1992). 
Other kinases were found to alter the affinity of tau for microtubules, including the 
AMPK-related protein kinase MARK, which was shown to phosphorylate tau at 
S262 in the first KXGS motif (Drewes et al., 1995). Subsequently, this family of 
kinases has been revisited multiple times in this context. After the two SAD/BRSK 
kinases were shown to regulate neuronal polarisation in mammals via tau protein 
phosphorylation at S262 (Kishi et al., 2005), the Moffat and Frenguelli laboratories 
began to examine BRSK in the context of neurodegeneration. BRSK2 has since been 
shown to phosphorylate tau in vitro at T212 and S262 (Yoshida and Goedert, 2011). 
This phosphorylation profile was all the more interesting for in vitro studies linked 
these residues to specific processes hypothesised to control tau toxicity. In the case 
of T212, phospho-mimetic mutation caused enhancement of tau aggregation (Alonso 
et al., 2010; Chang et al., 2011; Necula and Kuret, 2004). Conversely, a single 
phospho-mimetic mutation to aspartate at S262 has been shown to reduce tau-
microtubule affinity (Kiris et al., 2011). These in vitro studies of single or double 
phospho-mimetic mutations have yet to be replicated in vivo – non-phosphorylatable 
mutations at KXGS motifs have already been shown to mitigate tau toxicity in the 
fly (Iijima-Ando et al., 2010) – but the use of site-directed mutagenesis to decipher 
the phosphorylation code of tau has fallen out of favour, since highly-mutated tau 
genes such as S11A (Chatterjee et al., 2009) were found to produce results described 
as “uninterpretable” (Goedert, personal communication). These results were perhaps 
unsurprising, given the apparent compound effects of multiple tau mutations found 
by Kiris et al. in 2011. Single mutations were found not to be additive in double 
mutants, but instead to lead to a reversal in effects on microtubule binding.  
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With this in mind, the tau mutants shown in this chapter were generated to explore 
the effects of BRSK-induced tau phosphorylation in the fly, in the absence of any 
human kinase. Phospho-mimetic mutations were made to a wild-type human 2N4R 
tau gene contained within a pCMV-1 Flag plasmid using the Stratagene® 
QuickChange® mutagenesis kit. Sites mutated were T212, T231 and S262, with 
residues replaced with aspartate to simulate part of the negative charge of a 
phosphorylated residue (Biernat et al., 1993). T212 and S262 were chosen due to 
their purported phosphorylation by BRSK2; T231 was an alternative microtubule 
affinity-regulating site, with a similar (but reduced) effect according to Kiris et al. 
(2010), but external to the microtubule-binding domains which contain S262 and of 
reduced coverage in the literature. Tau was then spliced into the pUAST attP2 
plasmid commonly used for gene insertion into Drosophila. This insertion was 
performed by the Genetivision Corporation at the specific PhiC31 integrase-
mediated site P2 on chromosome 3, and resulted in the generation of multiple lines 
of transgenic flies containing wild-type and mutant, human, flag-tagged 2N4R tau 
protein, controlled by UAS. These lines together with others containing 
corresponding non-phosphorylatable mutants created the beginnings of a library of 
tau phosphorylation mutants. The effects of these mutations when expressed in the 
fly eye were compared by QED, bespoke software to measure ommatidial distortion 
caused by developmental transgene toxicity. These lines were also probed for the 
effects of mutations on phosphorylation at other sites on the protein.  
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3.2 Results 
3.2.1 Generation of a library of human tau phosphorylation mutants in 
Drosophila 
One aim of this project was the generation of a library of human tau phosphorylation 
mutants to be inserted into Drosophila. The plasmid source of tau to be mutated and 
cloned was pCMV-1 2N4R tau Flag (a kind gift of Dr Calum Sutherland, Dundee 
University), containing the wild type human 2N4R tau gene with attached 1kd Flag 
tag sequence. Mutations were designed to replace phosphorylatable serine and 
threonine residues with phospho-mimetic aspartate residues. The sites chosen for 
mutation were T212 (shown in vitro to be involved in promotion of tau aggregation), 
T231 and S262 (both shown in vitro to be involved in regulation of microtubule 
binding). Both T212 and S262 have also been shown in vitro to be phosphorylated 
by BRSK2. The codon changes were designed to be as small as possible, exploiting 
the degenerate amino acid code to make two-nucleotide changes in each case. These 
changes are illustrated in Table 3.1.  
Construct 
Amino acid 
change 
DNA codon 
change 
T212D T212D ACC to GAC 
T231D T231D ACT to GAT 
S262D S262D TCC to GAC 
Table 3.1 2N4R tau amino acid and codon changes 
Phospho-mimetic mutations were generated at sites T212, T231 and S262  
The Stratagene®  QuickChange® mutagenesis kit was used to insert the mutations 
into the pCMV-1 2N4R tau Flag vector, which was cloned, excised and ligated into 
pUAST attP2 for insertion into the Drosophila genome, as shown in Figure 3.1. 
pUAST contains the Upstream Activating Sequence for control of transgenes by the 
GAL4-UAS expression system, as well as the white gene as a marker for successful 
integration. The tau gene within the final plasmid (named pUAST 2N4R tau Flag) 
was sequenced in its entirety to confirm the presence of the mutation as well as the 
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integrity of the rest of the gene. Sequences showing the successful mutations are 
shown in Figure 3.2. Minipreps of pUAST 2N4R tau Flag were sent to the 
Genetivision Corporation, Texas for insertion into Drosophila at the specific PhiC31 
integrase-mediated site P2 on chromosome 3. This specific insertion was necessary 
to eliminate variation in transgene expression due to position effect and to make 
these mutants as comparable as possible. These mutant lines were then combined 
with previously generated lines containing corresponding non-phosphorylatable 
2N4R tau alanine mutants at the same residues, created in-house by Dr Alessia 
Galasso (in the case of T231A and T262A) or kindly provided by Dr Guy Tear, 
King’s College London (in the case of T212A, with no Flag tag). The lines 
constituting this library are listed in Table 3.2. Flies were crossed to a 2nd 
chromosome GMR promoter line and balanced, on the 2nd chromosome with CyO 
and on the 3rd with MKRS. 
 
Construct Type of mutation 
2N4R WT Wild type 
T212A Non-phosphorylatable 
T231A Non-phosphorylatable 
S262A Non-phosphorylatable 
T212D Phospho-mimetic 
T231D Phospho-mimetic 
S262D Phospho-mimetic 
Table 3.2 The human 2N4R tau mutant library 
Mutagenesis of wild type human 2N4R tau was used to complete a library of 
phosphorylation mutants 
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Figure 3.1 2N4R tau cloning schematic 
The human 2N4R tau gene (wild type and each mutant) was excised from the pFlag-
CMV-1 vector using the restriction enzymes EcoRI and NotI. The pUAST attP2 
plasmid (pUAST) was also digested by the same enzymes in preparation for ligation 
to the 2N4R tau fragments. 
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Figure 3.2 2N4R tau mutant genotyping 
Sequencing chromatograms showing the codon changes made in each phospho-
mimetic mutant. Left (highlighted in red): the codon for the wild type sequence, in 
descending order threonine 212, threonine 231 and serine 262. Right (highlighted in 
red): the corresponding change at the same position to generate a mutant aspartate 
codon.   
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3.2.2 Quantification of transgene expression levels in Drosophila 
In order to ascertain whether any phenotypic differences found between these 
transgenic Drosophila lines were due to the introduced mutations, an indication of 
levels of transgene expression was required.  Western blots were performed on flies 
hemizygous for GMR and homozygous for tau using the total tau T46 antibody and 
the JL20 actin antibody as loading control (Figure 3.3). Bands were quantified using 
the Gel Analyser plugin for Fiji, with T46 values normalised to actin and then 
mutants normalised to the 2N4R WT band of the same blot.  No significant 
differences were found between mutant lines by ANOVA (analysis of variance), 
though there would appear to be a trend toward relatively reduced expression in 
T212A and T231A compared with their phospho-mimetic counterparts. (WT n=4, 
T212A 0.74 ±0.19 n=4, T212D 1.32 ±0.18 n=5, T231A 0.53 ±0.10 n=4, T231D 1.05 
±0.22 n=4, S262A 1.18 ±0.29 n=4, S262D 1.29 ±0.28 n=4) 
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Figure 3.3 Tau mutant expression levels were not found to differ significantly 
Total tau expression levels were verified by Western blot using the T46 antibody, 
with Drosophila actin loading control measured using the JL20 antibody. Quantified 
values were normalised to actin and to wild type tau levels on each corresponding 
blot. Expression levels of mutants were not found to differ significantly from wild 
type or from each other by ANOVA. Flies used were hemizygous for the GMR-GAL4 
promoter (over CyO balancer) and homozygous for the tau transgene. (WT n=4, 
T212A 0.74 ±0.19 n=4, T212D 1.32 ±0.18 n=5, T231A 0.53 ±0.10 n=4, T231D 1.05 
±0.22 n=4, S262A 1.18 ±0.29 n=4, S262D 1.29 ±0.28 n=4) 
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3.2.3 Quantification of tau mutant phenotypes 
Transgenic tau toxicity was measured in the fly eye using the QED program, and 
samples compared by Mann-Whitney U test. SEM images were taken at 150X 
magnification of female left eyes, in animals hemizygous for GMR and either hemi- 
or homozygous for tau transgenes.  
3.2.3.1 Wild-type 2N4R tau 
Figure 3.4 shows the comparison of 2N4R WT with the GMR promoter alone, which 
itself causes very little ommatidial disruption in single copies. It demonstrates the 
establishment of a visible rough-eyed phenotype (Figure 3.4A) and concomitant 
increase in ommatidial distortion as measured by QED (Figure 3.4B), with a median 
distortion coefficient (DC) of 0.24 for GMR and 0.29 for hemizygous 2N4R WT 
(P<0.0001). This toxicity is gene dosage dependant – homozygous 2N4R WT 
presents a significantly different DC of 0.38 (P<0.0001). For this reason, all 
comparisons between mutant 2N4R and WT have been made between samples of 
equivalent transgene zygosity. Figure 3.5 presents the degree of DC variation within 
each sample, with the lowest and highest examples as determined by QED shown. 
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Figure 3.4 Tau expression induces measurable levels of ommatidial distortion 
A. Scanning electron microscope images demonstrating the dosage-dependant 
median toxicity of wild type human 2N4R tau expressed in the fly eye under control 
of the GMR-GAL4 promoter. Dispersion coefficients shown on images.  
Genotypes: GMR: GMR-GAL4/CyO;MKRS/TM6B. 2N4R hem: GMR-
GAL4/CyO;2N4R WT/MKRS. 2N4R hom: GMR-GAL4/CyO; 2N4R WT/2N4R WT. 
Scale bar: 100μm. 
B. Quantitative analysis of the above phenotypes demonstrated significant difference 
in ommatidial roundness between GMR and 2N4R hem (P<0.0001), between GMR 
and 2N4R hom (P<0.0001) and between 2N4R hem and 2N4R hom (P<0.0001). A 
shift to the right is characteristic of increased toxicity. GMR n=8, 2N4R hem n=23, 
2N4R hom n=25. 
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Figure 3.5 The phenotypic extremes of wild type tau flies as measured by QED 
Scanning electron microscope images showing the lowest and highest distortion 
coefficients for roundness in the GMR, 2N4R hem and 2N4R hom samples. Scale 
bar: 100μm. 
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3.2.3.2 Mutations at T212 
The effects of mutation to site T212 are shown in Figure 3.6, with median DC 
images shown for hemi- and homozygous 2N4R T212A (DC of 0.31 and 0.33, 
respectively) and 2N4R T212D (DC of 0.27 and 0.32, respectively) mutants, along 
with 2N4R WT for reference. It would appear that the 2N4R T212D mutation in 
each case reduces tau toxicity. Any effect of 2N4R T212A mutation is less clear. 
Figure 3.7 shows quantification of these changes, separated by zygosity. 
Hemizygous T212D had a significantly lower DC than hemizygous T212A 
(P=0.035), but not compared with hemizygous 2N4R (P=0.081). Hemizygous T212A 
and 2N4R WT do not differ (P=0.61). Among the homozygous individuals, T212D 
had a significantly lower DC than 2N4R WT (P=0.004). Other comparisons were not 
significant. Figure 3.8 shows the minimum and maximum DCs for the samples. It 
would appear that phospho-mimetic T212D mutation does reduce the toxicity of 
2N4R tau in this context, and is also less toxic than the non-phosphorylatable T212A 
mutation, though this is not evident in every case.  
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Figure 3.6 Phospho-mimetic T212D mutation leads to reduced toxicity 
Scanning electron microscope images demonstrating the dosage-dependant median 
toxicity of human 2N4R tau, mutated at threonine 212 and expressed in the fly eye 
under control of the GMR-GAL4 promoter. Dispersion coefficients shown on 
images. The T212D mutants appear to be less distorted than 2N4R WT or T212A 
mutants. 
Genotypes: T212A hem: GMR-GAL4/CyO;T212A/MKRS. T212D hem: GMR-
GAL4/CyO; T212D/MKRS. T212A hom: GMR-GAL4/CyO; T212A/T212A. T212D 
hom: GMR-GAL4/CyO;T212D/T212D. Scale bar: 100μm. 
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Figure 3.7 Phospho-mimetic T212D mutant tau is less toxic than non-
phosphorylatable T212A mutants as measured by QED 
Quantitative analysis of the phenotypes of the samples shown in Figure 3.6. T212D 
hem DC is significantly less than that of T212A hem by Mann-Whitney U test 
(P=0.035). T212D hom is significantly less distorted than 2N4R hom by the same 
test (P=0.004). 
A: 2N4R hem n=23. T212A hem n=14. T212D hem=18. 
B: 2N4R hom n=25. T212A hom n=9. T212D hom n=24. 
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Figure 3.8 Phenotypic extremes of T212 mutants 
Scanning electron microscope images showing the lowest and highest distortion 
coefficients for roundness in the T212A hem, T212D hem, T212A hom and T212D 
hom samples. Scale bar: 100μm. 
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3.2.3.3 Mutations at T231 
Figure 3.9 shows the median phenotypes among the T231 mutants, with 2N4R WT 
for reference. T231A mutants were given DC values of 0.30 and 0.37 for hemi- and 
homozygous respectively; T231D mutants had DC values of 0.35 and 0.40 for hemi- 
and homozygous respectively. Quantification in Figure 3.10 found a significant 
increase in DC in the T231D hemizygous individuals compared with both 2N4R WT 
(P<0.0001) and T231A (P=0.0004). No change was found among the homozygous 
samples. Figure 3.11 shows the extremes of DC values for each sample. These data 
potentially show a slight increase in toxicity of 2N4R tau upon T231D mutation, 
though are not conclusive. Neither mutation leads to a reduction in toxicity. 
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Figure 3.9 T231 mutations do not cause any obvious phenotypic change 
Scanning electron microscope images demonstrating the dosage-dependant median 
toxicity of human 2N4R tau, mutated at threonine 231 and expressed in the fly eye 
under control of the GMR-GAL4 promoter. Dispersion coefficients shown on 
images. Any change in distortion is not evident by eye. 
Genotypes: T2131A hem: GMR-GAL4/CyO;T231A/MKRS. T231D hem: GMR-
GAL4/CyO; T231D/MKRS. T231A hom: GMR-GAL4/CyO; T231A/T231A. T231D 
hom: GMR-GAL4/CyO;T231D/T231D. Scale bar: 100μm. 
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Figure 3.10 T231D mutation increases tau toxicity as measured by QED 
Quantitative analysis of the phenotypes of the samples shown in Figure 3.9. The DC 
of T231D hem is significantly increased compared with 2N4R hem (P<0.0001) and 
T231A hem (P=0.0004), by Mann-Whitney U test. 
A: 2N4R hem n=23. T231A hem=16. T231D hem n=24. 
B: 2N4R hom n=25. T231A hom n=10. T231D hom n=21. 
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Figure 3.11 Phenotypic extremes of T231 mutants 
Scanning electron microscope images showing the lowest and highest distortion 
coefficients for roundness in the T231A hem, T231D hem, T231A hom and T231D 
hom samples. Scale bar: 100μm. 
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3.2.3.4 Mutations at S262 
The consequences of mutation of S262 are shown in Figure 3.12, it is possible to see 
a reduction in median ommatidial distortion in the hemizygous S262A mutant (DC 
of 0.28) compared with S262D (DC of 0.35), and in homozygous S262A (DC of 
0.32) compared with S262D (DC of 0.37). Analysis showed a significant reduction 
in S262A DC compared with S262D (in hemizygous, P<0.0001, and homozygous 
P=0.039 – Figure 3.13). S262A was only significantly reduced compared with 2N4R 
WT under homozygous conditions (P=0.004). Hemizygous S262D was significantly 
increased compared with 2N4R WT (P=0.0002), but not in homozygous conditions. 
Highest and lowest DC values for S262 mutants are shown in Figure 3.14. It appears 
that preventing S262 phosphorylation mitigates 2N4R tau toxicity in this model. It is 
also possible that artificially increasing S262 phosphorylation can lead to an increase 
in tau toxicity. 
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Figure 3.12 Non-phosphorylatable S262A mutation reduces tau toxicity 
Scanning electron microscope images demonstrating the dosage-dependant median 
toxicity of human 2N4R tau, mutated at serine 262 and expressed in the fly eye under 
control of the GMR-GAL4 promoter. Dispersion coefficients shown on images. 
S262A mutants appear less distorted than the S262D mutants. 
Genotypes: S262A hem: GMR-GAL4/CyO;S262A/MKRS. S262D hem: GMR-
GAL4/CyO; S262D/MKRS. S262A hom: GMR-GAL4/CyO; S262A/S262A. S262D 
hom: GMR-GAL4/CyO;S262D/S262D. Scale bar: 100μm. 
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Figure 3.13 Non-phosphorylatable S262A mutants are less toxic than phospho-
mimetic S262D mutants, as measured by QED 
Quantitative analysis of the phenotypes of the samples shown in Figure 3.12. The 
DC of S262D hem is significantly increased compared with S262A hem (P<0.0001) 
and 2N4R hem (P=0.0002), by Mann-Whitney U test. S262A hom DC is significantly 
decreased compared with S262D hom DC (P=0.04) and 2N4R hom DC (P=0.004), 
by the same test. 
A: 2N4R hem n=23. S262A hem n=20. S262D hem n=20. 
B: 2N4R hom n=25. S262A hom n=20. S262D hom n=19. 
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Figure 3.14 Phenotypic extremes of S262 mutants 
Scanning electron microscope images showing the lowest and highest distortion 
coefficients for roundness in the S262A hem, S262D hem, S262A hom and S262D 
hom samples. Scale bar: 100μm. 
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3.2.4 Exploring the phosphorylation status of the mutant library 
In order to begin to explore the mechanisms behind these mutation-induced changes 
in 2N4R tau toxicity, Western blots probing for the phosphorylated S262 epitope 
were performed, using the antibody anti-pS262. Quantification of these blots, 
performed using the Gel Analyser plugin for Fiji and by normalising the anti-pS262 
signal to actin, subsequently to the corresponding T46 signal of the same sample and 
finally to the 2N4R wild type sample of each series, is shown in Figure 3.15. No 
significant differences were found between mutants when compared by ANOVA. 
There are several caveats to this analysis however. Some samples, notably of T231D 
and S262D exhibited considerable variation. In addition, the specificity of this 
antibody is questionable given the signal found in both S262 mutants and their 
variation, which should eliminate the pS262 epitope. This suggests that this antibody 
finds more than one epitope on 2N4R tau. This also raises an interesting point, 
considering that both T212D and S262A have a very comparable pS262 signal and 
are both toxicity-reducing mutations when assessed by eye phenotype (shown in 
Figure 3.7 and 3.13) – it is possible both of these mutations lower tau toxicity by 
preventing S262 phopshorylation. (WT n=4, T212A 1.12 ± 0.33 n=4, T212D 0.58 ± 
0.17 n=5, T231A 1.03 ± 0.33 n=4, T231D 1.66 ± 0.69 n=4, S262A 0.61 ± 0.17 n=4, 
S262D 1.32 ± 0.47 n=4)  
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Figure 3.15 No significant differences in levels of S262 phosphorylation were 
found among the tau mutants 
Levels of pS262 immunoreactivity were verified by Western blot using the pS262 
antibody, with Drosophila actin loading control measured using the JL20 antibody. 
Quantified values were normalised to actin, to the total tau blot of the same sample 
and to wild type tau levels on each corresponding blot. pS262 immunoreactivity of 
mutants was not found to differ significantly from wild type or from each other by 
ANOVA. Flies used were hemizygous for the GMR-GAL4 promoter (over CyO 
balancer) and homozygous for the tau transgene. (WT n=4, T212A 1.12 ± 0.33 n=4, 
T212D 0.58 ± 0.17 n=5, T231A 1.03 ± 0.33 n=4, T231D 1.66 ± 0.69 n=4, S262A 
0.61 ± 0.17 n=4, S262D 1.32 ± 0.47 n=4) 
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3.3 Discussion 
Phenotypic analysis by QED was the heart of the initial screening process of this 
mutant library. By combining measurement of eye damage with that of transgenic 
protein levels, we obtain an indicator of tau toxicity, and how it can be changed by 
mutation.  
3.3.1 Wild-type 2N4R tau 
The hemizygous GMR line has been used as the initial baseline to demonstrate 
2N4R tau toxicity, as the GMR promoter has previously been shown to have a minor 
disruptive effect (unpublished data) and was present in all subsequent tested lines in 
this chapter. Hemizygous and homozygous 2N4R tau lines are both more distorted 
than this control. The homozygous 2N4R line exhibits significantly more distortion 
than the single-copy line, demonstrating the dosage-dependant nature of this toxicity 
and the need to factor in gene expression and protein levels in any discussion of 
mutation-controlled modulation of tau toxicity in vivo. Subsequent mutant 
comparisons were conducted in both hemi- and homozygous conditions, in the hope 
that the extra information provided by these two conditions would provide greater 
sensitivity in differentiating phosphorylation-dependant effects. 
3.3.2 Mutations of T212 
The phosphorylation site T212 has been shown to be the site most prone to BRSK2-
induced phosphorylation (Yoshida and Goedert, 2011), as well as heavily implicated 
in modulation of tau aggregation (Chang et al., 2011). This led us to propose that a 
major part of BRSK2-induced tau toxicity, as demonstrated previously using 0N4R 
tau, could be due to a change in tau aggregation kinetics induced by the kinase. Our 
2N4R T212D mutant was generated in order to test this hypothesis. As it transpired, 
levels of toxicity in the T212D mutant appeared to be less than in 2N4R WT and in 
T212A by eye, differences which were corroborated by QED analysis of the 
hemizygous individuals. It was also significantly less than 2N4R WT among the 
homozygous samples, but not when compared with homozygous T212A. This is 
potentially due to multiple factors: the extent of phenotypic variation within 
populations, variation in the quality of coating before SEM imaging or the method of 
ommatidial measurement by QED. Another possible cause could be the apparent 
trend in the quantified Western blot data toward higher levels of protein in the 
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T212D line. This could potentially explain the lack of a difference in the 
homozygous comparison between T212A and T212D. These findings were initially 
difficult to reconcile with the effects of BRSK in 0N4R tau, but were eventually 
better explained by tau isoform-specific effects (see Chapter 4). These data would 
imply a protective role for this aggregation-inducing mutation. The lack of change 
caused by the T212A mutation suggests a lack of T212 phosphorylation by 
endogenous Drosophila kinases. 
3.3.3 Mutations of T231 
As a site implicated in modulation of tau-microtubule binding, T231 was chosen as it 
had previously been shown to be phosphorylated by the prototypical AMPK-related 
kinase, AMPK (Thornton et al., 2011) but was not addressed in the study by Yoshida 
and Goedert (2011) demonstrating tau phosphorylation by this family of kinases. 
This mutant was designed as a second example of one affecting microtubule 
dissociation, alongside the better-studied and more widely-implicated S262. T231’s 
location within the proline-rich region also differentiated it from the microtubule-
binding domain KXGS motif site. The SEM images obtained were not strongly 
indicative of any change in toxicity from these mutations, but QED testing found a 
significant increase in distortion in the hemizygous T231D mutant, from both 2N4R 
WT and T231A. This increase was not found among the homozygous phenotypes. 
This change is potentially due to differences in protein levels which, although again 
not significant, appear to exhibit a trend of reduced T231A levels. It is possible that 
this difference in protein levels leads to phenotypic changes at lower expression 
values in the hemizygous examples. Why there should be such a difference in protein 
levels in the first place is intriguing – expression could differ, though this should be 
minimised or eliminated by PhiC31 integration. It is possible that the T231A 
mutation has a destabilising effect on tau, targeting it for removal by endogenous 
mechanisms of protein clearance. The ubiquitin-proteasome system (UPS) has been 
proposed to play some role in tau clearance in disease models (Tseng et al., 2008) 
and autophagy has been heavily implicated in mitigation of tau toxicity, including in 
Drosophila (Berger et al., 2006). Autophagy has recently taken the ascendancy due 
to its potential for removing tau aggregates (Schaeffer et al., 2012). Such aggregates 
are regarded as being too large for degradation by proteasomes, and instead removed 
by a system of specific macroautophagy, known as aggrephagy (Overbye et al., 
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2007), in which accumulated abnormal tau is sequestered into large, insoluble 
aggregates known as aggresomes. These aggresomes prevent free misfolded protein 
from forming other, potentially more toxic aggregates and are subsequently cleared 
by autophagy. Histone deacetylase 6 (HDAC6) has been shown to play a role in 
aggresome targeting, particularly following accumulation of misfolded protein due to 
proteasomal inhibition (Guthrie and Kraemer, 2011). Whether T231A mutant tau is 
more prone to degradation by autophagosomes, in a soluble or insoluble form, could 
be examined for example by probing for lysosome accumulation (Scott et al., 2004). 
Another method would be to probe for the autophagic substrate p62 (Bjorkoy et al., 
2005; Pankiv et al., 2007), the abundance of which is inversely related to stimulation 
of autophagy (Komatsu et al., 2007). The fly p62 orthologue, Ref(2)p has also been 
used in this way (Nezis et al., 2008). The slight changes in phenotype of T231D flies 
could be due to changes in microtubule affinity, which would be expected to be less 
severe than changes to S262 phosphorylation according to the in vitro work or Kiris 
et al (2011).  
3.3.4 Mutations of S262 
The tau phosphorylation site most strongly linked to microtubule binding is S262, 
often singled out as a key residue for tau toxicity (Iijima-Ando et al., 2010), 
including amyloid β-dependant toxicity (Iijima et al., 2010). It is a target of many 
non-proline-directed tau kinases including MARK (Biernat et al., 1993; Drewes et 
al., 1995) and protein kinase A (Liu et al., 2007). In the present study, S262A 
mutation appeared to reduce tau toxicity when examined by eye. Quantification of 
hemizygous samples instead revealed a significant increase in toxicity in the S262D 
mutants compared with 2N4R WT or S262A; S262A hemizygous was not 
significantly different to 2N4R WT. In the homozygous tests, S262A was found to be 
significantly less toxic than 2N4R WT and S262D. This correlates well with the 
SEM images, in which homozygous S262A flies demonstrate much smaller eyes 
with much less well-defined ommatidia than in S262D or 2N4R WT-expressing 
animals. This is consistent with previous data from Iijima-Ando et al (2010). 
Multiple sources have reported S262 phosphorylation or phospho-mimetic mutants 
to reduce tau-microtubule binding (Fischer et al., 2009; Kiris et al., 2011; Schneider 
et al., 1999), so we can hypothesise that this reduction in toxicity caused by S262A 
mutation could be due to higher affinity of the mutant human tau for Drosophila 
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microtubules. This also demonstrates a level of S262 phosphorylation by 
endogenous kinases. No differences between levels of transgenic tau in the S262 
lines were detected. 
3.3.5 Potential mechanisms of regulation of tau toxicity by phospho-mutation 
This partial human tau phospho-mutation library would seem to suggest that 
increasing both the affinity of human tau for Drosophila microtubules and the 
propensity of human tau for aggregation in the Drosophila eye protect against tau 
toxicity. Both of these results would support the idea that an excess of free tau is the 
principle driver of tau toxicity. However, there are caveats surrounding each of these 
proposed disease processes due to the use of Drosophila as a model.  
In the case of tau aggregation, for a long time there was simply not much cause to 
expect this to happen in the fruit fly. An early study showing suspected 
neurofibrillary pathology with AT100 immunoreactivity (the antibody used to probe 
for dual T212/S214 phosphorylation, a marker for PHF formation) in the fly eye, 
caused by overexpression of human tau and the fly GSK3 orthologue shaggy 
(Jackson et al., 2002), was not followed by other reported sightings for a decade. The 
author has since downplayed the likelihood of any tangle-like pathology playing a 
role in Drosophila models of tauopathy (Dr George R. Jackson, personal 
communication). It was argued that fruit fly models of tauopathy were something of 
a coup for the now prevailing view that larger tau aggregates are less important for 
toxicity than soluble aggregates and PHF formation (Wittmann et al., 2001), ideas 
which were later backed by work in mammals (Andorfer et al., 2005). Given the 
much longer timescales involved in progression to tangle-positive tauopathy in 
humans or mammalian models, it is perhaps unsurprising that evidence for the 
existence of the Drosophila tangle was unforthcoming. More recently however, some 
evidence for tau aggregation has been uncovered by different groups, with differing 
implications for oligomeric tau toxicity. One study demonstrated the ability of wild-
type human 0N4R tau to form large oligomers (>400kDa) in aged fly dopaminergic 
neurons, strongly resembling PHF-like filaments under electron microscope (Wu et 
al., 2013b). These were strongly associated with tau toxicity, with motor and learning 
deficits. Other insoluble granular tau oligomers (GTOs) have also been identified in 
fly models, and associated with a rescue of tau toxicity, either by inhibition of GSK-
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3β (Cowan and Mudher, 2013) or expression of nicotinamide mononucleotide 
adenylyl transferase (NMNAT), a known neuroprotectant (Ali et al., 2012). In each 
of these cases, reduction in toxicity was associated with a loss of tau monomers and 
the appearance of insoluble oligomers.  This leads to two possibilities surrounding 
the change in phenotype caused by T212D tau. One is that the mutation does indeed 
lead to an increase in tau-tau binding (which could potentially go no further than 
PHF formation or perhaps GTOs (Maeda et al., 2007)). The other is that the change 
in toxicity is due to another mechanism, perhaps a structural change caused by the 
mutation or even microtubule-binding and potentially leading to a reduction in tau 
phosphorylation at other sites, for example S262. 
The binding of human tau to Drosophila microtubules has been studied using 
specific assays based around the ability of taxol to stabilise microtubules with their 
associated proteins. In some cases, human tau has been shown to bind comparably to 
Drosophila tau (and even be capable of displacing it), and this binding to be 
modulated by phosphorylation status or mutation (Chatterjee et al., 2009; Cowan et 
al., 2010). However, a separate study showed very poor binding of human tau to fly 
microtubules and no reduction in binding rate of endogenous tau (Feuillette et al., 
2010). The same study also demonstrated a lack of improvement of human tau 
binding in a Drosophila tau null background, and an improvement in both binding 
and eye-specific toxicity of human tau when subject to multiple non-
phosphorylatable mutations (tau-AP, lacking in most proline-directed 
phosphorylation sites). The methods used by Cowan et al. (2010) and Feuillette et al. 
(2010) use the same taxol concentration, but differ in the tau isoform used: the 
former used 0N3R, the latter, 0N4R. If this is what accounts for the difference then it 
is surprising that the isoform with more microtubule-binding repeats has lower 
affinity, especially given its closer similarity to five-repeat endogenous fly tau. 
Ultimately however, the second study does not rule out the possibility that human tau 
can bind to microtubules, especially following non-phosphorylatable mutation. An 
increase in microtubule-binding could indeed explain the reduction in toxicity of 
2N4R tau following S262A mutation. 
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3.3.6 Examining the phosphorylation status of mutant tau 
In order to further examine the mechanisms underlying our ability to manipulate tau 
toxicity in this way, we began to explore the phosphorylation status of the tau 
mutants in our library. There were initially some assumptions we could verify based 
on our mutation-induced phenotypic changes – T212 would be unphosphorylated, 
S262 phosphorylated on wild-type human tau by endogenous Drosophila kinases. 
The first phospho-blot performed was a probe of S262 phosphorylation using the 
antibody anti-pS262, which label all of the tau species tested. This antibody was 
found to lack specificity – even in S262 mutant isoforms, immunoreactivity was 
found. This could be due to binding at other KXGS motifs in four-repeat tau 
isoforms. No significant changes in phosphorylation at this site were found between 
mutant isoforms, possibly due to this non-specific binding generating noise, but there 
did appear to be a trend toward reduced immunoreactivity in the S262A mutant 
compared with the S262D mutant. It is unlikely that the antibody recognised the 
aspartate mutant, which could indicate increased binding elsewhere, potentially at 
other KXGS motifs. Interestingly, this trend was also found between the T212 
mutants, with T212D (the less toxic isoform) exhibiting relatively reduced 
immunoreactivity. This is potential evidence for an association between tau toxicity 
and S262 phosphorylation. In order to test this, it would be useful to employ other 
KXGS-directed antibodies, for example pS356 or the dual S262/S356 phospho-
antibody 12E8 (Wittmann et al., 2001), which would also help determine the other 
pS262 epitopes. This leads back to one of the possible causes of T212-induced 
changes in toxicity – that it potentially controls S262 phosphorylation. This could be 
a normal structural change upon phosphorylation or an artifact induced by the 
aspartate mutation. In order to verify changes in tau aggregation, PHF-recognising 
antibodies would also be a useful next step. Although the classical AT100 antibody 
would not be suitable due to the mutation of part of its epitope, other PHF antibodies 
do exist, targeted against other phospho-residues in the proline-rich region and 
elsewhere on tau. These include AT8 (Goedert et al., 1995) and PHF-1 (Otvos et al., 
1994), both of which effectively label neurofibrillary deposits. Any increase in 
immunoreactivity would be cause to consider the possibility of an increase in PHF 
formation caused by T212 mutation. If not, the possibility for changes in tau 
secondary structure is real. The Alz50 antibody, which used been used to probe for 
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tangles was demonstrated to recognise a specific conformational epitope (Carmel et 
al., 1996). This involved a change from the so-called “paperclip” conformation of 
healthy tau, in which the C-terminus fold brings it close to the microtubule-binding 
domain (Jeganathan et al., 2006), to an Alz50 conformation in which the N-terminus 
holds this position (Himmelstein et al., 2012). This has been hypothesised to 
facilitate the stacking of tau into aggregates, but could potentially prevent 
phosphorylation of S262 by endogenous kinases. 
These data demonstrate the potential to change toxicity caused by transgenic human 
2N4R tau in the fly eye by single residue mutation. They show the lack of 
equivalence between phosphorylation sites, speaking to specific roles for sites 
potentially based on aggregation or microtubule-binding kinetics. In the next chapter, 
the relationship between the ability of the human kinase BRSK2 to modulate tau 
toxicity in this model is explored, demonstrating the effects of multiple tau mutation 
to mimic kinase activity and the importance of tau isoform-specific effects on 
toxicity. 
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4| Exploring the effects of BRSK-
induced tau phosphorylation 
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4.1 Introduction 
The AMPK-related protein kinases BRSK1 and BRSK2 are closely related to the tau 
kinase MARK. The Caenorhabditis elegans orthologue of the BRSKs was 
discovered in a screen for mutations affecting presynaptic development (Crump et 
al., 2001) and was named SAD-1 (for synapses of the amphid defective). 
Subsequently the mouse orthologues SAD-B and SAD-A (along with the respective 
human BRSKs) were identified by sequence homology and were characterised as 
expressing predominantly in the murine central nervous system, and were shown to 
be integral to the correct polarisation of neurons, potentially via tau phosphorylation 
(Kishi et al., 2005). SAD-B has also been shown to be localised presynaptically and 
to be associated with regulation of neurotransmitter release (Inoue et al., 2006). The 
pathway leading to BRSK phosphorylation and activation has also been explored, 
with LKB1 (Barnes et al., 2007) and CaMKKα (Fujimoto et al., 2008) both revealed 
to include BRSKs among their substrates. More recently, the phosphorylation of tau 
by BRSKs has been better characterised, demonstrating the ability of the kinases to 
phosphorylate tau at T212 and S262 (Yoshida and Goedert, 2011).  
Previous unpublished work here at Warwick has shown that the toxicity of human 
0N4R tau in a Drosophila model is greatly exacerbated by co-expression of BRSK2, 
in an LKB1 and CaMKK-dependant manner, with an increase in phosphorylation at 
S262. These data are all consistent with BRSK2 activity as it is understood in 
mammalian systems. However, whether these effects on transgenic tau toxicity in the 
fly are a direct result of phosphorylation by this kinase has not yet been shown. 
The characterisation of BRSK2-induced phosphorylation of 1N4R tau in vitro by 
Yoshida and Goedert (2011), though not definitive, demonstrates a particularly 
interesting phosphorylation profile for this kinase – it was shown to target both the 
aggregation-associated residue T212 and the modulator of microtubule binding, 
S262. The consequences of individual phospho-mutations at both of the BRSK2-
targeted residues (the aggregation-implicated T212 and microtubule binding-
associated S262) were explored in the human 2N4R tau isoform in the previous 
chapter, and shown to have opposing effects on tau toxicity. That BRSK2 should 
have a particularly drastic effect on 0N4R tau toxicity as a result of phosphorylation 
at each of these sites is unintuitive. However, as was demonstrated by Kiris et al. 
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(2011), the consequences of tau phospho-mimetic mutation (i.e. pseudo-
phosphorylation) are not necessarily additive. I therefore attempted to recapitulate 
the effect of BRSK2 phosphorylation by mutation, with the addition of an extra 
S262D mutation to the previously-generated 2N4R tau T212D mutant. By simulating 
putative BRSK2 phosphorylation of human tau without the presence of the 
additional transgene, the T212D S262D tau double mutant might potentially 
demonstrate the precise role played by changes to tau phosphorylation in the 
tau/BRSK2 phenotype, eliminating any secondary effects of the kinase due to 
possible interactions with other endogenous substrates. The mutant library of 
Chapter 3 has also allowed further exploration of the nature of the tau/BRSK2 
interaction, as well as raising questions regarding the differences between tau 
isoforms as relates to toxicity. 
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4.2 Results 
The GMR promoter and QED software were again used to evaluate the effect of 
BRSK2 on tau toxicity and the toxicity of BRSK2 phosphorylation-mimicking 
mutation. 
4.2.1 Tau isoform-specific effects of BRSK2 
In order to determine the effect of human BRSK2 on the 2N4R tau phenotype, 
Drosophila containing wild type BRSK2 on the third chromosome (named B2WT5) 
were crossed to the 2N4R WT tau line and also to a line containing 0N4R WT tau. In 
Figure 4.1, median DC images are shown for GMR (0.24), B2WT5 (0.22), 0N4R 
WT (0.50) and 2N4R WT tau (0.29), as well as flies containing either tau isoform 
alongside B2WT5 (0.78 for 0N4R/B2WT5, 0.25 for 2N4R/B2WT5). 0N4R/B2WT5 
recombinants shown were reared at 23°C due to lethality at 25°C. The drastic 
increase in toxicity in the 0N4R/B2WT5 recombinant line is clearly visible by eye. 
Analysis by QED (Figure 4.2) indicated a slight but significant reduction in DC of 
the GMR distribution when expressing B2WT5 alone (P=0.0017). The two different 
hemizygous tau isoform samples, of which 0N4R was not generated by specific 
insertion, have significantly differing DCs (P<0.0001). 0N4R  tau toxicity is 
drastically increased in the recombinant 0N4R/B2WT5 line (P=0.0002), in contrast 
to 2N4R tau toxicity, which is reduced in the non-recombinant 2N4R/B2WT5 line 
(P=0.0002). Eyes displaying minimum and maximum DC values for each genotype 
are shown in Figure 4.3.  
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Figure 4.1: Co-expression of BRSK2 with 0N4R tau increases tau-induced 
toxicity; co-expression with 2N4R tau does not 
Scanning electron microscope images demonstrating the lack of phenotype caused 
by expression of human BRSK2 in the fly eye, the disruption caused by human 0N4R 
or 2N4R tau, and the change in phenotype caused by co-expression of BRSK2 with 
the different tau isoforms. Images used were of sample median DC values, shown on 
images. 
Genotypes: GMR: GMR-GAL4/CyO;MKRS/TM6B. B2WT5: GMR-GAL4/CyO; 
BRSK2 WT5/TM6B. 0N4R hem: GMR-GAL4/CyO; 0N4R WT/TM6B. 0N4R/B2WT5: 
GMR-GAL4/CyO; 0N4R WT, BRSK2 WT5/TM6B. 2N4R hem: GMR-
GAL4/CyO;2N4R WT/MKRS. 2N4R/B2WT5: GMR-GAL4/CyO; 2N4R WT/BRSK2 
WT5. Scale bar: 100μm. 
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Figure 4.2 BRSK2 dramatically increases 0N4R tau toxicity; in contrast, BRSK2 
reduces 2N4R tau-induced toxicity as measured by QED 
Quantitative analysis of the phenotypes of the populations shown in Figure 4.1. 
B2WT5 has significantly lower DCs than GMR (P=0.0017) by Mann-Whitney U test. 
DCs of 0N4R/B2WT5 recombinants are significantly higher than 0N4R hem, also by 
Mann-Whitney U test (P=0.0002). DCs of 2N4R/B2WT5 are significantly less than 
2N4R hem by the same test (P=0.0002). 
GMR n=8. B2WT5 n=16. 0N4R hem n=14. 0N4R/B2WT5 n=13. 2N4R hem n=23. 
2N4R/B2WT5 n=17. 
 
  
97 
 
 
Figure 4.3 Phenotypic extremes of BRSK2-expressing flies 
Scanning electron microscope images showing the lowest and highest distortion 
coefficients for roundness among the 0N4R hem, 0N4R/B2WT5, 2N4R hem and 
2N4R/B2WT5 samples. DC values shown on images. Scale bar: 100μm. 
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4.2.2 Recapitulation of the tau/BRSK2 phenotype by phospho-mimetic mutation 
A double phospho-mimetic mutant, T212D/S262D was generated by site-directed 
mutagenesis in order to mimic tau phosphorylation by BRSK2 as described by 
Yoshida and Goedert (2011). The previously generated T212D mutant plasmid 
underwent further mutagenesis to add the S262D mutation. The resulting double 
mutant was then subcloned and inserted at the P2 PhiC3 integrase site as already 
described (Section 3.2.1). The median DC value images of this genotype are 
compared with 2N4R WT and 2N4R/B2WT5 in Figure 4.4. The double mutant 
exhibits visibly reduced toxicity compared with hemizygous 2N4R WT. QED 
analysis of these samples is shown in Figure 4.5. Hemi- and homozygous 2N4R tau 
DC values were found to be reduced significantly by introduction of these two 
mutations (P values of 0.0008 and <0.0001, respectively). T212D S262D hem DC 
values were not found to differ significantly from those of 2N4R/B2WT5 (P=0.41). 
Eyes showing minimum and maximum DC values for the double mutant phenotypes 
are shown in Figure 4.6. 
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Figure 4.4 Double phospho-mimetic T212D S262D mutation reduces tau toxicity 
Scanning electron microscope images. Dispersion coefficients shown on images.  
Genotypes: 2N4R hem: GMR-GAL4/CyO; 2N4R WT/MKRS. 2N4R/B2WT5: GMR-
GAL4/CyO; 2N4R WT/BRSK2 WT5. T212D S262D hem: GMR-GAL4/CyO; T212D 
S262D/MKRS. 2N4R hom: GMR-GAL4/CyO; 2N4R WT/2N4R WT. T212D S262D 
hom: GMR-GAL4/CyO; T212D S262D/ T212D S262D.  Scale bar: 100μm. 
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Figure 4.5 The phospho-mimetic double tau mutant exhibits a phenotype very 
similar to that of wild type 2N4R tau co-expressed with BRSK2, as measured by 
QED 
Quantitative analysis of the phenotypes of the samples shown in Figure 4.4. The DC 
of T212D S262D hem is significantly less than that of 2N4R hem (P=0.0008), by 
Mann-Whitney U test. The DC of T212D S262D hom is significantly less than that of 
2N4R hom (P<0.0001), by the same test. 
2N4R hem n=23. 2N4R hom n=25. 2N4R/B2WT5 n=17. T212D S262D hem n=10. 
T212D S262D hom n=14. 
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Figure 4.6 Phenotypic extremes of T212D S262D tau-expressing flies 
Scanning electron microscope images showing the lowest and highest distortion 
coefficients for roundness among the T212D S262D hem and hom samples. DC 
values shown on images. Scale bar: 100μm. 
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4.2.3 The effect of single-residue tau mutation on the tau/BRSK2 phenotype 
The double phospho-mimetic 2N4R tau mutations caused a very comparable change 
in phenotype to BRSK2, suggesting that phosphorylation at T212 and S262 
constituted the major part of tau phenotypic modulation by the kinase. However, this 
did not definitively prove that the effect of BRSK2 was solely due to these 
phosphorylation sites; indeed, the phenotypic correlation between the two could have 
been coincidental, with very similar phenotypes arising from different mechanisms 
in each case. Another possibility is that a larger number of phosphorylation sites are 
targeted by BRSK2, with a combined effect very similar to the double mutant. 
 The 2N4R tau mutant library provided an opportunity to explore the interaction 
between 2N4R tau and BRSK2 further. Non-phosphorylatable mutation at T212 or 
S262 should have predictable effects on BRSK2 phenotypic modulation, blocking its 
activity provided these sites are essential to this interaction. A similar experiment has 
previously been performed in 0N4R tau, in which an S262A mutation blocked 
exacerbation of toxicity by BRSK2 (Dr. Ceri Lyn-Adams, unpublished data). The 
T231 mutants were also tested as phosphorylation at this site by BRSK2 has not 
been examined previously.  
4.2.3.1 T212 mutation and BRSK2 
T212 mutant lines were crossed with B2WT5 to determine any change in the ability 
of BRSK2 to mitigate 2N4R tau toxicity in these mutants. Figure 4.7 shows the 
median DC value images for T212A hem (0.31) and T212D hem (0.27), alongside 
lines co-expressing BRSK2 on the third chromosome (0.24 And 0.27, respectively). 
Toxicity caused by T212A hem appears to be reduced by BRSK2. There is no clear 
reduction in phenotype in the T212D/B2WT5 sample compared with T212D hem. 
According to QED in Figure 4.8, BRSK2 significantly reduced T212A tau-induced 
ommatidial distortion (P<0.0001). There is no significant change between T212D 
hem and T212D/B2WT5 (P=0.19). Figure 4.9 contains eyes showing the lowest and 
highest DC values for the samples introduced in Figure 4.7.  
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Figure 4.7 Co-expression of BRSK2 alongside T212 mutant tau appears to reduce 
tau toxicity  
Scanning electron microscope images demonstrating the median toxicity of human 
2N4R tau, mutated at threonine 212, with or without BRSK2 co-expression and 
expressed in the fly eye under control of the GMR-GAL4 promoter. Dispersion 
coefficients shown on images. BRSK2 appears capable of reducing tau toxicity 
caused by T212A tau. 
Genotypes: T212A hem: GMR-GAL4/CyO; T212A/MKRS. T212D hem: GMR-
GAL4/CyO; T212D/MKRS. T212A/B2WT5: GMR-GAL4/CyO; T212A/BRSK2 WT5. 
T212D/B2WT5: GMR-GAL4/CyO; T212D/BRSK2 WT5. Scale bar: 100μm. 
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Figure 4.8 The ability of BRSK2 to mitigate 2N4R tau-induced toxicity is 
unaffected by T212 mutation 
Quantitative analysis of the phenotypes of the samples shown in Figure 4.7. The DC 
of T212A hem is significantly more than that of T212A/BRSK2 (P<0.0001), by 
Mann-Whitney U test. 
A: 2N4R hem n=23. 2N4R/B2WT5 n=17. T212A hem n=14. T212A/B2WT5 n=18. 
B: 2N4R hem n=23. 2N4R/B2WT5 n=17. T212D hem n=18. T212D/B2WT5 n=8. 
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Figure 4.9 Phenotypic extremes of flies co-expressing BRSK2 and T212 mutant 
tau 
Scanning electron microscope images showing the lowest and highest distortion 
coefficients for roundness in the T212A hem, T212A/B2WT5, T212D hem and 
T212D/B2WT5 samples. Scale bar: 100μm. 
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4.2.3.2 T231 mutation and BRSK2 
Figure 4.10 shows median DC value images for T231 mutants with (T231A hem 
DC=0.30, T231D hem DC=0.35) or without (T231A/B2WT5 DC=0.31, 
T231D/B2WT5 DC=0.27) BRSK2 co-expression. Visually, T231A/B2WT5 appears 
similar to T231A hem. T231D/B2WT5 appears to exhibit reduced toxicity. Analysis 
by QED (Figure 4.11) shows the inability of BRSK2 to reduce T231A toxicity 
(P=0.84). T231D/B2WT5 DC values are significantly reduced compared with 
T231D hem (P<0.0001). Figure 4.12 shows the lowest and highest DC value 
individual for each.  
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Figure 4.10 Co-expression of BRSK2 with T231A tau has no obvious phenotypic 
effect, unlike with T231D tau, in which a reduction in toxicity is noticeable  
Scanning electron microscope images demonstrating the median toxicity of human 
2N4R tau, mutated at threonine 231, with or without BRSK2 co-expression and 
expressed in the fly eye under control of the GMR-GAL4 promoter. Dispersion 
coefficients shown on images. BRSK2 appears unable to reduce toxicity caused by 
T231A. 
Genotypes: T231A hem: GMR-GAL4/CyO; T231A/MKRS. T231D hem: GMR-
GAL4/CyO; T231D/MKRS. T231A/B2WT5: GMR-GAL4/CyO; T231A/BRSK2 WT5. 
T231D/B2WT5: GMR-GAL4/CyO; T231D/BRSK2 WT5. Scale bar: 100μm. 
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Figure 4.11 The ability of BRSK2 to reduce 2N4R tau-induced toxicity is blocked 
by T231A mutation 
Quantitative analysis of the phenotypes of the samples shown in Figure 4.10. T231D 
hem DC is significantly more than that of T231D/B2WT5 by Mann-Whitney U test 
(P<0.0001).  
A: 2N4R hem n=23. 2N4R/B2WT5 n=17. T231A hem n=16. T231A/B2WT5 n=13. 
B: 2N4R hem n=23. 2N4R/B2WT5 n=17. T231D hem n=24. T231D/B2WT5 n=15. 
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Figure 4.12 Phenotypic extremes of flies co-expressingBRSK2 and T231 mutant 
tau 
Scanning electron microscope images showing the lowest and highest distortion 
coefficients for roundness in the T231A hem, T231A/B2WT5, T231D hem and 
T231D/B2WT5 samples. Scale bar: 100μm. 
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4.2.3.3 S262 mutation and BRSK2 
The effect of S262 mutation on the 2N4R tau/BRSK2 interaction was examined in 
the same way. Figure 4.13 shows the median DC values for S262A hem (0.28), 
S262A/B2WT5 (0.20), S262D hem (0.35) and S262D/B2WT5 (0.24). In each case it 
would appear that BRSK2 retains its capacity for reducing 2N4R tau toxicity. 
Analysis by QED (Figure 4.14) shows both S262A and S262D toxicity can be 
reduced by BRSK2 (P<0.0001 for S262A, P=0.0003 for S262D). Images with 
extreme DC values are shown in Figure 4.15.
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Figure 4.13 Co-expression of BRSK2 with S262 mutant tau leads to a reduction in 
tau toxicity 
Scanning electron microscope images demonstrating the median toxicity of human 
2N4R tau, mutated at serine 262, with or without BRSK2 co-expression and 
expressed in the fly eye under control of the GMR-GAL4 promoter. Dispersion 
coefficients shown on images. BRSK2 appears capable of reducing tau toxicity in 
each case. 
Genotypes: S262A hem: GMR-GAL4/CyO ; S262A/MKRS. S262D hem: GMR-
GAL4/CyO; S262D/MKRS. S262A/B2WT5: GMR-GAL4/CyO; S262A/BRSK2 WT5. 
S262D/B2WT5: GMR-GAL4/CyO; S262D/BRSK2 WT5. Scale bar: 100μm. 
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Figure 4.14 The ability of BRSK2 to reduce 2N4R tau-induced toxicity is 
unaffected by S262 mutation 
Quantitative analysis of the phenotypes of the samples shown in Figure 4.10. S262A 
hem DC is significantly more than that of S262A/B2WT5 by Mann-Whitney U test 
(P<0.0001). S262D hem DC is significantly more than that of S262D/B2WT5 by the 
same test (P=0.0003). 
A: 2N4R hem n=23. 2N4R/B2WT5 n=17. S262A hem n=20. S262A/B2WT5 n=18. 
B: 2N4R hem n=23. 2N4R/B2WT5 n=17. S262D hem n=20. S262D/B2WT5 n=6. 
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Figure 4.15 Phenotypic extremes of flies co-expressing BRSK2 and S262 mutant 
tau 
Scanning electron microscope images showing the lowest and highest distortion 
coefficients for roundness in the S262A hem, S262A/B2WT5, S262D hem and 
S262D/B2WT5 samples. Scale bar: 100μm. 
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4.3 Discussion 
This chapter has continued the exploration of the role of phosphorylation in human 
toxicity in a Drosophila model by examining the effect of the human kinase BRSK2. 
By expanding previous work by the Moffat and Frenguelli labs, demonstrating the 
ability of BRSK2 to exacerbate toxicity caused by the 0N4R isoform of human tau, 
this has revealed clear differences between tau isoforms in phenotypic changes 
caused by BRSK2.  
4.3.1 BRSK2 influences tau toxicity in an isoform-dependent manner 
Previous, unpublished data on the transgenic Drosophila lines expressing BRSK2 
(B2WT5) and human 0N4R tau (0N4R) had demonstrated a severely neurotoxic 
interaction between the two human transgenes in the fly eye. Expression of BRSK2 
alone, controlled by GMR led to no detectable increase in eye phenotype. Indeed 
QED analysis indicated a slight reduction in distortion compared with the GMR line, 
due either to variation in image quality leading to slight changes in edgeset integrity, 
or potentially a rescue of the minor changes previously recorded in the GMR line. 
This BRSK2-expressing line was generated by random insertion; the transgene was 
located on the third chromosome. The same was also true of the 0N4R line. These 
lines were generated prior to the decision being taken to generate all subsequent lines 
using the PhiC31 integrase-mediated specific insertion system which led to the 
generation of the 2N4R library. As a result, expression levels of these transgenes are 
dependent on positional effects relating to the insertion point which complicates 
direct comparison of the potency of the two wild type tau isoforms. This could 
explain the significantly more severe DC values of the 0N4R samples, compared 
with those of the 2N4R WT line. Regardless, it is clear that both 0N4R and 2N4R tau 
are capable of driving neurotoxicity in the fly eye. It is in their response to BRSK2 
co-expression that the two isoforms differ dramatically. 
Previous work on the 0N4R tau/BRSK2 interaction demonstrated the ability of 
BRSK2 to dramatically increase 0N4R tau-induced toxicity. Indeed, the toxicity of 
the recombinant 0N4R/B2WT5 line shown in Figure 4.1 is such that it cannot be 
reared to eclosion at 25°C, likely due to a certain amount of leakiness in the GMR 
promoter, as has been described in some other studies (Mondal et al., 2007; Xu et al., 
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2003). To combat this, the 0N4R/B2WT5 samples analysed were reared at 23°C. 
This interaction was shown to be based upon conserved pathways of BRSK2 
induction, with suppression of LKB1 or the CaMKK homologue CG17698 by RNAi 
both capable of reducing BRSK2-induced exacerbation of the tau phenotype. This 
work also outlined a pathway leading from Ca2+ to tau toxicity; via the fly Ca2+ 
channel α subunit cac1, through CaMKK and BRSK2, to tau. This work was unusual 
in Drosophila as it introduced a human kinase alongside transgenic human tau, but 
this served to demonstrate the conservation of the pathway in Drosophila. The fly 
BRSK homologue, CG6114 or SFF (Baas et al., 2011) was not found to have any 
effect on toxicity caused by human tau, and the lack of phenotype caused by BRSK2 
in the fly eye alone would indicate that the reverse is also true. Kinase dead and non-
phosphorylatable, uninducible BRSK2 mutants were both incapable of altering tau 
toxicity. 
With this information in hand, the expectation was for 2N4R tau to behave similarly 
to 0N4R tau in response to BRSK2, especially given the similar S262-dependant 
nature of toxicity in each isoform. On the contrary, there is a dramatic reversal in 
phenotype, with a significant reduction as measured by ommatidial distortion. This 
came as a surprise, given that these two tau isoforms differ only by number of N-
terminal inserts, the rather more neglected alternative splicing products of the tau 
gene. All previously-identified target residues of AMPK-related kinases on tau have 
been contained with the proline-rich region, microtubule-binding domains or 
carboxy-terminal region. This contrasting response could raise important questions 
regarding the roles of different tau isoforms in disease; it certainly poses a challenge 
to any attempt to draw definitive conclusions based upon data obtained in single-
isoform animal models.  
4.3.2 2N4R tau mutation can mimic the BRSK2 phenotype 
One goal of this project had always been to examine the precise role of tau 
phosphorylation in the tau/BRSK phenotype, by eliminating the possibility of 
BRSK2 acting via other substrates or altering tau metabolism. This goal was still 
relevant after the discovery of the importance of tau isoform to this interaction. To 
this end, a double phospho-mimetic aspartate mutant was generated, T212D S262D 
tau, based on the study of AMPK-related kinases by Yoshida and Goedert (2011). 
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Given the study of the 2N4R mutant library in Chapter 3, wherein T212D mutation 
was found to be protective and S262D mutation toxic, and the demonstration of non-
additive effects of phosphorylation in the context of microtubule binding (Kiris et al., 
2011), it was difficult to make a prediction. This more recent discovery of BRSK2 
having a protective role when co-expressed alongside 2N4R tau in the fly eye was 
considered a better indicator of the effect of this double mutation.  
In Figures 4.4 through 4.6, the phenotype and DC values of the T212D S262D 
double mutants are shown and compared with 2N4R WT and 2N4R/B2WT5. There 
is a significant reduction in ommatidial distortion compared with wild type 2N4R 
tau, in both hemi- and homozygous cases. When hemizygous T212D S262D is 
compared with 2N4R/B2WT5 (containing a single copy of 2N4R tau) based on DC 
values, there is no significant change; the double mutant seems capable of 
recapitulating the effect of BRSK2 on 2N4R tau in the absence of transgenic kinase. 
This is a potential indication of conservation of BRSK2 phosphorylation targets 
across isoforms, with the two sites indicated by a study on 1N4R tau (Yoshida and 
Goedert, 2011) capable alone of reproducing the phenotype caused by the kinase 
with 2N4R tau. Additionally, it is helpful in demonstrating that the lack of BRSK2-
induced exacerbation of neurotoxicity in this isoform is not necessarily due to a loss 
of affinity, but can be reproduced by targeted phospho-mimetic mutation. It is also 
another indication of the difficulty in predicting the phenotypic consequences of 
multiple, individually contrasting phospho-mutations.  
This does not mean, however that the interaction between 2N4R tau and BRSK2 has 
been fully explained. The novel tau phospho-mutant library was used to further 
explore this relationship, and to determine whether mutant tau would respond to 
BRSK2 as predicted. 
4.3.3 BRSK2 and the 2N4R phosphorylation mutant library 
Crossing mutant 2N4R tau lines with B2WT5 demonstrated the importance of 
phosphorylation at T212, T231 and S262 to the 2N4R/BRSK2 phenotype, as 
demonstrated by Figures 3.7 through 3.15.  
At T212, DC values for the non-phosphorylatable alanine mutant were significantly 
reduced by BRSK2 co-expression, whereas those of the T212D mutant were not. The 
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T212D/BRSK2 result can be explained if we posit that the reduction in toxicity 
caused by the T212D mutant, which should be mimicking part of the 
phosphorylation caused by BRSK2, represents the major part of the effect of 
BRSK2. This is reinforced by the lack of difference between 2N4R WT/BRSK2 and 
T212D/BRSK2 when compared by Mann Whitney U test (P=0.23). The ability of 
BRSK2 to reduce toxicity in the T212A mutant however, especially in this light, is 
surprising – if T212D is essential for BRSK2-induced protection, how can it still 
have had such an effect on this non-phosphorylatable mutant? Indeed, if we assume 
that T212 and S262 are the only important residues affected by this kinase, the effect 
of BRSK2 would be reversed if S262 was its sole target, as shown by the S262D 
mutant in Chapter 3. This contradiction is perhaps partially explained by T231. 
The T231D mutant is predictably affected by BRSK2, with a significant reduction in 
DC values upon co-expression. However, any effect of BRSK2 is apparently entirely 
eliminated by T231A mutation. This could be due to a reduction in affinity for 
BRSK2 caused by this mutation, removing any interaction completely. Alternatively, 
this could be evidence of yet another target residue of BRSK2. As has previously 
been observed, the proline-directed T231 was not investigated in the only major 
screen of tau phosphorylation by AMPK-related kinases (Yoshida and Goedert, 
2011), and has been shown to be phosphorylated by AMPK itself (Thornton et al., 
2011). Given the complexity of the tau phosphorylation code, it is possible that some 
level of T231 phosphorylation is a prerequisite of the reduction in tau toxicity 
observed upon introduction of BRSK2, potentially even (at endogenous levels) of 
the T212D S262D double mutation. Endogenous levels of T231 phosphorylation are 
clearly not sufficient alongside S262D pseudo-phosphorylation to produce such 
protection, otherwise the S262D mutant would exhibit such an effect alone; thus, it 
can only explain the ability of BRSK2 to reduce toxicity in the T212A mutant if the 
kinase increases phosphorylation at this site beyond endogenous levels. One 
additional possibility is that there is at least one other target of BRSK2 on 2N4R tau, 
which together with T212 (and potentially T231) creates some redundancy. 
Toxicity caused by both S262 mutants can be reduced significantly by BRSK2, 
which would indicate a lack of importance of this residue in the BRSK2 phenotypic 
changes. This is perhaps supported by the similarity in phenotype between the 
T212D mutant and the T212D S262D double mutant. However, direct comparison of 
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hemizygous DC values between these two do show a significant reduction in the 
double mutant (P=0.026), which is eliminated after addition of BRSK2 to T212D 
(P=0.27) so there would appear to be some extra effect in the double mutant.  
Together, these studies suggest a much more complex phosphorylation profile 
underlying the 2N4R tau/BRSK2 phenotype than that represented by the double 
phospho-mimetic mutant already generated. To summarise, BRSK2 leads to a 
phenotype suggestive of T212 pseudophosphorylation and recapitulated by a 
T212D/S262D mutant, but which is independent of T212 and S262 phosphorylation 
status, whilst being dependant on T231 phosphorylation. These data suggest that the 
similarity between the T212D S262D phenotype and that of 2N4R WT/BRSK2 is 
not evidence of these mutations representing the entirety of the effect of BRSK2. 
Perhaps inevitably given the complex system being investigated, there appear to be 
multiple paths to reaching the same result (and degree) of reduced toxicity, with far 
more combinations than measurable potential outcomes. If the effect of BRSK2 is 
indeed due to phosphorylation, and if the 1N4R tau phosphorylation data in vitro are 
applicable to this 2N4R model in vivo, then at the very least there must be some 
redundancy in this phosphorylation code. This would require phosphorylation of tau 
at other residues, likely T231 and others. A simple initial set of experiments would 
be to probe for changes in phosphorylation at T212, T231 and S262 in 2N4R tau in 
samples from flies co-expressing BRSK2. This would give an indication of relevance 
of the in vitro work as well as examining the relationship between T231 and BRSK2. 
Ultimately though, such small scale screens are likely to lead to uncertain 
conclusions given the number of potential residues of interest. Equally, expansion of 
the tau mutant library can only be effective with enough information to direct 
targeted mutation of residues of interest – the process is too slow and costly to 
explore every possible combination, even among the few sites listed here. This is 
rendered all the more pressing by the unearthed differences between tau isoforms 
and potential interest in replicating the library in 0N4R tau. One potential method of 
exploring BRSK2-induced phosphorylation could come from phosphoproteomics. 
Advances in the field of mass spectrometry over the past decade have begun to allow 
quantitative evaluation of the phosphorylation state of proteins. For example, SILAC 
(stable isotope labelling with amino acids in cell culture) is a method which uses 
heavy isotope-labelled growth media to differentiate between cell populations, 
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before aligning cleaved peptides by liquid chromatography prior to analysis (Ong et 
al., 2002). This method has been used proteome-wide to explore Cdk1(cyclin-
dependent kinase 1) phosphorylation (Holt et al., 2009). Less expensive stable 
isotope labelling methods have also been developed, in which deuterium labelling 
occurs at the peptide level, following digestion which would likely be more practical 
for study of a single protein (Boersema et al., 2009). Given the number of post-
translational modifications tau is subject to, such comprehensive data would be very 
useful for informing any future addition to the phosphorylation library or phospho-
antibody collection. 
The other possible explanation for the discrepancy between the predicted importance 
of BRSK2 phosphorylation and the apparent reality would be for the kinase to play 
an entirely different role in determining tau toxicity.  
 
4.3.4 An alternative hypothesis for the tau/BRSK phenotype 
The phosphorylation mutants have demonstrated a previously unknown importance 
for T231 in the 2N4R tau/BRSK interaction, which is completely prevented in the 
T231A mutant. This is also the only mutation shown to be capable of preventing this 
phenotypic suppression, despite other BRSK2 target residues being studied. The 
T231A mutant was also shown to present the lowest protein levels in Figure 3.3, 
which, it was hypothesised, could be caused by changes in tau stability. Previous 
work on BRSK2, using 0N4R tau found evidence of a drastic increase in autophagic 
activity in the developing eye disc (as measured by lysotracker stain) in samples co-
expressing both human transgenes (unpublished data). The severe eye phenotype 
was also found in preliminary experiments to respond to modulation of two elements 
of autophagic machinery, Atg1 and TorTED. One possibility is that the observed 
ability of BRSK2 to modulate tau toxicity in the fly eye is due to changes in 
transgene removal. In the highly toxic 0N4R tau/BRSK2, it is possible that the high 
lysotracker stain was due to either a massive upregulation of autophagy in response 
to changes in tau post-translational modification, or to a blockage in autophagic flux 
leading to an accumulation of unused lysosomes. Potentially, in the context of the fly 
eye, it is tau removal which is most important in determining toxicity, rather than 
levels of microtubule binding or aggregation. Indeed, the innocuous nature of 
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BRSK2 in the eye in the absence of tau has been shown to be tissue-dependant, with 
BRSK2 expression lethal in the fly when driven by the pan-neuronal ELAV driver 
(unpublished data), indicating that this model may not be able to tell the full story of 
neurotoxicity. It is also possible that changes in tau clearance could help explain the 
isoform-specific differences in the effect of BRSK2. 
The roles of the six tau isoforms in disease remain unclear. In particular, the 
significance of the N terminal inserts in disease has historically received little 
attention. In this work, two tau isoforms each with four microtubule-binding repeats 
have been found to demonstrate remarkably different responses to the AMPK-related 
kinase BRSK2. The current understanding of the role of exons 2 and 3 provides no 
clear answers. Whereas the effect of an extra microtubule-binding domain on 
cytoskeletal dynamics has fairly intuitive consequences (Goode et al., 2000), 
variation in tau projection domain length is a less obvious potential contributor to 
disease. Quantitative analysis has shown the importance of the N-terminal domain in 
balancing out kinesin-based transport velocity (Tarhan et al., 2013), with the 
increased negative charge of the projection domain helping the kinesin to sidestep 
intervening tau “roadblocks”, a charge which could also help tau maintain its healthy 
axonal localisation (Haass and Mandelkow, 2010; Ittner et al., 2010). This could 
point to a potential link between transgenic tau and microtubule-based transport 
disruption, with an overabundance of 0N4R tau impeding kinesin passage. The 
projection domain has also been shown to be responsible for creating a negatively-
charged “polyelectrolyte brush” around tau aggregates (Wegmann et al., 2013), 
which would presumably be larger and of even greater charge if predominantly 
composed of 2N tau. This does seem unlikely to be relevant to the fly model given 
the short developmental period for the formation of large aggregates. One area of 
interest in which the tau N terminal domain may be of interest is in the link between 
conformational changes of tau and disease. 
Alz-50, one of the first antibodies to be discovered for pathological tau (Wolozin et 
al., 1986) evaded easy classification for several years owing to its complex epitope, 
furthering the mystery surrounding the A68 antigen which was later discovered to be 
hyperphosphorylated tau (Brion et al., 1991). This conformational antibody would in 
fact only recognise tau possessed of a specific secondary structure (Carmel et al., 
1996), enriched in cases of neurodegenerative disease, in which the extreme N 
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terminus was brought into proximity with the microtubule-binding region. This 
Alz50 conformation differs from the normal “paperclip” conformation (Himmelstein 
et al., 2012) and has been hypothesised to greatly increase the likelihood of tau 
aggregation. Further studies have indicated the potential of conformational control 
for reducing tau aggregation (Akoury et al., 2013) and microtubule dissociation 
(Fischer et al., 2009). Isoform-specific differences in secondary structure have not 
been found, and in the case of Alz-50 all isoforms are capable of exhibiting 
reactivity. Nonetheless, conformational changes could potentially underlie the 
different responses to BRSK2 between 0N4R and 2N4R tau, or even some phospho-
mutant phenotypes. Phosphorylation-induced tau conformational changes have been 
recorded, particularly in proline-rich regions (Bielska and Zondlo, 2006). The 
additional charge of the projection domain could also lead to an increased likelihood 
of binding to the microtubule-binding region in an Alz50 conformation. This leads to 
one possible explanation of BRSK2’s isoform-specific effects: that there may be no 
direct (or relevant) interaction between BRSK2 and 2N4R tau. The apparent ability, 
according to QED, of BRSK2 to reduce slight GMR-induced ommatidial distortion 
could be evidence of the same mechanism causing a rescue of 2N4R tau toxicity. 
This could again implicate BRSK2 as a regulator of protein clearance, but also in the 
absence of any tau protein. BRSK2 could directly effect changes to 0N4R tau which 
it cannot in the longer isoform, or each isoform could provoke entirely different 
autophagic responses, with 0N4R tau leading to an extreme cytotoxic response. 
Differences in secondary structure could underlie this distinction. Any such change 
in tau clearance should lead to a change in total tau levels, detectable by Western blot 
with a total tau antibody such as the T46 used in the previous Chapter. Whether this 
is due to changes in the autophagic process could be examined using Lysotracker or 
Ref(2)P stain (Nezis et al., 2008). The Alz-50 antibody could also be one method of 
examining the secondary structure of human tau in this model, although there is no 
guarantee that this conformation can arise in the fly eye. 
 
This chapter has demonstrated the isoform-specific effects of the tau kinase BRSK2. 
It has begun to show the complexity of the phosphorylation code of tau, with a 
double mutant phenotype and unexpected resistance to BRSK2 activity. The fly eye 
could play host to a great deal more experiments to explore the tau/BRSK2 
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interaction further, including further forays into phosphorylation, autophagy and tau 
secondary structure. One drawback has been underlined by comparison of eye 
phenotypes: the low resolution of quantification in this unusual tissue. In the next 
chapter, the potential of other expression systems in Drosophila is explored.  
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5| Establishing a Drosophila CNS 
model of progressive, tau-
dependent functional impairment 
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5.1 Introduction 
The Drosophila eye has been used as a model for the study of tau-induced 
neurodegeneration for more than ten years (Jackson et al., 2002; Wittmann et al., 
2001). The regular nature of ommatidial organisation is determined by the Ras 
signalling pathway (Wassarman et al., 1995), with correct development of each of 
the eight photoreceptors present per ommatidium dependent upon specific genes; for 
example, differentiation of the R7 photoreceptor is regulated by the receptor tyrosine 
kinase Sevenless (Tomlinson et al., 1987). Another example of using the fly eye as a 
model is in the study of cell death pathways (Hay et al., 1994; Ollmann et al., 2000). 
As a measure of neurotoxicity, ommatidial disruption has ample sensitivity for 
differentiating individual tau mutations, whether of phosphorylation sites, as shown 
in this work, or FTDP-17 mutations such as R406W (Wittmann et al., 2001). 
However, the commonly-used eye-specific promoter GMR has a limitation when 
studying particularly toxic genotypes: leakiness in control of expression (Mondal et 
al., 2007; Xu et al., 2003), which can lead to lethality, as found in the previous 
Chapter. This necessitated a change in the rearing temperature for the recombinant 
0N4R tau/BRSK2 line. In addition, a limitation of this model is that it bases its 
quantification of toxicity on developmental cell death, with the adult eye essentially 
formed following eclosion. Alternative methods of studying and quantifying tau-
induced toxicity were thus sought. 
In order to move beyond the study of developmental toxicity, a mechanism of 
transgene expression control was required. This would also allow the study of 
toxicity in essential tissues of the CNS without developmental lethality, as had been 
found in the case of constitutive expression of BRSK2 by the ELAV pan-neuronal 
promoter (unpublished observation). This was considered desirable as it would allow 
quantification of toxicity by more varied means and in contexts more comparable to 
the tissues affected by tauopathy. Helpfully, multiple methods allowing temporal 
control of expression exist, involving pharmacological and environmental factors. 
The first system tested, known as the TARGET system (temporal and regional gene 
expression targeting) was based around temperature-dependent control of expression 
(McGuire et al., 2004a). This system uses a temperature-sensitive mutant of GAL80, 
the repressor of GAL4 activity to allow repression of transgene expression at 18°C 
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and de-repression at 29°C. An ELAV promoter line under the control of this GAL4-
GAL80TS was kindly provided by Dr. Kyung-An Han of the University of Texas at 
El Paso. This repressor was shown to function effectively in a study on the dopamine 
receptor dDA1 and its role in aversive and appetitive learning in the mushroom body 
(Kim et al., 2007). This system would allow the examination of the consequences of 
adult-onset transgene expression throughout the CNS, with the possibility of 
multiple behavioural and activity-based measures of morbidity and mortality.  
Initially, a simple mortality curve experiment was attempted, but the high 
experimental temperature resulted in very rapid desiccation of food and led to many 
early deaths as animals became trapped in cracks in their food. In order to increase 
the amount of data obtained and to create a more stable environment, the TriKinetics 
Inc. Drosophila Activity Monitor, or DAM2 System was used to record activity and 
survival over long time periods. This also reduced the danger of animals becoming 
trapped on food as the small vials are held horizontally within the machines. This 
system was also designed for the study of circadian rhythm analysis and as such was 
ideal for the study of transgene expression within the PDF (pigment dispersing 
factor) neurons which act as the fly circadian pacemaker (Helfrich-Forster et al., 
2000; Park and Hall, 1998; Park et al., 2000).  
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5.2 Results 
5.2.1 Effects of ELAV-GAL4 GAL80TS-controlled transgene expression on 
activity and survival 
In order to explore the post-developmental toxicity of tau in neuronal tissue other 
than the eye, a recombinant ELAV-GAL4 GAL80TS line (hereafter referred to as 
ELAV) was crossed with transgenes described in the previous two Chapters. These 
crosses were performed and the progeny maintained at 18°C in order to suppress 
transgene expression. Adults of up to one week of age were then transferred to the 
DAM2 monitoring system at 29°C for transgene induction and activity recording. 
These experiments were performed under conditions suitable for study of a free-
running period to enable retrospective examination of circadian rhythm changes, and 
were consequently exposed to equal light/dark cycles for 5 full days before onset of 
constant darkness for the remainder of the experiment. 
5.2.1.1 0N4R tau and BRSK2 
The first experiments performed were attempts to examine the effect of 0N4R tau 
and BRSK2 transgenes on behavioural activity. It was expected that expression of 
these transgenes would lead to measurable effects on total activity due to morbidity 
or mortality if they had any toxic effect in the CNS. Crosses were thus performed 
between the ELAV line and the 0N4R and B2WT5 lines, as well as the recombinant 
0N4R/B2WT5 line introduced in Section 4.2.1. Recording by the DAM2 system 
sorted data into 1 minute bins which, upon completion of the recording, could be re-
binned into 30 minute intervals, using the software DAM Filescan 1.07. These bins 
were then summed into values for each 24 hours of activity, using a simple 
spreadsheet in Origin 7. All measurements of total daily activity in this Chapter 
underwent this re-binning procedure.  In Figure 5.1, the average daily activity over a 
three week time course of each of these lines, as well as ELAV controls, is plotted. 
Data from individuals were discarded if they did not survive past the first week in 
order to remove particularly sickly animals from the analysis. In order to determine 
whether the activity levels of each of the genotypes evolved differently over the 
period studied, a two-way ANOVA with repeated measures was performed in 
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GraphPad Prism 6. Both the genotype (P=0.0062) and day (P<0.0001) were found to 
be significant sources of variation in total daily activity. In addition, the interaction 
of these two variables was also found to be significant (P<0.0001), indicating that 
the rate of change in daily activity is dependent on the genotype. This was still found 
to be significant if the first week of data was removed from the analysis to avoid 
taking into account the early acclimatisation period and any possible increase in 
variance it may have caused: this was the case for genotype (P=0.0048), day 
(P<0.0001) and their interaction (P<0.0001). This also removes the earliest periods 
of expression, likely with the lowest transgenic protein levels of the experiment. 
When compared individually, 0N4R tau was not found to lead to a significant change 
in activity over the final two weeks of data (genotype/day interaction P=0.1231). 
BRSK2 expression was found to cause significant changes in activity (P=0.0271 
under the same conditions), as was the recombinant 0N4R/B2WT5 line (P=0.001). 
Both B2WT5 and 0N4R/B2WT5 differed significantly from 0N4R tau alone 
(P=0.0007 and P=0.0011, respectively). 0N4R/B2WT5 differed significantly from 
B2WT5 if all three weeks of data were compared (interaction P=0.0025), but not if 
the first week was omitted (P=0.12). Flies expressing both 0N4R tau and BRSK2 die 
off earliest, with 100% lethality by day 12. There is an increase in 0N4R-induced 
activity decline compared with ELAV after day 11, but there are still some survivors 
after 21 days. As had been suspected after previous unpublished data revealed the 
lethality of ELAV-controlled developmental BRSK2 expression, the offspring of the 
ELAV cross to B2WT5 exhibit a severe decline in activity, with 100% lethality by 
day 20. It would seem that BRSK2 is toxic in at least some vital tissues of the CNS. 
It was also noted that the high temperatures used here were having an effect on 
behaviour, with animals becoming predominantly nocturnal in response – this was 
not surprising given recorded effects of temperature on periodicity (Sawyer et al., 
1997) diurnal activity levels (Tomioka et al., 1998). It was also likely responsible for 
the shortened lifespan of control animals (Miquel et al., 1976).  
128 
 
 
Figure 5.1: BRSK2 expression in the CNS, with or without 0N4R tau, reduces 
lifespan 
A: Total daily activity measured in number of beam break events. Genotype was 
shown to control rate of decrease over time by two-way repeated measures ANOVA 
(P<0.0001). Error bars represent standard error. The black and white bar above the 
plot indicates the duration of alternating light/dark. 
B: Total values normalised to readings of day 7, in order to reduce line-specific 
differences in baseline activity, and to avoid exaggeration caused by light/dark 
change.  ELAV n=10. 0N4R n=18. B2WT5 n=23. 0N4R/B2WT5 n=10.  
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5.2.1.2 2N4R tau and mutants 
The 2N4R tau mutant library was also crossed with the ELAV line to determine 
whether the differences in toxicity found in the eye upon GMR-controlled expression 
could also be reproduced in the CNS of adults. The 2N4R WT line and all single tau 
mutations were crossed with ELAV and the progeny studied using the DAM2 
system, this time for a longer period of 33 days. Figure 5.2 shows total activity, 
Figure 5.3 activity relative to day 7. Animals not surviving after the first week were 
again disregarded from analysis. Two-way repeated measures ANOVA initially 
indicated a significant interaction between genotype and time point (P<0.0001), but 
re-analysis of the data obtained under constant dark (after day 7) failed to find a 
significant relationship (P=0.097). Given that acclimatisation to the conditions of the 
experiment is likely to lead to increased variation between all individuals over the 
first week, and that transgene levels would be expected to be lowest during this 
period, it seems appropriate to consider the latter measure more applicable. It is 
possible to speculate on some trends, for example comparing S262A to S262D the 
phospho-mimetic mutant consistently exhibits lower activity levels than its non-
phosphorylatable counterpart. The T212A mutant exhibited a long period of hyper-
activity before a sharp decline, with maximum lifespan comparable with all other 
lines. Indeed, upon normalisation of the data in Figure 5.3, it would appear that a 
certain level of hyperactivity is witnessed in all 2N4R tau and mutant lines. The two 
T231 mutants produced curves which are particularly close to 2N4R WT, also in line 
with the smaller range of eye phenotypes produced by mutation at this site. 
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Figure 5.2: Absolute activity levels over 33 days do not reveal any 2N4R tau-
induced reduction in lifespan 
Data from flies expressing 2N4R tau was recorded for 33 days. No significant 
difference was found between the curves by two-way ANOVA with repeated measures 
(P=0.097). The black and white bars above the plots indicate the duration of 
alternating light/dark. 
A: Data from ELAV controls and WT 2N4R tau-expressing individuals.  
B: Data from controls and WT 2N4R, overlaid with data from individuals expressing 
T212A or T212D mutant tau.   
C: Data from controls and WT 2N4R, overlaid with data from individuals expressing 
T231A or T231D mutant tau.   
D: Data from controls and WT 2N4R, overlaid with data from individuals expressing 
S262A or S262D mutant tau.   
ELAV n=9. 2N4R n=9. T212A n=9. T212D n=10. T231A n=8. T231D n=9. S262A 
n=10. S262D n=10. 
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Figure 5.3: Normalised data from Figure 5.2 reveals consistently higher levels of 
activity after three weeks in 2N4R tau-expressing lines 
Data from flies expressing 2N4R tau was recorded for 33 days. Data has been 
normalised to day 7 values to remove line-specific differences in baseline activity 
and to avoid additional variation caused by light/dark acclimatisation. The black 
and white bars above the plots indicate the duration of alternating light/dark. 
A: Data from ELAV controls and WT 2N4R tau-expressing individuals.  
B: Data from controls and WT 2N4R, overlaid with data from individuals expressing 
T212A or T212D mutant tau.   
C: Data from controls and WT 2N4R, overlaid with data from individuals expressing 
T231A or T231D mutant tau.   
D: Data from controls and WT 2N4R, overlaid with data from individuals expressing 
S262A or S262D mutant tau.   
ELAV n=9. 2N4R n=9. T212A n=9. T212D n=10. T231A n=8. T231D n=9. S262A 
n=10. S262D n=10. 
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5.2.2 Effects of PDF-GAL4-controlled transgene expression on activity and 
survival 
In the search for novel methods of quantification of neurotoxicity in the fly, it was 
hoped that the diverse array of techniques developed for the study of circadian 
rhythmicity could be of use. To this end, we set out to determine whether expression 
of human tau under the control of the PDF promoter, driving expression of the 
transgenes within the interneurons of the Drosophila circadian pacemaker, could 
have any destabilising effect on periodicity. Flies were generated by crossing all of 
the transgenic lines described in Section 5.2.1 with the PDF promoter line rather than 
with the ELAV line. Crosses were performed at 25°C in order to maximise transgene 
exposure; this temperature was kept constant throughout the experiment. Animals 
were exposed to an alternating 12 hours of light, 12 hours of darkness cycle for the 
first five full days of recording. 
5.2.2.1 PDF expression and survival 
One expected advantage of using the PDF promoter over ELAV is the non-essential 
nature of the target tissues. As a result, it was possible to cross flies without any 
attempt to suppress expression during development. In order to verify that there was 
no additional morbidity or mortality associated with transgene expression, total daily 
activity levels were monitored for each individual. Figure 5.4 presents the total 
activity curves for all 11 genotypes tested. The same data is shown normalised to day 
7 activity values in Figure 5.5. Animals were again disregarded if they did not 
survive past the first week. Under these more conventional conditions of 
temperature, there was a marked decrease in activity upon entry into constant 
darkness. Analysis of the curves by two-way ANOVA with repeated measures 
showed no significant variation due to genotype alone (P=0.082), but highly 
significant variation with interaction (P<0.0001). This could be removed by reducing 
the period of analysis to the final 10 days (interaction P=0.12). The statistical 
differences in activity levels are concentrated within the first week of recording, 
suggesting any variation is due to early differences in acclimatisation, rather than 
toxicity due to leaky expression elsewhere in the nervous system, which would 
presumably become more pronounced over time. For example, 0N4R/B2WT5 is 
initially found to differ in activity levels to all other genotypes except WT 2N4R tau, 
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as measured by Turkey’s multiple comparisons test; by day 7, no significant 
difference remains. 2N4R tau is found to differ from both T212 mutants and S262D 
until day 5. Some initial differences were also found between 0N4R tau and T212A 
mutant 2N4R tau. Turkey’s multiple comparisons test ceases to find any significant 
differences between genotypes by day 7. After this time, repeated measures ANOVA 
continues to find significant variation with interaction until day 11. Again, this 
reduction in variation over time is consistent with a lack of transgene-induced 
toxicity, suggesting expression is limited to non-essential regions. Visually, the data 
indicated T231D exhibited reduced activity for the duration of the phase of constant 
darkness. The only genotype which appeared to have had an effect on the rate of 
decline in activity is 0N4R/B2WT5. The majority of 2N4R lines do not exhibit any 
obvious differences in their total activity levels under constant darkness.  
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Figure 5.4: Absolute activity levels do not reveal any effect of tau or BRSK2 
expression on lifespan 
Data was recorded for 21 days. Two-way ANOVA with repeated measures showed 
significant variation in activity curves between genotypes from 7 days (P<0.0001) 
but not from 12 days (P=0.12). The black and white bars above the plots indicate the 
duration of alternating light/dark. 
A: Data from PDF controls and individuals expressing 0N4R tau, BRSK2 and 0N4R 
tau and BRSK2 together.  
B: Data from controls, WT 2N4R and both T212 tau mutants.   
C: Data from controls, WT 2N4R and both T231 tau mutants. 
D: Data from controls, WT 2N4R and both S262 tau mutants. 
PDF n=9. 0N4R n=8. B2WT5 n=7. 0N4R/B2WT5 n=9. 2N4R n=8. T212A n=10. 
T212D n=4. T231A n=9.T231D n=8. S262A n=8. S262D n=9. 
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Figure 5.5: Normalised data from Figure 5.4. No significant effects on lifespan 
caused by PDF-controlled transgene expression were found 
Data was recorded for 21 days. Data has been normalised to day 7 values to remove 
line-specific differences in baseline activity and to avoid additional variation caused 
by light/dark acclimatisation. The black and white bars above the plots indicate the 
duration of alternating light/dark. 
A: Data from PDF controls and individuals expressing 0N4R tau, BRSK2 and 0N4R 
tau and BRSK2 together.  
B: Data from controls, WT 2N4R and both T212 tau mutants.   
C: Data from controls, WT 2N4R and both T231 tau mutants. 
D: Data from controls, WT 2N4R and both S262 tau mutants. 
PDF n=9. 0N4R n=8. B2WT5 n=7. 0N4R/B2WT5 n=9. 2N4R n=8. T212A n=10. 
T212D n=4. T231A n=9.T231D n=8. S262A n=8. S262D n=9. 
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5.2.2.2 PDF expression and circadian periodicity 
In order to determine whether human tau isoforms or BRSK2 were toxic to PDF 
neurons, the DAM2 activity data was also analysed to compare periodicity. Where 
previous analysis was based around total values for each 24 hours of activity, for 
analysis of circadian rhythms the data were kept in 30 minute bins. These were 
suitable for analysis by the ImageJ plugin Actogram J. This program provided 
multiple methods of analysing periodicity. The most effective of these are Chi square 
and Lomb-Scargle. As the Chi square method requires at least 10 cycles of data to be 
accurate, and we were only interested in the free running period of these flies, all 
individuals with fewer than 10 days of data in constant darkness were discarded. 
Figure 5.6 demonstrates the spread and mean of the periods for each sample. In 
Figure 5.6A, the periods are based on chi square periodograms; in Figure 5.6B, they 
are based on Lomb-Scargle periodograms. Comparison of the data by Kruskal-Wallis 
test (non-parametric one-way ANOVA) revealed a significant difference between 
genotypes (P=0.011), due to some variation in T231A and B2WT5. The Lomb-
Scargle data did not reveal any significant differences by the same test (P=0.079). 
Comparing the two spreads of data, the only genotypes which contained consistently 
high levels of variation were the two lines expressing BRSK2, with T231A only 
differing due to a single sample in the chi square test, and PDF and T231D by single 
readings in the Lomb-Scargle data. It appears unlikely based on these data that 
human tau is having any severe effect on PDF neurons in these animals. It is possible 
however, that BRSK2 is causing some disruption. 
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Figure 5.6: BRSK2 expression was found to have a greater effect on periodicity 
than 0N4R or 2N4R tau 
A: Mean and spread of period of each genotype, by chi square periodogram. 
Variances were found to differ significantly by Kruskal-Wallis test (P=0.011). 
B: Mean and spread of period of each genotype, by Lomb-Scargle periodogram. 
Variances were not found to differ significantly by the same test (P=0.079). 
Grey bars represent mean +/- standard error of the PDF control line. PDF n=9. 
0N4R n=8. B2WT5 n=7. 0N4R/B2WT5 n=9. 2N4R n=8. T212A n=10. T212D n=4. 
T231A n=9.T231D n=8. S262A n=8. S262D n=9. 
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5.3 Discussion 
This chapter has documented the attempts made to complement the Drosophila eye-
based model used in Chapters 3 and 4 with alternative, CNS expression-based 
functional assays. The primary goal was to determine whether the fruit fly could 
effectively become a useful model for the demonstration of progressive, adult-onset 
neurotoxicity due to expression of human proteins implicated in disease. In addition, 
we sought to establish alternative methods of quantification, in order to help 
distinguish between the many genotypes already screened in the eye. 
5.3.1 Inducible CNS expression using the TARGET system 
The Drosophila eye is a useful model for tau toxicity as it provides a sensitive, 
visible, non-lethal and quantifiable platform for neurotoxicity. However, this model 
is reliant on developmental transgene expression disrupting the formation of the eye, 
and consequently provided no information on the toxicity of these transgenes in the 
adult. Since the ommatidia, once developed, are no longer capable of reporting 
strong external signs of neurotoxicity, the CNS was considered an apt target for 
adult-onset toxicity experiments.  Given that previous attempts to express BRSK2 
under the control of ELAV had failed, due to apparent developmental lethality, a 
powerful method of transgene repression was required for the experiment. The use of 
the TARGET system of expression control meant the experiments had to be 
performed at unusual temperatures (18°C during development, 29°C during 
monitoring), which caused behavioural changes in the animals studied as their 
activity patterns shifted to nocturnal. As a result, the decision was made to limit 
analysis of DAM2 data of GAL80TS-controlled subjects to sums of daily activity, to 
look for differences in morbidity, mortality or gross activity changes. 
The recombinant 0N4R/B2WT5 line was used in an experiment to test whether this 
interaction would exhibit comparably toxic effects in the CNS to those witnessed in 
the eye. When plotted in Figure 5.1, the daily activity levels of each genotype do 
seem to differ, particularly when normalised to account for initial differences in 
activity for each genotype in Figure 5.1B. What is most clear is the drastic reduction 
in lifespan in both lines expressing BRSK2, with 100% mortality of B2WT5 at day 
20, and of 0N4R/B2WT5 at day 12. Neither ELAV nor 0N4R alone reached 100% 
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mortality within three weeks. Comparison of these activity data by two-way ANOVA 
with repeated measures did not find any significant change between these latter two 
samples. This is potentially due to the large degree of error in the ELAV samples, 
caused by the accumulation of dead animals among other healthy, relatively very 
active individuals and the smaller sample size. However, what is clear is that 0N4R 
tau alone did not have as much of an effect as did expression of BRSK2 alone. This 
result makes sense in the light of the earlier finding of the developmental toxicity of 
ELAV-driven BRSK2. There would appear to be some additional toxicity in the 
recombinant line when comparing mortality rate, but differences in activity were not 
found to be significant. These data differ remarkably from those of eye-based 
experiments, which find BRSK2 alone to be completely benign (Section 4.2.1). This 
certainly begs questions of other tau kinases previously studied in the fly eye, 
particularly the AMPK-related kinases. This tissue-specific toxicity could offer some 
potential insight into BRSK2’s mechanism of action on human tau in the fly eye. In 
Section 4.3.4, it was speculated that BRSK2 could play some role in the removal of 
the transgenes involved in the eye experiments, as the kinase appeared to mitigate 
the low-level disruption caused by the GMR promoter; hypothetically, this could also 
be the cause of the reduction in toxicity of 2N4R tau when co-expressed with 
BRSK2. It is possible that among the wider array of tissues being exposed to BRSK2 
by ELAV, this hypothetical increase in degradation could affect a number of 
essential, endogenous proteins. A potential first candidate to investigate is 
Drosophila tau. The existence of a d-tau null allele (Doerflinger et al., 2003), and the 
success of experiments using homozygous d-tau -/- flies (Feuillette et al., 2010) 
make this a testable possibility. Equally however, given that d-tau is clearly not an 
essential component of the fly microtubule cytoskeleton, likely due to some element 
of redundancy with other MAPs (Doerflinger et al., 2003), it is unlikely that removal 
of d-tau would be a significant contributor to toxicity. BRSK2-induced dysfunction 
could be an alternative hypothesis, and one with a more manageable number of 
potential research targets. Given the growing number of BRSK substrates, including 
the cell cycle regulators Cdc25-C  and Wee1 (Lu et al., 2004; Muller et al., 2010), 
the synaptic vesicle-priming factor RIM1 (Inoue et al., 2006) and γ-tubulin directly 
(Alvarado-Kristensson et al., 2009), there are many mechanisms potentially being 
misregulated. Any and all of these processes could play essential roles as BRSKs 
emerge as conductors of axonal morphogenesis (Lilley et al., 2013). Drosophila 
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homologues of Wee1 (Campbell et al., 1995) and Cdc25 (Edgar and O'Farrell, 1989) 
are well-documented and could be useful avenues of research into this novel 
BRSK2-induced toxic effect. 
As for 0N4R tau, it is tempting to see a trend toward reduced activity among the 
older surviving flies, or perhaps reduced survival compared with the ELAV controls. 
Expanding the size of the experiment to enable a proper analysis of survival would 
perhaps be one avenue of further inquiry. Another simple next step would be to use 
homozygous 0N4R tau transgenics, which would likely emphasise any effect of 
0N4R tau. It would be interesting to be able to examine individuals of different ages 
more closely, perhaps with transverse paraffin sections (Kucherenko et al., 2010) of 
the heads of aged flies. This would enable visual determination of the nature of 
neuronal damage in these individuals, which if severe should lead to visible lesions, 
and would also be the best indication of whether this model is capable of 
representing progressive neurodegenerative conditions over a relatively short time 
period. 
Given the lack of significant change in activity levels between the ELAV controls 
and 0N4R tau flies, it is unsurprising that none of the 2N4R mutants exhibit a 
significant change compared with controls in Figures 5.2 and 5.3. The trends in both 
average daily activity and maximum lifespan are very similar in virtually every case, 
with only activity of the T212A line standing out as having changed differently over 
the course of the experiment. Over the second and third weeks of monitoring, a 
consistent increase in activity was recorded among the majority of T212A 
individuals, before dropping down to control levels at day 26. It does not appear as 
though this increase in activity led to any deleterious effect, as the maximum lifespan 
for this genotype was in line with all others. It is interesting to note that the increase 
coincides with the onset of the phase of constant darkness – it is possible that T212A 
tau was causing disruption of a subset of neurons responsible for regulating 
behavioural responses to light. However, this trend becomes common to several 
other 2N4R lines upon normalisation of the data, including 2N4R WT, T231D and 
S262A. Such normalisation somewhat exaggerates the difference between S262A 
and S262D in the final days of the experiment, with S262D appearing to drop off 
more quickly, a possible indicator of increased toxicity though not to any statistically 
significant degree. 
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The primary drawback of the TARGET system in this experiment is the high 
temperature required for derepression, leading to reduced lifespan and changes in 
behaviour. In order to validate more in-depth study of activity patterns and survival 
curves, it would be desirable to consider alternative methods of temporal transgene 
control. One possibility is the GeneSwitch system, a pharmacological method of 
regulating gene expression. The system makes use of a mutated progesterone 
receptor ligand-binding domain in a GAL-4 chimera, and allows induction of 
transgene expression in the presence of RU486 (Burcin et al., 1998; McGuire et al., 
2004b), the progesterone receptor antagonist and abortifacient commercialised as 
Mifepristone. It has been used effectively in Drosophila, including inducing ELAV-
controlled expression (Osterwalder et al., 2001). The system boasts high levels of 
transcriptional control through modulation of RU486 concentration in food and little 
leakiness, ideal characteristics for these experiments. 
These experiments studying transgene expression throughout the CNS raised the 
possibility of tissue-dependent tau kinase toxicity but were unable to effectively 
demonstrate human tau toxicity. More specific experiments were then designed, 
using the PDF promoter to drive expression within the 16 interneurons of the fly 
circadian pacemaker to attempt to quantify human tau toxicity through circadian 
rhythm defects. 
5.3.2 Quantification of transgene toxicity in the PDF neurons 
In order to demonstrate the non-essential nature of the PDF neurons, the total daily 
activity levels of all 10 test lines and PDF controls were compared, as was performed 
for the ELAV crosses in Section 5.2.1. The expectation was for no significant 
changes in activity decline. Although no significant differences in variance were 
recorded between genotypes across any individual days, the change in activity levels 
over time was found to exhibit significant differences unless only the final 10 days of 
data were compared. This could be due to changes in activity from PDF neuron 
disruption, though if that were the case it would seem logical for the differences to 
become more pronounced as the duration of free running increased. It is possible that 
these differences are primarily due to basal activity level discrepancies. The 
0N4R/B2WT5 recombinant line exhibited a steeper decline in total activity, made 
marginally clearer in the normalised data of Figure 5.5, perhaps evidence of 
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transgene leak, though this was not the case in the B2WT5 line which was found to 
be similarly toxic when controlled by ELAV. The T231D line had consistently lower 
average activity under constant darkness.  
Expression of toxic transgenes within the PDF neurons would have been expected to 
lead to disruption of circadian rhythmicity. This was measured by evaluation of 
periodicity using the ActogramJ program. This software provided multiple methods 
of analysis of period. In Figure 5.6, both the chi square and Lomb-Scargle methods 
were used to generate periods for each individual surviving at least 15 days. Both 
methods were used in order to provide greater certainty in cases of highly unusual 
periods. The nature of the analysis meant that every individual received a value, 
regardless of the strength of rhythmicity. In some cases, this led to extremely 
unlikely scores (such as the 16.5 hour period of one individual in Figure 5.6A), 
which can be considered as examples of arrhythmicity. No genotype was found to be 
consistently arrhythmic, though both BRSK2-expressing lines contained one 
arrhythmic individual according to each method. The chi square method finds 
significant variation between both BRSK2-expressing lines and the PDF control, 
whereas the Lomb-Scargle method does not. The strength of the Lomb-Scargle 
method lies in analysis of unequally-spaced time series (Van Dongen et al., 1999), 
which is of no benefit in this case, and it is based on the older, now less used Fourier 
analysis, initially developed for analysis of short-term rhythmic bioluminescence 
(Plautz et al., 1997). The chi square method (Sokolove and Bushell, 1978) is much 
more commonly used, and its requirement of at least 10 cycles of data for effective 
analysis (Refinetti et al., 2007) was considered a useful quality control guideline 
among these samples. Consequently, it is possible to say that BRSK2 has again been 
shown to have neurotoxic effects in the Drosophila CNS, including in the PDF 
neurons. It would appear however that this model is not sensitive enough to detect 
toxicity caused by human tau expression, using both 0N4R and 2N4R tau. Again, it 
would be interesting to examine whether tau homozygotes exhibited any detectable 
changes. Anti-PDF antibody has also been widely used to stain dissected adult fly 
brains (Park et al., 2000; Peng et al., 2003; Shang et al., 2008), allowing visualisation 
of the well-characterised PDF-expressing interneurons, including eight each of the 
large and small lateral ventral neurons (Helfrich-Förster, 1995). The highly specific 
number and structure of these neurons means they are extremely well suited for 
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probing in this manner, and could provide visual verification of transgene expression 
and neuronal damage. 
So far, these attempts to exploit the DAM2 activity monitoring system to explore 
neurotoxicity in Drosophila have had limited success. Though they may well have 
led to several future lines of inquiry regarding the consequences of BRSK2 
expression in the fly, so far they have not been shown to be sensitive enough to 
provide useful insights into tau toxicity. There is still potential for further 
examination, to determine whether increased expression or visual examination could 
demonstrate and quantify human tau-induced CNS toxicity in the fly. The 
demonstration of BRSK2-induced toxicity adds an intriguing extra dimension to the 
role played by BRSK2 in exacerbating tau-induced neurodegeneration in the fly eye. 
In the next chapter, this interaction has been explored further, using a Drosophila 
deficiency screen to explore the pathways surrounding the tau/BRSK interaction. 
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6| A deficiency screen to isolate 
novel regulators of the 0N4R 
tau/BRSK2 eye phenotype 
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6.1 Introduction 
The clear eye phenotype of 0N4R-B2WT5 flies has previously been shown to be 
dependent on two endogenous Drosophila kinases (unpublished data). These were 
LKB1 and CG17698, the fly CaMKKα homologue. The kinase domain of 
Drosophila LKB1 displays 66% amino acid identity with that of its mammalian 
homologue (Martin and St Johnston, 2003). This serine/threonine kinase was shown 
to be required for several cellular processes, including establishment of cell polarity 
in the fly (Martin and St Johnston, 2003) and in mammals (Baas et al., 2004). After 
LKB1 had been shown to regulate 13 members of the AMPK-related kinase family 
(Lizcano et al., 2004), the BRSKs, as substrates of LKB1, were revealed to be 
essential for neuronal polarisation (Kishi et al., 2005). That the BRSKs were also 
shown to be tau kinases, and also activated by the calcium-dependent CaMKKα 
(Fujimoto et al., 2008), made them suitable targets for research into tauopathies, 
particularly given the well-established links between calcium homeostasis and 
Alzheimer’s disease (Berridge, 2011; Grynspan et al., 1997; Murray et al., 1992). 
That the pathways regulating human BRSK2 activation were conserved in 
Drosophila raised the possibility of discovering other BRSK2 modulators by virtue 
of the extensive screening methods available to Drosophila biologists. Once the tau 
isoform-specific nature of the BRSK2-induced eye phenotype became apparent, it 
was also hoped that such a screen would unearth an explanation for this specificity. 
The more detailed study of the relationship between modulation of tau toxicity by 
BRSK2 and the phosphorylation status of tau has given cause to look beyond 
phosphorylation pathways to help solve the questions surrounding tau isoform-
specific BRSK2-induced toxicity.  
Arguably the greatest strength of Drosophila as a model organism is its extensive 
genetic toolkit, allowing multiple methods of exogenous gene insertion and 
expression control. Deficiency screens are also important elements of modern 
Drosophila research. Deficiency lines lack a discrete, defined chromosomal region 
(Bridges, 1917), effectively generating null alleles for multiple genes without need 
for random mutagenesis (Roote and Russell, 2012). The modern deficiency kits, 
including the DrosDel and Bloomington projects, consist of libraries of hundreds of 
categorised deficiency lines. This was made possible by an adaptation of yeast FLP 
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recombinase (Golic and Lindquist, 1989), placed under control of the heat-sensitive 
hsp70 promoter. This could be inserted in transposable P elements alongside FLP 
recombination target (FRT) sequences; heat shock treatment activates recombination 
which can then be identified thanks to the location of FRT within a copy of the white 
gene, for eye pigmentation (Golic and Golic, 1996). Thanks in particular to the large-
scale Bloomington project, deficiency screens have become increasingly 
comprehensive, now covering 98.4% of the fly genome (Cook et al., 2012). One 
established use of such kits is for pathway-expansion experiments, allowing chosen 
phenotypic analysis in hemizygous deficiency backgrounds, thus potentially 
uncovering likely upstream or downstream pathway components. Multiple genomic 
screens for modifiers of tauopathy have already been carried out in Drosophila, 
using alternative screening libraries or in conjunction with mouse microarray 
analysis (Ambegaokar and Jackson, 2011; Karsten et al., 2006; Shulman and Feany, 
2003). In this Chapter, a screen making use of the Bloomington and Exelixis 
deficiency stocks is described. These deficiency libraries together boast extremely 
comprehensive coverage. As they constitute the major part of the fly genome, 
chromosomes 2 and 3 were investigated in the screen as extensively as time allowed, 
with over 300 stocks obtained through the Bloomington stock centre. The screen 
made use of the 0N4R-BRSK2 recombinant line described in Chapter 4, facilitating 
examination of the interaction between the two transgenes. This line had already 
been used in experiments demonstrating the ability of its phenotype to be both 
enhanced and suppressed, a necessary characteristic for a deficiency screen. 
Suppression of the phenotype was witnessed upon RNAi of the fly CaMKKα 
homologue, enhancement upon overexpression of the Ca2+ channel Cacophony 
(unpublished data). In addition, this recombinant line has been found to exhibit a 
more consistent phenotype than that generate by crossing of 0N4R tau and BRSK2 
lines, likely due to its origin as a result of a single recombination event. This 
indicates the ability of variation at other loci to modulate the phenotype, precisely 
what a deficiency screen seeks to demonstrate. The screen was initially as high-
throughput as possible, attempting merely to highlight genomic regions of interest 
which could then be examined for putative modulators of BRSK2 activity or tau 
toxicity. Likely candidates included kinases, phosphatases, regulators of calcium 
homeostasis or cell death pathways, and cytoskeletal proteins.  
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6.2 Results 
The Bloomington deficiency stocks for chromosomes 2 and 3 were acquired in order 
to perform screens of the majority of the fly genome for modulators of the 0N4R 
tau/BRSK2 eye phenotype. The chromosome 2 kit was obtained in October 2010, at 
the time containing 142 stocks. The chromosome 3 kit obtained in February 2013 
contained 178 stocks. Stock males were crossed with 0N4R-B2WT5 virgins at 23°C 
and screened under light microscope for phenotype-suppressing or enhancing 
deletions. These were then screened for their effect on 0N4R tau alone, in order to 
avoid duplication of previous tau studies and to focus on the BRSK2-induced 
phenotype. Where possible, once the primary screen using the predefined kit was 
finished, areas of interest were shortened using additional overlapping deficiency 
stocks, before potential genes of interest were examined using mutant or RNAi lines. 
6.2.1 Chromosome 2 
6.2.1.1 Primary screen of chromosome 2 
The initial chromosome 2 screen using the 142 lines which comprised the older 
deficiency kit revealed eleven regions of interest. Of these, one was isolated to a 
single gene, thanks to overlapping deficiencies – this was chickadee, encoding the 
Drosophila homologue of Profilin, the actin-binding protein. Of the remaining ten 
chromosomal regions, nine led to a suppression of the phenotype and one to an 
enhancement (as defined by visual inspection). In order to reduce the number of 
candidate genes in these regions, a further 35 overlapping lines were ordered. 
Following evaluation of these deficiencies, three of the regions were eliminated 
entirely from the study due to complete coverage by deficiencies which were not 
found to alter the phenotype. These included the only phenotype-enhancing region. 
Overlapping lines within three other regions were found to lead to suppression, while 
the remaining four had no phenotype-changing, overlapping deficiencies but were 
not ruled out due to a lack of complete coverage. The remaining regions of interest 
on chromosome 2 are shown in Figure 6.1.  
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6.2.1.2 Secondary screen of chromosome 2 
The secondary screen began with the search for putative BRSK2-affecting genes 
within these regions. A number of mechanisms were considered, including kinase 
activity, cell death mechanisms, proteolytic processing, calcium homeostasis, 
neurogenesis, energy metabolism and cytoskeletal association. Eighteen RNAi lines 
were obtained, suppressing individual genes within four of the target areas. These 
lines are listed in Table 6.1, together with any phenotypic effect they were found to 
exhibit. 
Among the four regions studied using RNAi lines, two were found to contain genes 
with a phenotypic effect upon inhibition. These were also the two regions with the 
most lines examined. In each case, two genes were found, perhaps demonstrating the 
greater sensitivity of RNAi screening; this could also imply some propensity for 
false positives in the screen. Time constraints prevented any further investigation of 
these genes, or of any of the other regions of interest on chromosome 2. 
Gene Location Target Region Phenotype Associated with 
CG4238 22B8-22C1 22B8;22D1  No change Ubiquitination 
Su(dx) 22C1 22B8;22D1 Suppression Notch binding 
DPR3 22C1-22C3 22B8;22D1  No change Calcium metabolism 
GlyP 22C3-22D1 22B8;22D1  No change Glycogen catabolism 
CG7261 22D1 22B8;22D1  No change Tubulin binding 
AIF 22D1 22B8;22D1 Suppression Apoptosis 
Spire 38C5 38B4;38F5  No change Cytoskeleton 
Arpc2 38C6 38B4;38F5  No change Actin binding 
Debcl 42B2-42C1 42A14;42C7  No change Apoptosis 
CG8726 43F9 43F8;44D4  No change Protein kinase 
CG14763 43F9 43F8;44D4 Suppression Cytoskeleton 
CSN4 43F9-44A1 43F8;44D4  No change Ubiquitination 
Hey 44A2 43F8;44D4  No change Notch binding 
Sut3 44A4 43F8;44D4  No change Sugar metabolism 
Sut2 44A4 43F8;44D4  No change Sugar metabolism 
Sut1 44A4 43F8;44D4 Suppression Sugar metabolism 
Nup50 44B2-44B3 43F8;44D4  No change Neurogenesis 
Pnut 44C2 43F8;44D4  No change Apoptosis 
 
Table 6.1: RNAi lines used in the chromosome 2 secondary screen 
Information on the genes studied using RNAi, including location, proposed function 
and any effect on phenotype. Changes were recorded for four lines (blue), located 
within two regions of the chromosome.  
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6.2.1.3 Chickadee 
Four suppressing deficiencies were found to overlap a 737 bp region, located entirely 
within the gene chickadee. Chickadee is an actin-binding protein, the Drosophila 
homologue for Profilin. Given the deficiency data and the cytoskeleton-associated 
target, chickadee mutants were obtained and studied further. These lines were 
numbered Bl. 4891, carrying a loss-of-function allele generated by P-element 
insertion, and Bl. 4892, with an amorphic chic221 allele encoding a shorter 
transcription product (Verheyen and Cooley, 1994). These will be referred to as 4891 
and 4892, respectively from here on. Stock 4891 was sickly, with few progeny. Each 
line was crossed with 0N4R-B2WT5 and evaluated as with the deficiencies. Figure 
6.2 shows scanning electron micrographs of progeny from the cross using 4892. 
Images shown were those given the highest, lowest and median DC values by QED. 
Cumulative distribution plots for the progeny are shown in Figure 6.3. 
Purely visual examination of the SEM images appears to show a consistently larger 
surface area for the eye in individuals possessed of the chic221 allele. This is visible 
at both extremes of DC values, with an attenuation of the inverted teardrop shape 
characteristic of 0N4R-B2WT5 flies. The DC values themselves do not register any 
difference due to chic mutation when compared by Mann-Whitney U test (P=0.95). 
It is important to remember however that QED does not measure eye size and so is 
insensitive to any change in this metric; it is possible that ommatidial disruption is 
very similar in each sample in spite of the change in size, leading to similar DC 
values. QED values are low across all samples when compared with those recorded 
for 0N4R-B2WT5 in Chapter 4, perhaps evidence of a difference in incubator 
temperature or genetic background in the 4892 line, demonstrating the importance of 
repeating controls for each experiment. 
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Figure 6.2: Chic mutation increases eye size of 0N4R-BRSK2 flies  
SEM images of 0N4R-B2WT5 flies without or with the 4892 chic mutation. Lowest, 
highest and median DC values are shown. The chic mutation appears to lead to an 
increase in eye size across the sample. This is not accompanied by a suppression of 
ommatidial distortion when measured by QED. 
Genotypes: 0N4R-B2WT5: GMR/CyO; 0N4R, B2WT5/+. 4892: GMR/chic221; 
0N4R, B2WT5/+. 
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Figure 6.3: QED analysis does not reveal any effect of Chic mutation on 
ommatidial distortion 
Cumulative distribution plot of DC values of the samples shown in Figure 6.2. 
Quantitative analysis of the phenotypes shown in Figure 6.2. There was no 
significant difference found between DC values of each genotype when compared by 
Mann-Whitney U test (P=0.95). 
0N4R-B2WT5 n=7. 4892 n=6.  
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6.2.2 Chromosome 3 
The Bloomington deficiency kit for chromosome 3 was also examined for 
modulators of the 0N4R-BRSK2 phenotype. This kit contained 178 deficiencies at 
the time of ordering. Study of these lines was less comprehensive due to time 
constraints but initial screening isolated fourteen chromosomal regions of interest, 
eight identified as phenotypic suppressors and six as enhancers. These regions are 
represented on the chromosome 3 polytene map in Figure 6.4. 
These regions have not yet undergone any further analysis to reduce their size 
through the study of overlapping deficiencies not contained within the kit and as a 
result are still generally very large, with too many potential genes of interest for 
RNAi screening. The exception is 92F13;93A1, which contains only the gene 
syncrip, associated with neurogenesis. Some candidates are listed in Table 6.2, based 
on recorded gene function in the literature and prioritising association with the 
mechanisms listed in Section 6.2.1.2.  
Both of the known BRSK2 modulators in Drosophila, LKB1 and CG17698 are 
located within chromosome 3, though neither is contained within standard 
deficiencies of the Bloomington kit. CG17698 is not covered by any deficiency 
stock, as it is extremely proximal to the centromere at 80F9, and so could not be 
examined in this screen. LKB1 (at 87F7-87F9) is covered by a single stock in the 
entire Bloomington library, numbered 7648 (covering 87F2-87F10). No phenotypic 
change was recorded upon crossing this stock. 
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Gene Location Target Region Associated with 
MED24 66B11-66B12 66B11;66C3 Apoptosis 
Ubc12 66B12 66B11;66C3 Ubiquitination 
UbcD4 67C5 67C5;67D1 Ubiquitination 
CDK8 67C10 67C5;67D1 Protein kinase 
Inhibitor-2 67C10 67C5;67D1 Phosphatase regulation 
Calpain-B 67D1 67C5;67D1 Calcium metabolism 
CG11261 69F5 69E6;69F6 Ubiquitination 
MICAL-like 69F5 69E6;69F6 Actin-binding 
Reaper 75C6 75B11;75E4 Apoptosis 
MYPT-75D 75D4-D4 75B11;75E4 Phosphatase regulation 
Canoe 82F4-82F6 82E7;82F8 Eye development 
Katanin 60 82F6 82E7;82F8 Microtubule severing 
Retinophilin 82F6 82E7;82F8 Apoptosis 
CG12163 82F6-82F7 82E7;82F8 Autophagy 
Unc-115A 85E4-85E5 85E5;85E9 Actin-binding 
Hyperplastic discs 85E5-85E5 85E5;85E9 Ubiquitination 
Whamy 85E8-85E8 85E5;85E9 Microtubule formation 
CG31391 86C4 86B1;86C7 Phosphatase regulation 
Cadherin 86C 86C7 86B1;86C7 Calcium ion binding 
Heartless 90E2-90E2 90E2;90F4 Protein kinase 
PP2A-B' 90F4-90F5 90E2;90F4 Phosphatase regulation 
Frayed 91B4-91B5 91A5;91F1 Protein kinase 
MEKK1 91C5 91A5;91F1 Protein kinase 
Syncrip 92F12;93A1 92F13;93A1 Neurogenesis 
Ublcp1 94D10 94D10;94E7 Protein phosphatase 
CG13830 94D12-94D13 94D10;94E7 Calcium ion binding 
Unkempt 94E1-94E2 94D10;94E7 Eye development 
Cadherin 96Ca 96C4-96C5 96C3;96C8 Calcium ion binding 
Cadherin 96Cb 96C7 96C3;96C8 Calcium ion binding 
Table 6.2: Putative modulators of the 0N4R-BRSK2 phenotype on chromosome 3 
Information on potential candidate genes, including location and proposed function.  
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6.3 Discussion 
The deficiency screen is a very powerful method of pathway expansion. Now that 
coverage of the fruit fly genome is relatively comprehensive, deficiency kits are very 
useful as a first step in isolating novel research targets. In this case, the possibility of 
finding novel elements modulating the 0N4R-BRSK2 pathway was improved by the 
prior knowledge of the conserved BRSK kinases LKB1 and the CaMKKα 
homologue CG17698, and their importance to the eye phenotype. This method 
cannot guarantee to uncover the entirety of any given pathway, as evidenced by the 
inability of the screen to identify CG17698 or LKB1. Nonetheless, in the case of an 
obvious phenotype such as that seen here in the eye it allows relatively rapid 
screening of the majority of the genome by a single individual. Given the diverse 
aetiology of the tauopathies, this screen has unearthed a large number of candidate 
genes across 22 regions of the two largest Drosophila chromosomes. 
6.3.1 Candidate genes on chromosome 2 
The screen of chromosome 2 isolated eight regions of phenotypic suppression and 
began to examine these regions at the level of individual genes. The use of additional 
deficiencies to reduce the size of these regions greatly reduced the number of 
candidate genes. In the case of tau toxicity, there are a great many associated cellular 
processes, as has been revealed by past screens (Ambegaokar and Jackson, 2011). 
For BRSK2-associated modulation of tau toxicity, I decided to focus on potential 
components of the pathway, and on processes with which BRSK2 has previously 
been implicated. Among the former, protein kinases and phosphatases were obvious 
candidates. For the latter, the potential of calcium as a BRSK modulator, as well as 
the potential of BRSK2 to alter cell death or protein clearance mechanisms 
(autophagy in particular) gave some obvious target categories. Some genes 
associated with sugar metabolism were also considered, given the similarity between 
the BRSKs and AMPK. Additionally, cytoskeleton-associated proteins were included 
as potential indicators of BRSK2’s effect on tau function, and genes associated with 
neurogenesis or eye development were included. 
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6.3.1.1 RNAi-based silencing of candidate genes 
Among the polygenic phenotype-suppressing regions, eighteen genes were screened 
with RNAi, with another seven also considered candidates. As shown in table 6.1, 
four RNAi lines were found to lead to suppression of toxicity. These were contained 
within only two regions, and although it is possible for multiple BRSK2 modulators 
to be found within the same small chromosomal area, there is also the potential for 
false positives when performing a visual screen, given the subjective nature of the 
classification and the potential for phenotypic variation in the model. It is also 
possible that multiple deletions of relevant genes were responsible for the loss of 
phenotype seen in the deficiency, whereas suppression by RNAi tends to be stronger 
and could thus amplify the effect of individual genes. Six genes were tested within 
the approximately 163kb region of 22B8;22D1, containing 54 genes in total. RNAi 
against two of these genes was found to lead to phenotypic suppression: su(dx) 
(suppressor of Deltex) and AIF (apoptosis-inducing factor). Su(dx) was chosen as a 
potential candidate owing to the various recorded functions of the Notch signalling-
associated deltex (Xu and Artavanis-Tsakonas, 1990), located on the X chromosome. 
These include influencing eye morphology (Gorman and Girton, 1992). An 
alternative hypothesis is based on Deltex acting in a similar manner to the tau kinase 
Shaggy, the GSK3 homologue and tau kinase which is also heavily implicated in 
regulation of Notch signalling. Indeed, mutations in these two proteins have the 
same ability to suppress specific Notch mutants (Ramain et al., 2001), leading to the 
possibility of an important role for Notch in BRSK2-mediated toxicity. Multiple 
components of the Notch signalling pathway have been implicated in tau toxicity in 
this model (Ambegaokar and Jackson, 2011). Su(dx) is itself a ubiquitin ligase of 
which Deltex is not presumed to be the sole target (Cornell et al., 1999), with a 
putative proline-rich binding site potentially found within other components of the 
0N4R-BRSK2 pathway. The other possibility is that loss of Su(dx) leads to changes 
downstream of BRSK2, with loss of the ubiquitin ligase, proteasome-targeting 
activity of Su(dx) (Ramain et al., 2001) mitigating the dramatic upregulation of 
autophagy and potentially of protein turnover seen in 0N4R-B2WT5 fly eyes (Dr 
Alessia Galasso, unpublished data).  
The alternative gene within this region is AIF, regulator of programmed cell death 
during development (Joza et al., 2008). Given that no increase in apoptosis was 
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observed in the eye disc in 0N4R-B2WT5 larvae as measured by TUNEL stain (Dr 
Alessia Galasso, unpublished data), it seems unlikely that a reduction in apoptosis 
could lead to a reduction in BRSK2-induced toxicity. However, it is still possible that 
apoptosis has an important role to play at a later developmental stage than that 
studied, or that a reduction in programmed cell death could lead to an appearance of 
larger eyes in these individuals when screened. One untested candidate in this region 
was kebab, a microtubule-associated protein which has been shown to play a role in 
mitosis, though an apparently dispensable one (Meireles et al., 2011). 
The second region successfully probed using RNAi was much larger, covering over 
600kb and 127 genes (43F8;44D4). Seven genes were studied, of which RNAi of 
two, CG14763 and sut1 (sugar transporter 1), was reported to lead to phenotypic 
suppression. CG14763 has yet to be studied in depth. Its function is predicted to be 
involved in microtubule-based transport, with an ATPase domain and a TCTEX1 
dynein light chain domain associated with cargo binding, as well as actin dynamics 
during neurite outgrowth (Chuang et al., 2005). This associates this gene with two 
possible mechanisms of interest to this screen – it is both microtubule-associated and 
potentially involved in neuronal development. The second gene, sut1 was the only 
glucose transporter of the three within this region studied to be identified by the 
screen. The decision to study the sugar transporters was speculative, based on the 
links between sugar metabolism, diabetes and Alzheimer’s disease as well as 
AMPK’s more recent classification as a tau kinase (Thornton et al., 2011). It is 
perhaps more likely than CG14763 to be the result of a false positive, given that 
neither of the other sut genes exhibited any proclivity for BRSK2 phenotypic 
modulation. If not, then it is potential evidence for a metabolic influence on 0N4R-
BRSK2-induced neurodegeneration. Besides the seven genes tested, other candidates 
for this region included four genes involved in eye development and neurogenesis 
(vps28, pabp2, nito and optix) and an ubiquitin ligase (cul-4). 
Outside of these two regions, no other candidate genes have been successfully shown 
to have an effect on our phenotype by RNAi. Other potential genes to be tested are 
spinster, basigin, CG31687, anterior open, eyes shut and decapentaplegic. 
Mutations in spinster lead to a reduction in programmed cell death in the developing 
nervous system (Nakano et al., 2001). It is also implicated in autophagy – 
specifically, in reactivation of mTOR and autophagic inhibition following starvation 
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(Rong et al., 2011). If silencing spinster were found to lead to suppression of the 
0N4R-BRSK2 phenotype, this would be evidence of a protective role for autophagy 
in this context. CG31687 has been implicated in cell polarity, though only in planar 
cells (Weber et al., 2012). The other four genes listed are all implicated in eye 
development. 
6.3.1.2 Chickadee as a regulator of BRSK 
The actin-binding protein Chickadee (Chic) is the Drosophila Profilin homologue, a 
protein family of highly conserved structure but only weakly conserved amino acid 
sequence (Cooley et al., 1992), thought to be ubiquitous among eukaryotes 
(Reichstein and Korn, 1979). It was originally thought to reduce actin polymerisation 
through sequestering actin monomers (Carlsson et al., 1977), though at physiological 
concentrations actually performs the opposite function. Profilin promotes the 
replenishment of ATP on actin filaments by decreasing the affinity of actin for its 
bound nucleotide, allowing replacement of ADP with ATP, in excess in the cell 
(Pantaloni and Carlier, 1993; Theriot and Mitchison, 1993). Its importance to the 
dynamics of the actin cytoskeleton is thus well characterised – what relevance could 
it have for the MAP-associated neurotoxicity studied here? 
Although QED did not register any effect on ommatidial distortion in chic mutants, 
there appeared to be a consistent increase in eye size which could be evidence of an 
amelioration of 0N4R tau/BRSK2-induced neurodegeneration. The method of 
analysis of QED involves use of the edge set to recreate ommatidia as complete 
circles, eliminating any circle differing too severely from the expected size. As a 
result, there is no measure based on changes in whole eye size or shape. It would 
appear that a reduction in Chickadee function is capable of mitigating some aspects 
of 0N4R-BRSK2 toxicity. I would like to propose two hypotheses regarding the 
influence this actin-binding protein could have on tau-induced neurodegeneration. 
One possibility stems from research performed specifically on Chickadee. In the fly, 
Chic is heavily involved in the transport (dumping) of cytoplasm from nurse cells 
into oocytes. Loss of chic has been shown to reduce dumping by 25 to 50% (Cooley 
et al., 1992), indicating a role for actin in this process. The actin cytoskeleton is 
involved in the establishment and maintenance of the ring canals connecting the 
cells, through which cytoplasm is transported via cytoplasmic microfilaments 
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(Mahajan-Miklos and Cooley, 1994). Interestingly, this process is also dependant on 
the microtubule-based cytoskeleton, which controls the rapid cytoplasmic streaming 
– loss of the microtubule-associated proteins Cappuccino and Spire leads to a very 
similar phenotype to that of chic mutants. In each case, disruption of streaming 
occurs due to a premature bundling of microtubules prior to streaming and ring canal 
formation (Manseau et al., 1996). Here then, Chic is involved in the synchronisation 
of the actin- and microtubule-based cytoskeletons and it has been hypothesised that 
these proteins could form the interface between them. Although Chic mutant 
phenotypes have not been recorded within neural tissues, this idea remains a 
tantalising prospect for its implications regarding the importance of both 
cytoskeletons in this model of tauopathy. It should be noted however that spir was 
tested in the RNAi screen, and was not found to lead to a change in phenotype. 
An alternative hypothesis for the role of Chic returns to the idea of autophagic cell 
death being the cause of the phenotypes observed here. As was already noted in 
Chapter 3, HDAC6 has been shown to be important in aggresome targeting (Guthrie 
and Kraemer, 2011). This deacetylase has been shown to control microtubule-
dependent cell motility via deacetylation of tubulin (Hubbert et al., 2002), some of 
the first evidence for the importance of acetylation in processes more diverse than 
control of gene transcription via histones. The deacetylase has also been shown to 
interact with the actin cytoskeleton (Gao et al., 2007). Subsequently, the first 
evidence was found for HDAC6 controlling selective autophagy via actin, and 
ubiquitin-dependent aggrephagy specifically (Lee et al., 2010). This study 
demonstrated that aggrephagy was dependent upon both HDAC6 and the actin 
cytoskeleton, both of which were entirely dispensable for conventional, starvation-
induced autophagy. HDAC6 was shown to be necessary for autophagosome-
lysosome fusion, but again only in quality-control aggrephagy, with this effect 
reversed under other conditions of autophagy. Finally, the study showed that this 
function of HDAC6 was F-actin dependent. The fly HDAC6 homologue is located 
within the X chromosome and was not covered by this screen. It is possible that loss 
of Chic could disrupt F-actin, leading to a reduction in aggresome formation. This 
would imply a cytotoxic role for autophagy in this model, with cell death caused by 
an overzealous upregulation of the process in response to 0N4R tau and BRSK2. 
This could be investigated via study of autophagy levels in chic mutants, via probing 
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for lysosomes or p62 as described in Chapter 3. 
Profilin has previously been implicated in neurodegenerative disease, specifically as 
a genetic risk factor in amyotrophic lateral sclerosis (Wu et al., 2012). Though 
speculative, this screen may indicate a link between this protein and tau-induced 
neurodegeneration. 
6.3.2 Candidate genes on chromosome 3 
The screen of chromosome 3 was not pursued in as much detail as that of 
chromosome 2 due to time constraints. As a result, only the 178 lines of the standard 
Bloomington deficiency kit were examined, with no extra lines acquired to reduce 
the regions of interest, or RNAi screening performed. In addition, the lines have not 
yet been screened to remove deficiencies altering the phonotype of tau alone. 
Consequently, the majority of the 14 regions of interest are extensive, with a large 
list of potential candidate genes, as listed in Table 6.2.  
It was hoped that the knowledge of modulators of BRSK2-induced toxicity would 
allow the use of deficiencies containing CG17698 or LKB1 as positive controls for 
the screen. With CG17698 not contained within any deficiency line, and the LKB1-
containing deficiency not identified by screening, this was not the case. That 
hemizygosity for LKB1 should not noticeably alter the phenotype is ultimately not 
wholly unexpected – two copies of LKB1 RNAi were required for effective 
suppression of BRSK2-induced toxicity, likely reducing LKB1 activity far more than 
loss of a single gene copy. This illustrates one shortcoming of the deficiency screen 
when compared with RNAi as a method of gene suppression – it is generally less 
sensitive. 
The only region containing a single gene is 92F13;93A1, which overlaps syncrip 
(synaptotagmin-binding, cytoplasmic RNA-interacting protein), encoding a protein 
originally isolated in mouse brain lysate (Mizutani et al., 2000). In the fly, this 
mRNA-binding protein has been shown to bind and localise multiple transcripts in 
the oocyte (McDermott et al., 2012). It was also shown to be highly expressed in the 
larval nervous system, though precisely which tissues require SYNCRIP for correct 
development has yet to be determined. A developmental role for the gene puts it at 
the right time to influence our phenotype; whether it is also in the right place has yet 
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to be seen. The same group, led by Professor Ilan Davis at Oxford, also claims to 
have evidence for the control of some synaptic kinase transcripts by SYNCRIP, 
including those of CamKII and Discs large (DLG). Loss of DLG in particular has 
been shown to cause disruption of the cytoskeleton and cell polarity (Woods et al., 
1996). 
Multiple calcium-dependent proteins are also found by the screen, across three 
regions, including the protease Calpain-B and three Cadherins. There are a number 
of genes associated with protein turnover, including multiple ubiquitin-protein 
ligases (hyperplastic discs and CG11261), regulators of apoptosis (MED24 and 
reaper) and a single gene associated with autophagy (CG12163). Hyperplastic discs 
in particular is associated with differentiation of the photoreceptor cells of the eye 
imaginal disc (Lee et al., 2002). Among the regulators of phosphorylation found by 
the screen, the stress response-associated mitogen-activated protein kinase kinase  
kinase MEKK1 (Inoue et al., 2001) is unsurprising given that it was also found in the 
screen by Ambegaokar and Jackson (2011). Cyclin-dependent kinase 8 (CDK8) has 
not yet been implicated in tau phosphorylation, neither have the serine-threonine 
kinase Frayed or the tyrosine kinase Heartless. Among the other genes in Table 6.2, 
MYPT, canoe and unkempt are associated with development of the eye and likely of 
limited interest. Further screening of the chromosome would be necessary before 
committing to further study of any of these genes, as was performed for chromosome 
2. The majority of these candidate genes would likely be eliminated by additional 
screening with overlapping deficiencies and RNAi lines. 
The complex, tau isoform-dependent nature of the effect of BRSK2 on tau-induced 
neurotoxicity was revealed in Chapter 4 of this work, and the tissue-specific toxicity 
of BRSK2 in Chapter 5. This chapter has described attempts to uncover the 
endogenous pathways responsible. This screen was incomplete but has uncovered 
some promising leads, particularly the potential of chic to help explain the nature of 
the toxicity observed in the eye, or the role of the cytoskeleton in this model of 
tauopathy. Completion of the chromosome 3 screen is an obvious next step in the 
search for 0N4R tau-BRSK2 modulators.  
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7| General Discussion 
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The work described in this thesis has been an attempt to expand current 
understanding of the relationship between tau phosphorylation and toxicity. This 
work began with the goal to further characterise the tau kinase BRSK2, which had 
already been examined in some detail by the Moffat and Frenguelli labs, and was 
thus firmly in the domain of examining the consequences of tau 
hyperphosphorylation. This was at a time when several laboratories had begun to 
express frustration with the term “hyperphosphorylation”, which had become 
something of a catch-all for any and all instances of recorded tau dysfunction. One of 
the most vocal critics of the term was Guy Lippens, of Lille University, whose 
dissatisfaction with the broad definition of tau hyperphosphorylation was perhaps 
spurred on by a background in chemistry and nuclear magnetic resonance (NMR) 
spectroscopy (Lippens et al., 2012; Lippens et al., 2007). That tau 
hyperphosphorylation can only be defined stoichiometrically (as an increase in the 
number of phosphate groups per molecule of tau) due to the overlap between healthy 
and diseased phosphorylation patterns speaks to a complex code of tau 
phosphorylation, if indeed phosphorylation is the primary mechanism of tau 
dysfunction. That tau hyperphosphorylation as a concept may be overly simplistic is 
perhaps best illustrated by studies involving tau species bearing large numbers of 
phospho-mutations. Hypo-phosphorylated S11A tau was shown to exhibit increased 
toxicity in the fly retina (Chatterjee et al., 2009); in contrast E14 tau, supposed to 
simulate a hyper-phosphorylated state, was found to be less toxic to dopaminergic 
neurons than wild-type (Wu et al., 2013b). Clearly, these data do not sit well with the 
idea that tau phosphorylation should correlate directly with toxicity. Interpretation of 
these results, based on wholesale mutation of large numbers of residues on tau, is 
extremely difficult without better understanding of the importance of individual 
phosphorylation sites, or smaller combinations of them.  
 In vitro studies of mutant tau species have demonstrated the ability of individual 
phosphorylatable residues on tau to alter both normal tau function (microtubule 
stabilisation) and disease-associated processes (tau aggregation), testament to their 
relevance to disease. These in vitro experiments also hinted at a tau phosphorylation 
“bar code” (Lippens et al., 2007), establishing hierarchies of importance to specific 
processes among residues. For example, a 2N4R tau S262D mutant was shown to be 
particularly inefficient in stabilising microtubules, with a greater loss of function 
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than a T231D mutant (Kiris et al., 2011). On the other hand, a study of tau 
aggregation found a 2N4R tau T212E mutant to be far more prone to fibrillisation 
than an S262E mutant, which was found to be no different to WT 2N4R tau (Chang 
et al., 2011; Necula and Kuret, 2004). Such mutants have also been shown to 
demonstrate unexpected combinatorial effects; mutants were found to not exhibit 
additive effects on microtubule stability (Kiris et al., 2011). In contrast exponential 
increases in apoptosis were witnessed in cell culture models transfected with poly-E 
mutants, as measured by TUNEL stain (Alonso et al., 2010).  
The relevance of these experiments to our study of BRSK2 was underlined by the 
study of tau phosphorylation by a number of AMPK-related kinases, including 
BRSK2, by Yoshida and Goedert (2011). This study demonstrated the 
phosphorylation profile of recombinant 1N4R tau in the presence of BRSK2 in vitro, 
which was shown to include both T212 and S262. BRSK2 had already been shown 
by our lab to induce an unusually strong eye phenotype upon co-expression with 
0N4R tau in the fly eye (see Figure 4.1 for an example), much stronger than 
observed with MARK-induced phenotypes (Chatterjee et al., 2009). Given that 
BRSK2 was shown to be apparently less potent a tau kinase than MARK1 in vitro 
(Yoshida and Goedert, 2011) but more able to phosphorylate T212, this suggested 
the possibility of T212 phosphorylation being the primary determinant of tau-
induced neurotoxicity in this model. The tau mutants examined in Chapters 3, 4 and 
5 of this thesis were created as a result, and the reality was found to be more 
complicated. 
This project has attempted to transplant in vitro studies into the effects of 
phosphorylation mutants into an in vivo model, in order to gain insights into the 
fundamental mechanisms and functional consequences of tau toxicity, including 
microtubule binding, tau aggregation and kinase activity. At the close of the project, I 
would like to consider the most interesting aspects of the data presented herein with 
regard to current ideas of tauopathy. 
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7.1 Tau aggregation and neurotoxicity 
When planning the tau mutations which would later be inserted into Drosophila, one 
aspect of interest was the relative importance of tau aggregation versus microtubule 
binding. The T212A and T212D mutations were considered most likely to alter tau 
aggregation (Necula and Kuret, 2004), if indeed aggregation was a relevant 
phenomenon to tau toxicity in Drosophila models given the apparent dispensability 
of large tau aggregates to toxicity in the fly (Wittmann et al., 2001). Thus, the 
phenotypic expectation of T212D animals was for either a lack of effect (with an 
aggregation-inducing mutation of no consequence in the fly) or for a partial 
recapitulation of the increase in toxicity witnessed in flies co-expressing BRSK2 and 
0N4R tau. That the T212D mutant phenotype was less severe than that of 2N4R WT, 
or the S262D mutant, was consequently seen as the most important discovery of the 
individual 2N4R tau mutant library, particularly given the concurrent upsurge in 
evidence for the formation of insoluble tau aggregates in fruit fly tauopathy models.  
Colodner and Feany (2010) were able to demonstrate the accumulation of insoluble, 
hyperphosphorylated 0N4R tau in glia of aged flies (evident at 20 days old), after 
aging at 30°C to boost expression. One interesting aspect of their experiments was 
the demonstration of a disconnection between insoluble tau levels and toxicity – 
reducing the temperature from 30°C to 17°C was shown to reduce both tau 
expression and cellular toxicity (as measured by apoptosis using TUNEL stain), with 
no concomitant drop in insoluble tau levels. Other studies have since associated the 
formation of insoluble tau oligomers in Drosophila with a suppression of toxicity, 
via inhibition of GSK-3β (Cowan and Mudher, 2013) or upregulation of NMNAT 
(Ali et al., 2012). In each of these cases, the mitigation of human tau-induced 
behavioural phenotypes was accompanied by an increase in the formation of 
insoluble oligomers. In another case, in which fibrillar tau aggregates were witnessed 
in neurons, no indication of the relative levels of oligomer formation in WT or E14 
mutant tau was given, though the E14 mutant was found to be less toxic (Wu et al., 
2013b). Conversely, highly mutated S11A tau was found to exhibit increased toxicity 
in the fly eye compared with wild-type or S2A tau; this increase in toxicity was not 
accompanied by any increase in insoluble tau levels, but rather by radically 
improved microtubule binding (Chatterjee et al., 2009).  In the fly, it would seem that 
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tau toxicity is heavily dependent upon solubility, with smaller, soluble oligomers 
present in two of these studies (Ali et al., 2012; Wu et al., 2013b). 
I hypothesise that the reduction in toxicity of tau following T212D mutation is due to 
a change in its aggregation kinetics, leading to a decrease in levels of soluble tau in 
animals expressing this mutant. With the recent examples of tau aggregation in 
Drosophila all involving neuronal expression, the eye may not be the best target 
tissue to demonstrate this. It is likely that ELAV would constitute a better driver, 
although Chau et al. (2006) appear to have had some success in demonstrating tau-
immunoreactive aggregates in the eye. The temperature-sensitive GAL80 repressor 
could be used to ensure healthy development, before driving high levels of 
expression at 30°C, as in Colodner and Feany (2010). Insoluble tau appears to 
accumulate and be stable over time, facilitating comparison between different tau 
species after aging the animals. Western blotting would allow quantification, with 
visualisation of oligomers possible using electron microscopy as used by Wu et al. 
(2013). If it is the case that aggregation can be protective, potentially by sequestering 
soluble, toxic tau, then this could explain why the T212D S262D double mutant 
exhibited a phenotype extremely close to that of T212D. This would make any 
aggregation-increasing mutation effectively dominant in the panoply of tau phospho-
mutations. In this context, any change of microtubule-binding or other effect caused 
by S262 mutation would be effectively silenced. That S262A mutation also reduces 
toxicity is potentially further evidence for the benefits associated with binding tau 
either in insoluble oligomers or to microtubules, again preventing soluble tau from 
initiating neurodegeneration. Such a hypothesis certainly depends upon soluble tau 
exhibiting some gain of function; perhaps, as suggested by Cowan et al. (2010), such 
species are capable of disrupting the microtubule cytoskeleton by sequestration of 
native tau and other MAPs, leading to axonal transport defects. Tau phosphorylated 
at serines 199 and 202 has been shown to sequester MAPs 1 and 2 (Alonso et al., 
1997), which could help to explain the additional effect of transgenic tau in this 
model beyond simply the loss of native dtau, given that toxicity is still evident in a 
dtau null background (Feuillette et al., 2010). Figure 7.1 provides an overview of this 
hypothesis. Further assays in order to classify tau solubility and microtubule-binding 
in each of these mutants would be required to support this model of tau toxicity. 
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Figure 7.1 Hypothetical effects of tau phospho-mutation on toxicity 
Observations from this work in vivo combined with in vitro data from other sources 
(Kiris et al., 2011; Necula and Kuret, 2004) suggest the ability of S262A mutation to 
increase microtubule binding and T212D to increase aggregation. Both of these 
mutations led to decreased toxicity the fly eye, potentially by reducing the pool of 
soluble tau. This soluble tau appears to exhibit some toxic gain of function, including 
disruption of the microtubule cytoskeleton, likely via sequestration of other MAPs. It 
may also lead to cell death via oxidative stress, DNA damage and apoptosis (see 
below).   
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In all, the results of this screen of the tau phospho-mutant library conform well to 
ideas privileging tau solubility over tangle formation as the cause of 
neurodegeneration in tauopathy. It is with regards to BRSK2 that this work has 
raised the most challenging questions, particularly that of the relationship between 
tau isoform and disease. 
 
7.2 The prospects for BRSK2 as a tau kinase 
The unusually strong eye phenotype of 0N4R tau/BRSK2 flies was the principal 
motivation for further study of this kinase. That 2N4R tau would not respond in the 
same way was unexpected, and not easily explained. It may also serve to provide 
some insight into the effect of BRSK2 expression in the fly eye. 
The previously observed, S262-dependent toxicity of 0N4R tau/BRSK2 animals 
(unpublished data) bears significant resemblance to the interaction between 0N4R 
tau and Drosophila checkpoint kinase 2 (Chk2) shown by Iijima-Ando et al. (2010). 
Chk2 was shown to exhibit no external eye toxicity when overexpressed without tau, 
but to drastically increase toxicity caused by 0N4R tau. Chk2 overexpression had no 
effect on an S262A mutant, or on toxicity caused by PAR-1 in the absence of tau. 
The eye phenotype caused by co-expression of 0N4R tau and Chk2 is reminiscent of 
our recombinant 0N4R/B2WT5 line and is more severe than recorded phenotypes for 
co-expression of 0N4R tau and either Sgg or PAR-1 (Jackson et al., 2002; Nishimura 
et al., 2004). Such a similarity in effect between BRSK2 and Chk2 is perhaps to be 
expected, given the existing evidence for BRSK2 itself being a checkpoint kinase. 
SAD1 kinase was shown to relocate to the nucleus following UV treatment and be 
activated specifically following UV-induced DNA damage, leading to cell cycle 
arrest at G2/M (Lu et al., 2004). This is likely due to phosphorylation and 
downregulation of the checkpoint kinase Wee1 by both of the BRSKs, an essential 
step in the establishment of neuronal polarity (Muller et al., 2010). It is interesting to 
note that this last step appears to not involve microtubule regulation and is thus 
presumably tau-independent, indicating a dual role for the BRSKs in neuronal 
differentiation. This distinction between tau-dependent and tau-independent 
functions of BRSKs could be relevant to our model. Indeed, regulation of cell cycle 
170 
 
progression has been shown to influence tau toxicity in Drosophila, with cell cycle 
interference reducing toxicity and tau-induced apoptosis (Khurana et al., 2006). 
One possible explanation for the increase in 0N4R tau toxicity due to BRSK2 is that 
the kinase serves to amplify cell death during development in response to a threshold 
level of tau-induced DNA damage, potentially via oxidative stress (Dias-Santagata et 
al., 2007) or cytoskeletal disruption (Cowan et al., 2010). In this case, our WT 0N4R 
tau transgenic line (which has been shown to lead to greater distortion of the eye in 
the absence of BRSK2 than any of the 2N4R lines or S262A/S2A mutant 0N4R tau) 
passes this threshold leading to activation of BRSK2-induced cell cycle arrest and 
cell death. This would all take place during development in our model, leading to the 
shrunken eyes found in the 0N4R/B2WT5 line. This process would effectively 
sideline any phosphorylation of tau by BRSK2 (the assumed primary function of 
BRSKs) unless the threshold of damage for initiation of cell cycle arrest was 
reached; this could explain the reduction of 2N4R tau toxicity in the presence of 
BRSK2, in line with the double phospho-mimetic mutant shown in Chapter 4. The 
other possible explanation for this reduction would be an induction of DNA repair by 
the kinase in response to a lower level of DNA damage. One potential complication 
for this hypothesis is the lack of apoptosis witnessed in the developing larval eye of 
these flies (as measured by TUNEL stain – Dr Alessia Galasso, personal 
communication), and the increase in lysosomal numbers (as measured by 
LysoTracker stain – Dr Alessia Galasso, personal communication). It is possible that 
apoptosis does occur, at a later stage of development to that observed, via expected 
apoptotic pathways involving Chk2 and p53 (Hirao et al., 2000). As for the 
upregulation of lysosomal activity, this could be protective, in an attempt to forestall 
cell death via apoptosis, as has been observed in cancer (Abedin et al., 2007; 
Katayama et al., 2007). This would situate autophagy as an antecedent to apoptotic 
cell death. The other possibility is that in this case BRSKs induce cell death via an 
overactivation of autophagy alone (Rodriguez-Rocha et al., 2011). Overall, this 
explanation for the discrepancy between tau isoforms in their response to BRSK2 
appears to be the most straightforward, and is outlined in Figure 7.2. Examination of 
levels of cell death and autophagy in 2N4R tau-expressing larvae would be the 
obvious first step in investigating this theory, as was performed previously. As has 
already been performed in the fly, modification of antioxidant pathways in order to  
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Figure 7.2 Level of tau-induced toxicity appears to determine the consequences of 
BRSK2 co-expression 
A potential role for the checkpoint kinase function of BRSK2 in our model. Putative 
DNA damage caused by transgenic tau expression activates BRSK2, causing cell 
cycle arrest. The severity of tau-induced toxicity then determines whether BRSK2 
activity leads to either cell death or DNA repair and cell survival. 
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determine their effect on the tau/BRSK interaction could be very informative (Dias-
Santagata et al., 2007). Superoxide dismutase (SOD) downregulation, for example, 
has been shown to increase tau neurotoxicity, leading to an increase in apoptosis. 
Would such modification activate BRSK2 if performed on 2N4R tau-expressing 
flies? Conversely, would SOD overexpression eliminate the 0N4R tau/BRSK2 
interaction? Indeed, simply increasing levels of 2N4R tau expression could be an 
alternative method of investigation; given the genetics of the flies we have 
generated, it would be necessary to generate a recombinant 2N4R/B2WT5 line to 
pursue this. Another question would be whether this interaction was tau-specific, or 
whether it could be activated in response to other sources of DNA damage. Iijima-
Ando et al. (2010) tested this in their study of Chk2 using Aβ42 peptide and found 
no effect due to the kinase. However, it is worth noting that the apparent level of 
external eye disruption caused by Aβ42  
alone was less than that witnessed in their 0N4R tau-expressing fly, perhaps creating 
a similar situation to our 2N4R tau model. On the other hand, this could be due to 
differing mechanisms of cellular toxicity between tau and Aβ. 
Were such experiments not able to increase 2N4R/BRSK2-induced toxicity, then the 
implication would be that the interaction was tau isoform-dependent. Although very 
little work has been performed directly comparing the effective differences between 
0N4R and 2N4R tau in disease, some comparisons have already been made 
(Papanikolopoulou and Skoulakis, 2011). The presence of two amino-terminal 
inserts in the S11A tau used by Chatterjee et al. (2009) was postulated to result in its 
increased toxicity relative to a previously-studied 0N4R S14A construct (Steinhilb et 
al., 2007), though it is also worth noting that only eight of residues were similarly 
altered in both constructs. A simpler and stronger comparison was made by Kosmidis 
et al. (2010), who demonstrated that 2N4R tau was more toxic to mushroom body 
neurons than 0N4R tau, even when expressed at lower levels. Although this differs 
from the relative toxicity we have found in the retina, this is likely due to more 
drastic differences in expression levels due to their respective insertion sites, or 
potentially tissue-specific differences in toxicity (Grammenoudi et al., 2006). I have 
already speculated about potential mechanisms of N-domain-dependent changes in 
tau toxicity in Section 4.3. BRSK2-induced changes in tau levels would be relatively 
easily detectable via Western blotting. In addition, the possibility of N-domain-
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determined secondary structure changes could be an interesting avenue of 
investigation, given the ability of the amino terminus to alter tau polymerisation 
kinetics (Gamblin et al., 2003). The increased negative charge of the projection 
domain in the 2N4R isoforms could conceivably lead to an increase in the Alz50 
conformation, in which the microtubule-binding domains exhibit affinity for the N 
terminus, rather than tubulin (also negatively charged). Whether BRSK2-induced 
phosphorylation is capable of increasing the likelihood of such a conformational 
change, particularly in an isoform-specific manner, is admittedly speculative. That 
this conformation has been particularly associated with neurofibrillary tangles, and 
thus insoluble tau aggregation, does make it consistent with a reduction in toxicity in 
this model. Alternatively, it is possible that some change in tau secondary structure 
caused by amino-terminal differences could alter the ability of BRSK2 to interact 
with 2N4R tau. Thorough quantification of BRSK2-induced tau phosphorylation, 
ideally via mass spectrometry, would likely be a good source of leads in such an 
investigation. Alternatively, replication of the phospho-mutant library in 0N4R tau 
would provide an indication of whether any phosphorylation-induced changes were 
isoform-specific. Given that 0N4R S262A mutants have already been studied and 
shown to exhibit reduced toxicity (Iijima-Ando et al., 2010), the most interesting 
mutation to replicate would be T212D, the toxicity-reducing, putative aggregation-
increasing mutation. 
 
7.3 Concluding remarks 
Two observations of this work are likely consequential to tauopathy studies in animal 
models more generally. For any tau isoform-specific effects to be observable 
highlights the importance of looking beyond single isoforms or transgenes, as has 
been suggested by the study of FTDP-17 mutations, which alter 3R:4R expression 
ratios, and other tauopathies (Hong et al., 1998; Majounie et al., 2013). If N-terminal 
domains are also relevant to disease, then potentially all six isoforms could play 
different roles. The second observation is that of tissue-specific effects of the tau 
kinase BRSK2. That human tau undergoes differential phosphorylation in the fly in a 
tissue-dependent manner, and that this leads to different cellular outcomes has 
already been noted by the laboratory of Efthimios Skoulakis (Grammenoudi et al., 
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2006; Kosmidis et al., 2010). Specifically, tau driven by ELAV was shown to be 
phosphorylated at T212 and S214, whereas tau driven in the retina was not. That 
BRSK2 overexpression alone leads to toxicity in the fly CNS, indeed significantly 
more than does tau, suggests that tissue-specific studies would be useful in any 
investigation of tau kinases. I have already speculated that this could be due to 
additional targets of BRSK2 in the brain (see Chapter 5). Given the hypothesis raised 
earlier regarding the role of BRSKs as checkpoint kinases, disruption of cell cycle 
mechanics seems a likely cause. Both upstream and downstream components of the 
BRSK2 cell cycle pathway are conserved in Drosophila, including its target Wee1 
(Campbell et al., 1995) and the regulator of BRSK2, c-Jun activation domain-
binding protein 1 or Jab1 (Gemmill et al., 2002; Zhou et al., 2012). Neither of these 
elements of the cell cycle pathway was revealed by the deficiency screen of Chapter 
6, perhaps because of its use of the eye as an expression system (in which BRSK2 
exhibits no toxicity alone), or due to the relative insensitivity of the deficiency 
screen. It is possible that the CNS is more sensitive than cells of the Drosophila 
retina to disruption of the cell cycle or indeed of neuronal polarisation by BRSK2. 
In attempting to demonstrate the nature of BRSK2 as a conventional tau kinase, as 
well as a regulator of tau toxicity via phosphorylation, this project has generated 
evidence of a far more complex phosphorylation code. BRSK2 appears to modulate 
tau toxicity in an isoform-, or potentially a concentration-dependent manner, and via 
at least three phosphorylation sites on tau (T212, T231 and S262). I have shown the 
inequivalence between tau phosphorylation and toxicity, and provided evidence 
supporting the idea that individual phosphorylation sites play specific roles in the 
regulation of tau function and dysfunction. Future examination of the nature of tau 
phosphorylation in vivo would benefit from expansion of this work, and further 
attempts are required to link residues and regions of tau to the different processes of 
microtubule binding, aggregation and toxicity. 
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Table 9.1 Full genotypes of stocks described in this work  
Label Description Full Genotype Source 
GMR 
Driver of GAL4 in eye 
photoreceptors 
w
[1118]
; P{w[
+
mc], UAS-
GMR::GAL4}/CyO ; 
MKRS/TM6B 
Lab stock 
ELAV 
Temperature sensitive 
driver of GAL4 
throughout the nervous 
system 
w
[1118]
; P{w[
+
mc], UAS-
ELAV::GAL4},P{w[
+
mc], 
UAS-ELAV::GAL4}/CyO ; 
MKRS/TM6B 
Kind gift of 
Kyung-An Han 
PDF 
Driver of GAL4 in 
lateral ventral neurons 
yw
[1118]
; P{w[
+
mc], UAS-
PDF::GAL4}/ P{w[
+
mc], UAS-
PDF::GAL4} ; +/+ 
Lab stock 
0N4R WT human 0N4R tau 
w
[1118]
; + ; P{w[
+
mc], UAS-
4Rtau}/TM6B 
Lab stock 
B2WT5 WT human BRSK2 
w
[1118]
; + ; P{w[
+
mc], UAS-
B2WT5}/TM3 
Lab stock 
0N4R/B2WT5 
Recombinant WT 
human 0N4R tau and 
WT human BRSK2 
w
[1118]
; CyO/If ; P{w[
+
mc], 
UAS-B2WT5},P{w[+mc], 
UAS-4Rtau} /TM6B 
Lab stock 
2N4R tau 
T212A 
2N4R human tau with 
T212A mutation 
w
[1118]
; CyO/If ; P{w[
+
mc], 
UAS-2N4Rtau T212A}/MKRS 
A kind gift of 
Guy Tear and 
Giulia Povellato 
2N4R tau 
T231A 
2N4R human tau with 
T231A mutation and 
FLAG tag 
w
[1118]
; CyO/If ; P{w[
+
mc], 
UAS-2N4Rtau T231A}/MKRS 
Generated by 
Alessia Galasso 
2N4R tau 
S262A 
2N4R human tau with 
S262A mutation and 
FLAG tag 
w
[1118]
; CyO/If ; P{w[
+
mc], 
UAS-2N4Rtau S262A}/MKRS 
Generated by 
Alessia Galasso 
2N4R tau 
T212D 
2N4R human tau with 
T212D mutation and 
FLAG tag 
w
[1118]
; CyO/If ; P{w[
+
mc], 
UAS-2N4Rtau T212D}/MKRS 
This work 
2N4R tau 
T231D 
2N4R human tau with 
T231D mutation and 
FLAG tag 
w
[1118]
; CyO/If ; P{w[
+
mc], 
UAS-2N4Rtau T231D}/MKRS 
This work 
2N4R tau 
S262D 
2N4R human tau with 
S262D mutation and 
FLAG tag 
w
[1118]
; CyO/If ; P{w[
+
mc], 
UAS-2N4Rtau S262D}/MKRS 
This work 
2N4R tau 
T212D S262D 
2N4R human tau with 
T212D and S262D 
mutations, and FLAG 
tag 
w
[1118]
; CyO/If ; P{w[
+
mc], 
UAS-2N4Rtau T212D 
S262D}/MKRS 
This work 
Chic 4891 
Mutated gene 
chickadee, amorphic 
allele 
w
[1118]
 ; P{PZ}chic01320 
cn1/CyO ; ry506 
BDSC 
Chic 4892 
Disruption of gene 
chickadee by 
transposable element 
insertion 
w
[1118]
 ; chic221 
cn1/CyO; ry506 
BDSC 
 
202 
 
Table 9.2 Details of additional chromosome 2 deficiencies acquired from 
Bloomington 
Stock Insertion Full Genotype Donor 
7648 
87F2;87F10, 
3R:9369363;9509679 
w[1118]; Df(3R)Exel6169, P{w[+mC]=XP-
U}Exel6169/TM6B, Tb[1] 
Exelixis, 
Inc. 
7804 
27F2;28A3, 
2L:7364976;7495492 
w[1118]; Df(2L)Exel7031/CyO 
Exelixis, 
Inc. 
7859 
44A4;44B3, 
2R:3948670;4019248 
w[1118]; Df(2R)Exel7094/CyO 
Exelixis, 
Inc. 
7885 
52E11;52F1, 
2R:12030362--
12030372;12046356 
w[1118]; Df(2R)Exel9060, 
PBac{w[+mC]=RB5.WH5}Exel9060 
 
Exelixis, 
Inc. 
7886 
53B1;53C4, 
2R:12176759;123127
94 
w[1118]; Df(2R)Exel7142/CyO 
Exelixis, 
Inc. 
8876 43A3;43F6 Df(2R)CA58/CyO 
Michael 
Ashburner 
9275 
43F8;44D4, 
2R:3849654;4487956 
w[1118]; Df(2R)ED1735, 
P{w[+mW.Scer\FRT.hs3]=3'.RS5+3.3'}ED1735/
SM6a 
DrosDel 
Project 
9413 
55B8;55E3, 
2R:14028250;145267
73 
w[1118]; Df(2R)ED3636, 
P{w[+mW.Scer\FRT.hs3]=3'.RS5+3.3'}ED3636/
SM6a 
DrosDel 
Project 
23664 
45A9;45E3, 
2R:5009694;5403346 
w[1118]; Df(2R)BSC279/CyO 
 
Kevin Cook 
23665 
45C4;45F4, 
2R:5180164;5466121 
w[1118]; Df(2R)BSC280/CyO Kevin Cook 
23692 
52F11;53B1, 
2R:12117729--
12117731;12176803 
w[1118]; Df(2R)BSC309/CyO Kevin Cook 
24128 
27F7;28C4, 
2L:7423926;7800182 
w[1118]; Df(2L)ED501, 
P{w[+mW.Scer\FRT.hs3]=3'.RS5+3.3'}ED501/S
M6a 
DeosDel 
Project 
24339 
42A8;42B2, 
2R:1911160;2536218 
w[1118]; Df(2R)BSC313/CyO Kevin Cook 
24351 
42A14;42C7, 
2R:2123567;2633535 
w[1118]; Df(2R)BSC326/CyO Kevin Cook 
24362 
54F1;55B1, 
2R:13742225--
13742255;13928168 
w[1118]; Df(2R)BSC338/CyO Kevin Cook 
24912 
45D4;45F4, 
2R:5296452;5466121 
w[1118]; Df(2R)BSC408/CyO Kevin Cook 
24987 
55A1;55B7, 
2R:13778659;140159
80 
w[1118]; Df(2R)BSC483/CyO Kevin Cook 
25442 
52F6;53A5, 
2R:12075259;121697
83 
w[1118]; Df(2R)BSC609/CyO Kevin Cook 
7493 
22D1;22E1, 
2L:2175607;2362917 
w[1118]; Df(2L)Exel6007, P{w[+mC]=XP-
U}Exel6007/CyO 
Exelixis, 
Inc. 
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Stock Insertion Full Genotype Donor 
7528 
38C2;38C7, 
2L:20205107;20449190
—20458307 
w[1118]; Df(2L)Exel6046, P{w[+mC]=XP-
U}Exel6046/CyO 
Exelixis
, Inc. 
7779 
22B2;22B8, 
2L:1737960;2010136 
w[1118]; Df(2L)Exel8005/CyO 
Exelixis
, Inc. 
7780 
22B8;22D1, 
2L:1989057--
1989058;2152458 
w[1118]; Df(2L)Exel7008/CyO 
Exelixis
, Inc. 
7813 
30B1;30B4, 
2L:9388129;9448660—
9448833 
w[1118]; Df(2L)Exel8022/CyO 
Exelixis
, Inc. 
7814 
30B2;30B3, 
2L:9415663;9431473 
w[1118]; Df(2L)Exel9064, 
PBac{w[+mC]=RBr}Exel9064/CyO 
Exelixis
, Inc. 
7851 
38C7;38D5, 
2L:20449190--
20458307;20680624 
w[1118]; Df(2L)Exel7078/CyO 
Exelixis
, Inc. 
7852 
38E9;38F3, 
2L:20770538;20874804 
w[1118]; Df(2L)Exel7079/CyO 
 
Exelixis
, Inc. 
8000 
22B5;22D1, 
2L:1911627;2175599 
w[1118]; Df(2L)Exel6006, P{w[+mC]=XP-
U}Exel6006/CyO 
Exelixis
, Inc. 
9175 
38D1;38F5, 
2L:20638580;20917519 
w[1118]; Df(2L)ED1317, 
P{w[+mW.Scer\FRT.hs3]=3'.RS5+3.3'}ED1317/SM
6a 
DrosDe
l Project 
9222 
38B4;38C6, 
2L:20085397;20382385 
w[1118]; Df(2L)ED1305, 
P{w[+mW.Scer\FRT.hs3]=3'.RS5+3.3'}ED1305/SM
6a 
DrosDe
l Project 
9704 
28E8;29B1, 
2L:8155863;8346414 
w[1118]; Df(2L)BSC227/CyO 
Kevin 
Cook 
2650
0 
44A2;44D1, 
2R:3885081;4350143 
w[1118]; Df(2R)BSC266/CyO 
Kevin 
Cook 
9705 
28E5;28F4, 2L:8092128-
-8092225;8221250 
w[1118]; Df(2L)BSC228/CyO 
Kevin 
Cook 
2435
7 
38F1;39A6, 
2L:20831386;21155355 
w[1118]; Df(2L)BSC333/CyO 
 
Kevin 
Cook 
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Table 9.3 Details of RNAi stocks from VDRC examined in this work 
Gene Transformant ID Construct ID Library 
CG4238 41982 11260 GD 
Su(dx) 103814 102798 KK 
DPR3 106517 111766 KK 
GlyP 109596 100434 KK 
CG7261 105428 101739 KK 
AIF 109615 101231 KK 
Spire 107335 109380 KK 
Arpc2 104396 108258 KK 
Debcl 106669 100738 KK 
CG8726 109451 108815 KK 
CG14763 104043 112546 KK 
CSN4 103803 100065 KK 
Hey 103570 101381 KK 
Sut3 4009 1865 GD 
Sut2 102028 110424 KK 
Sut1 104983 112749 KK 
Nup50 100564 108150 KK 
Pnut 11791 1512 GD 
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Tau mutagenic primers: 
 
T212D sense: 5’ CAGCCGCTCCCGCGACCCGTCCCTTCCA 3’ 
T212D antisense: 5’ TGGAAGGGACGGGTCGCGGGAGCGGCTG 3’ 
 
T231D sense: 5’ AGAAGGTGGCAGTGGTCCGTGATCCACCCAAGTC 3’ 
T231D antisense: 5’ GACTTGGGTGGATCACGGACCACTGCCACCTTCT 3’ 
  
S262D sense: 5’ GTCAAGTCCAAGATCGGCGACACTGAGAACCTGAAGCA 3’ 
S262D antisense:  
5’ TGCTTCAGGTTCTCAGTGTCGCCGATCTTGGACTTGAC 3’ 
  
Tau sequencing primers: 
 
Tau sense 24: 5’ CGA AGTGATGGA AGATCACG 3’  
Tau sense 508: 5’ AGGATTCCAGCA AAA ACCCC 3’  
Tau sense 550: 5’ AGCTCTGGTGAACCTCCAAAAT 3’  
Tau sense 1074: 5’ CAATATCACCCACGTCCCTG 3’  
Tau sense 1199: 5’ CTGGGGACACGTCTCCACG 3’  
Tau amtisense 123: 5’ AATGCCTGCTTCTTCAGCTG 3’  
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Subcloning primers for pUAST attP2: 
 
pUASTattP2 sense: 5’ TGCAACTACTGAAATCTGCC 3’ 
pUASTattP2 antisense: 5’ ACACCACAGAAGTAAGGTTCC 3’ 
 
